false false FY 0000835662

 2023-06-30

 2024-03-29

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: ProductMember

 us-gaap: ProductMember

 AIXN:RoomRevenueMember

 AIXN:RoomRevenueMember

 AIXN:FoodAndBeverageRevenuesMember

 AIXN:FoodAndBeverageRevenuesMember

 AIXN:OtherMember

 AIXN:OtherMember

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 AIXN:ChinaConcentricCapitalGroupMember

 2017-02-01
 2017-02-02

 AIXN:ChinaConcentricCapitalGroupMember

 2017-12-12

 AIXN:EquityTransferAgreementMember
 AIXN:AixinShangyanHotelManagementMember

 2021-05-25

 AIXN:AixinShangyanHotelManagementMember

 2021-05-24
 2021-05-25

 AIXN:ChengduAixintangPharmacyCoLtdMember
 AIXN:PharmaciesPurchaseAgreementMember

 2021-06-01
 2021-06-02

 AIXN:AixintangPharmacisesMember

 2021-06-01
 2021-06-02

 AIXN:YunnanShengshengyuanTechnologyCoLtdMember
 AIXN:TransferAgreementMember

 2022-07-18

 AIXN:YunnanShengshengyuanTechnologyCoLtdMember

 2022-07-18

 2023-02-17
 2023-02-17

 2023-02-17

 AIXN:SinceAprilOneTwoThousandNineteenMember

 srt: HotelMember

 us-gaap: HealthCareMember

 AIXN:ManufactureAndSaleMember

 us-gaap: SalesRevenueNetMember
 us-gaap: CustomerConcentrationRiskMember
 AIXN:NoCustomerMember

 us-gaap: SalesRevenueNetMember
 us-gaap: CustomerConcentrationRiskMember
 AIXN:NoCustomerMember

 AIXN:OfficeFurnitureMember

 AIXN:OfficeFurnitureMember
 srt: MinimumMember

 AIXN:ElectronicEquipmentMember
 srt: MaximumMember

 AIXN:MachineryMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: VehiclesMember

 us-gaap: CostOfSalesMember
 us-gaap: SupplierConcentrationRiskMember
 AIXN:SupplierAMember

 us-gaap: CostOfSalesMember
 us-gaap: SupplierConcentrationRiskMember
 AIXN:SupplierBMember

 us-gaap: CostOfSalesMember
 us-gaap: SupplierConcentrationRiskMember
 AIXN:SupplierBMember

 us-gaap: CostOfSalesMember
 us-gaap: SupplierConcentrationRiskMember
 AIXN:SupplierCMember

 AIXN:ProductsMember

 AIXN:ProductsMember

 AIXN:PharmaciesMember

 AIXN:PharmaciesMember

 srt: HotelMember

 AIXN:ManufactureAndSaleMember

 AIXN:ProductsMember

 AIXN:ProductsMember

 AIXN:PharmaciesMember

 AIXN:PharmaciesMember

 srt: HotelMember

 srt: HotelMember

 AIXN:ManufactureAndSaleMember

 AIXN:ManufactureAndSaleMember

 us-gaap: VehiclesMember

 AIXN:OfficeFurnitureMember

 AIXN:ElectronicEquipmentMember

 AIXN:ElectronicEquipmentMember

 AIXN:MachineryMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: PropertyPlantAndEquipmentOtherTypesMember

 us-gaap: PropertyPlantAndEquipmentOtherTypesMember

 AIXN:ValueAddedMember

 AIXN:ValueAddedMember

 AIXN:IncomeMember

 AIXN:IncomeMember

 AIXN:CityConstructionMember

 AIXN:CityConstructionMember

 AIXN:EducationMember

 AIXN:EducationMember

 AIXN:OtherMember

 AIXN:OtherMember

 2021-12-01
 2021-12-01

 srt: MinimumMember
 AIXN:AiXinZhonghongBiologicalTechnologyCoLtdMember

 srt: MaximumMember
 AIXN:AiXinZhonghongBiologicalTechnologyCoLtdMember

 AIXN:AixinShangyanHotelManagementMember

 AIXN:AixintangPharmacisesMember
 srt: MinimumMember

 AIXN:AixintangPharmacisesMember
 srt: MaximumMember

 AIXN:ChengduWenjiangAixinNanjiangPharmacyCoLtdMember

 AIXN:ChengduWenjiangAixinNanjiangPharmacyCoLtdMember

 AIXN:ChengduLishengHuirenTangPharmacyCoLtdMember

 AIXN:ChengduLishengHuirenTangPharmacyCoLtdMember

 AIXN:ChengduFuxiangTangPharmacyCoLtdMember

 AIXN:ChengduFuxiangTangPharmacyCoLtdMember

 AIXN:ChengduWenjiangDistrictHenengHupuPharmacyCoLtdMember

 AIXN:ChengduWenjiangDistrictHenengHupuPharmacyCoLtdMember

 AIXN:ChengduAixinInternationalTravelServiceCoLtdMember

 AIXN:ChengduAixinInternationalTravelServiceCoLtdMember

 us-gaap: OtherAffiliatesMember

 us-gaap: OtherAffiliatesMember

 AIXN:LuquanShengcaofengBiotechnologyCoLtdMember

 AIXN:LuquanShengcaofengBiotechnologyCoLtdMember

 AIXN:SichuanAixintangXinfuChainPharmacyCoLtdMember

 AIXN:SichuanAixintangXinfuChainPharmacyCoLtdMember

 AIXN:ChengduZhiweibingPharmacyCoLtdMember

 AIXN:ChengduZhiweibingPharmacyCoLtdMember

 AIXN:SichuanAixinInvestmentCoLtdMember

 AIXN:SichuanAixinInvestmentCoLtdMember

 AIXN:QuanzhongLinMember

 AIXN:QuanzhongLinMember

 AIXN:YirongShenMember

 AIXN:YirongShenMember

 AIXN:HuiliangJiaoMember

 AIXN:HuiliangJiaoMember

 AIXN:TianfengLiMember

 AIXN:TianfengLiMember

 AIXN:MianyangAixinCunshanPharmacyCoLtdMember

 AIXN:MianyangAixinCunshanPharmacyCoLtdMember

 2014-05-01
 2014-05-31

 AIXN:RenewedMember

 2014-05-01
 2014-05-31

 2020-04-01
 2023-02-28

 AIXN:YunnanRuncangshengMember

 2020-04-01
 2023-02-28

 us-gaap: ForeignCountryMember

 us-gaap: ForeignCountryMember
 AIXN:AixinShangyanHotelAndAixintangPharmaciesMember

 2020-08-16
 2020-08-17

 AIXN:TwoThousandAndNineteenEquityIncentivePlanMember

 2019-10-21
 2019-10-22

 AIXN:TwoThousandAndNineteenEquityIncentivePlanMember

 2019-10-22

 AIXN:TwoThousandAndNineteenEquityIncentivePlanMember

 2019-10-23
 2019-10-24

 AIXN:TwoThousandAndNineteenEquityIncentivePlanMember

 2019-10-24

 AIXN:YunnanShengshengyuanTechnologyCoLtdMember

 srt: MinimumMember

 srt: MaximumMember

 2020-12-01
 2020-12-31

 AIXN:FirstExecutionOfJudgementMember

 2021-04-01
 2024-04-30

 AIXN:RestorationOfExecutionMember

 2023-06-13
 2023-06-13

 AIXN:FirstExecutionOfJudgementMember

 2023-06-13
 2023-06-13

 AIXN:FrozenCaseMember

 2024-03-27
 2024-03-27

 AIXN:YunnanShengshengyuanMember

 AIXN:YunChenMember

 AIXN:YunnanRuncangshengMember
 AIXN:TransferAgreementMember

 2021-01-01

 AIXN:YunnanRuncangshengMember

 AIXN:YunnanRuncangshengMember

 us-gaap: SubsequentEventMember

 2024-02-29

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

 FORM

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2023

 Commission
File Number: 000-17284

 AIXIN

 (Exact
 name of registrant as specified in its charter)

 Colorado

 84-1085935

 (State
 or Other Jurisdiction

 IRS
 Employer

 of
 Incorporation)

 Identification
 Number

 Hongxing
International Business Building 2, 14 th FL,
 No. 69 Qingyun South Ave.,
 Jinjiang District

 Chengdu
City, Sichuan Province, China

 (Address
of principal executive offices)

 86 - 313-6732526

 (Registrant's
telephone number, including area code)

 Securities registered pursuant to Section 12(b) of the Act: None

 Securities
registered pursuant to Section 12(g) of the Act:

 Common
Stock, $0.00001 par value

 (Title
of class)

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. (Check one):

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment
of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b))
by the registered public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 As
of June 30, 2023, the aggregate market value of our common stock held by non-affiliates was $ 25,656,989 based on 8,580,933 shares of
outstanding common stock held by non-affiliates, and a price of $2.99 per share, which was the last reported sale price of our common
stock on OTCQB on that date.

 As
of March 29, 2024, we had outstanding 24,999,945
 shares of common stock.

 DOCUMENTS
INCORPORATED BY REFERENCE: None

 AIXIN

 Page
 No.

 Item

 Business

 Item
 1A

 Risk Factors

 Item
 1B

 Unresolved Staff Comments

 Item
 1C

 Cybersecurity Policy

 Item

 Properties

 Item

 Legal Proceedings

 Item

 Mine Safety Disclosures

 Item

 Market For Registrant's Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities

 Item

 [Reserved]

 Item

 Management's Discussion And Analysis Of Financial Condition And Results Of Operations

 Item
 7A

 Quantitative And Qualitative Disclosures About Market Risk

 Item

 Financial Statements And Supplementary Data

 Item

 Changes In And Disagreements With Accountants On Accounting And Financial Disclosure

 Item
 9A

 Controls And Procedures

 Item
 9B

 Other Information

 Item 9C

 Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 Item

 Directors And Executive Officers And Corporate Governance

 Item

 Executive Compensation

 Item

 Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters

 Item

 Certain Relationships And Related Transactions, And Director Independence

 Item

 Principal Accountant Fees And Services

 Item

 Exhibits And Financial Statement Schedules

 Consolidated Financial Statements

 SPECIAL
NOTE REGARDING FORWARD LOOKING STATEMENTS

 This
Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future
results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as "anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "plans," "potential," "predicts," "projects,"
"should," "would" and similar expressions intended to identify forward-looking statements. Forward-looking statements
reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given
these uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements include, among other
things, statements relating to:

 our
 goals and strategies;

 our
 future business development, financial condition and results of operations;

 our
 expectations regarding demand for, and market acceptance of, our products;

 our
 expectations regarding keeping and strengthening our relationships with merchants, manufacturers and end-users; and

 general
 economic and business conditions in the regions where we provide our services.

 Also,
forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and
the documents that we reference and filed as exhibits to the report completely and with the understanding that our actual future results
may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements
publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even
if new information becomes available in the future.

 REVERSE
STOCK SPLIT

 On
February 17, 2023, we effected a 1-for-2 reverse split of our shares of common stock reducing the number of shares of our
outstanding common stock from 49,999,891 to 29,999,842. Except as otherwise indicated, all share and per share numbers contained
herein including those set forth in the financial statements beginning on page F-1, have been adjusted to give effect to the 1-for-2
reverse stock split.

 PART
I

 Item

 Business.

 Overview

 As used in this report, unless the
context requires otherwise, all references to "AiXin Colorado" refer to AiXin Life International, Inc., a Colorado holding
company, and references to "Aixin Life," we," "us," "our," the "Registrant," the
"Company" or "our Company" are to AiXin Colorado and its subsidiaries.

 We
are a Colorado holding company and conduct substantially all of our operations through our operating companies established in the
People's Republic of China, or the PRC.* O ur focus is on providing health and wellness
products to the growing middle class in China. We currently develop, manufacture, market and sell premium-quality healthcare,
nutritional products and wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such
as weight management products, probiotics, foods and drinks. We also provide advertising and marketing services to clients which
engage us to market and distribute their products. We offer our products and those of clients for which we provide marketing
services, through a diversified, omni-channel business model which generates revenues through retail and wholesale product sales,
through company-owned pharmacies, direct marketing and online activities.

 Through
our subsidiary, AixinZhonghong, we offer nutritional products through a direct marketing team, at large scale entertainment style events
which we organize for the benefit of our clients and more recently, through online activities. AixinZhonghong also provides marketing
and distribution services to other manufacturers and suppliers of healthcare products. We have a proactive approach to marketing, reaching
out to customers to provide information as to how to live a healthy lifestyle. We believe this approach is ideally suited to marketing
health and wellness products as sales of these products are strengthened by ongoing personal contact and support, coaching and education
of clients, as to the benefits of a healthy and active lifestyle.

 In
September 2021 we completed the acquisition of nine pharmacies located in Chengdu. Since that time we have added additional pharmacies
and currently operate 25 pharmacies. We utilize these pharmacies to distribute our health and wellness
products and serve as learning centers for our clients along with their traditional business. We intend to seek to continue to expand
our chain of pharmacies and to use these outlets as part of our overall marketing strategy. As part of our marketing efforts, we will
educate the employees at our pharmacies as to the benefits of our health and wellness products so they can closely work with our clients.

 In
September 2022, we acquired Yunnan Runcangsheng which
engages in the research, development, manufacture and wholesale distribution of health and wellness products. Yunnan Runcangsheng operates
a 13,000 square meter production facility, including, R&D centers, extraction facilities, preparation workshops and a warehouse.
Yunnan Runcangsheng has more than 30 brand names under which it distributes products and maintains and operates planting facilities where
it grows some of the key ingredients used in its products. Many of the products it has developed are specifically targeted to alleviate
ailments associated with the increasingly competitive and pressured lifestyle of Chinese people, such as hypertension and obesity, which
result from a more pressured yet sedentary lifestyle, symptoms associated with changing eating habits and the presence of environmental
toxins that are becoming more widespread through the use of western style pesticides and fertilizers. When we entered into the agreement
to acquire Yunnan Runcangsheng we began to distribute its products through our distribution channels and continue to do so.

 In
addition to our acquisitions in the health and nutritional sector, in July 2021, we acquired Chengdu AiXin Shangyan Hotel Management
Co., Ltd ("AiXin Shangyan Hotel"). Until the end of March 2024, AiXin Shangyan Hotel operated the
Shangyan Hotel located in the Jinniu District, Chengdu City. We terminated the lease for the Shangyan Hotel effective March 31, 2024, and entered into a 30-year lease for a hotel
in the Xindu District of Chengdu. While we will continue the hotel's pre-acquisition business, we
intend to use the hotel to host events at which we educate our team members and customers as to the benefits of a healthy lifestyle,
introduce new products and offer our complete product line for sale.

 We
intend to look for additional opportunities to profit from the growing healthcare market in China. Though currently we are not party
to any agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary
products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics
which provide medical care to clients.

 * Our "Chinese Operating Companies" are Chengdu AiXinZhonghong Biological
Technology Co., Ltd, ("AiXinZhonghong"), AiXin Shangyan Hotel Management Co. Ltd. ("AiXin Hotel"), Chengdu Aixintang
Haichuan Pharmacy (which together with certain affiliated entities is referred to as "Chengdu Aixintang Pharmacies"), and
Yunnan Runcangsheng Technology Co., Ltd. ("Runcangsheng)." The Chinese Operating Companies are wholly owned through an intermediary
company established in Hong Kong named HK AiXin International Group Co., Limited ("AiXin HK" and collectively with our Chinese
Operating Companies our "PRC Subsidiaries"), which is owned by an intermediary company (AiXin (BVI) International Group, Ltd.,
"AiXin BVI") established in the British Virgin Islands. We are not a Chinese operating company. We are a holding company and
do not directly own any substantive business operations in China. Therefore, you will not directly hold any equity interests in our Chinese
Operating Companies, AiXin BVI or AiXin HK.

 Business
Objectives

 Key
elements of our strategy are detailed below:

 Leading
brand of nutritional supplements. Our primary goal is to develop recognized brand names with a reputation as a provider of quality
health and wellness products which deliver demonstrable benefits to our customers. Our objective is to provide members of the growing
Chinese middle class with the information necessary to maintain a healthy lifestyle and to offer them a broad and deep mix of products
whether the customer is looking to treat a specific health-related issue, maintain their overall wellness or improve their performance.
Our premium, value-added offerings will include both proprietary branded products and other branded products provided by third parties
to meet needs not met by our in-house products.

 We
believe that by offering a variety of branded exclusive products and a wide range of merchandise, and close customer support and services,
we will be able to differentiate our Company from competitors and effectively compete against other food, drug and mass channel players,
specialty stores, independent vitamin, supplement and natural food shops and online retailers. We further believe that if we succeed
in developing and maintaining a positive reputation, we will be able to offer additional products and services to our clients.

 Product
development and innovation. With the acquisition of Yunnan Runcangsheng we have the facilities and, more importantly, knowledgeable,
experienced personnel, to develop high-quality, innovative health foods and nutritional supplements that will be offered by our direct
marketing team and available through our company-owned pharmacies, our website and, as demand grows other, select marketplaces and wholesale
partners. To the extent desirable we will grow some of the key ingredients in our products. When we choose to use ingredients of third
parties, they will be rigorously tested before they are added to our products, undergoing multiple quality checks to ensure that they
meet our high standards for purity, composition and absence of contaminants.

 We
believe our capability to innovate and respond to customer needs by designing new products gives us a significant competitive advantage.
At Yunnan Runcangsheng we directly employ scientists, nutritionists, formulators, and quality control experts who work at our research
and manufacturing facilities.

 A
differentiated customer experience. One of the key differentiators to our marketing strategy is the continued development of
well-trained team members that work closely with customers. We will provide our team members with training and education focused on the
benefits of a healthy lifestyle, the advantages of our products and solution-based selling. We will also maintain and make available
to our team members data bases of our customers purchasing patterns. With their knowledge of the available products our team members
can engage customers in conversation, access the customer's purchasing history through our data base, share product information
and testimonials and recommend solutions and help customers add complimentary products and build wellness regimens. We operate in a highly
personalized, aspirational sector and believe that health food and nutritional supplement consumer often desires and seeks out product
expertise and knowledgeable customer service.

 We
have developed loyalty programs to reward customers and incentivize them to introduce our products to their friends. A number of our
customers in fact act as independent marketers, buying products from us and distributing them to others at a profit. We intend to continue
to use loyalty programs to develop and maintain a large and loyal customer base, provide targeted offers and information, and connect
with our customers on a regular basis. We will harness data generated by these programs to better understand customers' buying
behaviors and needs, so we can deliver a more rewarding experience, encourage our customers to introduce our products to their friends
and make well-informed decisions about the direction of our business.

 As
we grow and develop our customer base, we can use our hotel as a site for educational seminars, conferences and marketing events featuring
well known experts in the wellness sector. These events can be used to increase customer loyalty and to educate our team members as to
the benefits of a healthy life style and our products so they can better serve our customers by guiding them to products that meet their
needs.

 Omni-channel
development. We believe our diversified, omni-channel model, which includes company-owned offices open to clients, pharmacies,
direct marketing by our team members, individually and at large scale company sponsored marketing events, wholesale locations and online
activities, can differentiate us from many of our competitors, particularly those that rely exclusively on online marketing efforts.
Our strategy is to give consumers a seamless, integrated experience across digital, mobile and in-store channels and in every interaction
with us and our products.

 Through
our website and in conversations with our well-trained team members, customers can research our products and purchase them online or
at one of our local pharmacies or sales offices. We believe our physical store base provides a competitive advantage, allowing customers
to experience our products and get expert advice from our team members.

 Our
omni-channel model can enhance the customer experience and increase the value of a customer to us and we will implement strategies to
blend our digital, online and in-store platforms, always stressing the availability and benefits of a conversation with one of our team
members. These initiatives will include increased cross-channel marketing, online and in-store subscription services, giving customers
the option of picking up online purchases at our stores, delivering products purchased via e-commerce directly from stores, and providing
educational content, information and advice online, at our pharmacies or through a personal visit by one of our team members.

 Vertical
Integration. We believe that our multi-channel distribution model, combined with our research, development and manufacturing
capabilities offers us a unique advantage over our competitors. The daily feedback received from interactions between our team members
and customers will be monitored to recognize what our customers want and rapidly develop products to meet their desires. Instead of simply
responding to trends in the market, we will seek to bring new topical products to the market before they are generally available.

 Our
pharmacies offer a wide variety of personal healthcare products and traditional Chinese remedies in addition to our health and wellness
products. They began to carry the products developed by Yunnan Runcanscheng prior to completion of that acquisition. The primary products
currently distributed by us, including those of Yunnan Runcangsheng, include rhino king, colostrum powder derived from goat's milk,
tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules.

 Marketing

 Our
target customer is the growing population of middle- and upper-class Chinese who are willing to devote increasing amounts to healthcare
products as their incomes grow. We believe that as this group grows, becomes more affluent and adopts a more western sedentary life-style
and diet, it will experience obesity, hypertension, heart disease, back pain and some of the negative symptoms common in developed countries.
Our marketing efforts include proactively approaching these customers through person-to-person marketing and by hosting educational and
informative events, which we believe is ideally suited to marketing our products and those of our clients for which we perform advertising
services because sales of health and wellness products and supplements are strengthened by ongoing personal contact and support, coaching
and education towards how to achieve a healthy and active lifestyle.

 We
currently market our products through our pharmacies, at large scale marketing events which feature popular local entertainers, at our
offices which customers are encouraged to use for social gatherings, at wholesale and online. Key to our marketing efforts are the members
of our marketing team who make themselves available to individual customers and work with such customers to develop a healthy well balanced
dietary regimen. As part of our educational efforts, we distribute informational videos to our clients on-line and make multiple posts
on social media daily. Off-line, in addition to distributing products through our pharmacies, we utilize person-to-person marketing to
promote and sell products. These personal marketing efforts include hosting educational events and allowing customers to utilize our
facilities for social gatherings.

 In
addition to our marketing efforts, through our loyalty program we encourage our customers to distribute our products to others. Our program
for increasing the number of clients interested in reselling the products we offer and for developing new clients who demonstrate the
ability to sell our products to others, is to provide them with compensation, in the form of quantity purchase discounts and other incentives,
such as free meals, travel or vacations.

 We
offer our clients a customer satisfaction guarantee. Our sales policy allows for the return of unopened products for cash after deducting
certain service and transaction fees. As an alternative to returning a product, customers can exchange a product for another of the same
value.

 Manufacturing

 As
a result of the acquisition of Yunnan Runcangsheng, we now have a 13,000 square meter manufacturing center inclusive of office space,
R&D centers, extraction workshops, preparation workshops, traditional Chinese medicine decoction pieces workshops and storage areas.
The activities include research and development, extraction and intensive processing of traditional Chinese medicines and processing
to incorporate active ingredients into tablets, capsules, granules and pills according to market demand and product attributes. The facility
was designed and constructed and is operated in compliance with applicable national health food and pharmaceutical standards (GMP), and
has achieved ISO quality system certification and HACCP food safety system certification.

 Raw
Materials

 The
raw materials used in products we manufacture are generally readily available, subject to fluctuations in price due to supply and demand
issues. We do not look to enter into long term contracts with any of our suppliers as the materials we need shifts as demand for our
products changes.

 Intellectual
Property

 We
believe that we need to develop well recognized brand names and, when possible, obtain patents covering products we develop, their
formulae or the processes by which they are manufactured. Runcangsheng has received patents on certain manufacturing processes and
has used multiple brand names for its products. Given the early stage of Runcangsheng's development and the limited historical
operations of AiXinZhonghong, our products and brand names have yet to achieve the widespread recognition we envision. See,
"Item 1A. Risk Factors – Risks Associated with Our Company -, Our ability to adequately protect our trade names,
trademarks and patents could have an impact on our brand images and ability to penetrate new markets. "

 Competition

 The
category of nutritional products is very competitive and there are various channels through which such products are marketed to consumers,
including direct selling, through the internet, through specialty retailers, pharmacies and discount channels of food, drug and mass
merchandisers. We seek to differentiate ourselves by being familiar with our clients and providing a personalized sales experience and
focusing on after-sale services where sales employees focus on the consultative sales process through product education and the frequent
contact and support that many sales employees have with the clients. From a competitive standpoint, there are many providers and sales
outlets of nutritional products in China. We believe that none have effectively combined the product, personal coaching, education and
the product access provided by our sales employees and, further, that these efforts are compounded by the peer pressure our clients generate
through our organized group sales presentations.

 Employees

 As
of April 1, 2024, we had approximately 207 employees allocated amongst the functions set forth below.

 Function

 Number of
 employees

 Administration

 Finance

 Manufacturing

 Marketing (sales)

 R&D

 Procurement

 We
believe that we maintain a good working relationship with our employees, and to date we have not experienced any significant labor disputes.

 Government
Regulations

 We
are subject to numerous regulations applicable to businesses generally, including regulations relating to working conditions, employee
compensation and the maintenance of welfare plans, environmental regulation and truth in advertising. In addition, the manufacture and
distribution of nutritional products is subject to many laws, governmental regulations, administrative determinations and guidance. Such
laws, regulations and other constraints exist at the national, provincial and local levels, including regulations pertaining to: (1)
the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of products; (2) product claims and
advertising, including direct claims and advertising by us, as well as claims and advertising by manufacturers and distributors of the
products we offer, for which we may be held responsible; and (3) taxes. As a distributor, we are subject to only a portion of these laws
and regulations. We believe that we are fully compliant with those applicable to our activities.

 Prior
to commencing manufacture or distribution of a product, the manufacturer or distributor may be required to obtain an approval, license
or certification from the national, provincial or local government in China. Although we attempt to determine whether all regulatory
requirements have been met, we cannot monitor the manufacture of products we acquire for distribution from third parties and cannot be
certain that all applicable regulations are satisfied. Moreover, even if we were to determine that a manufacturer or distributor had
the requisite license or certification at the beginning of a relationship, we might not become aware if it were to forfeit any regulatory
approvals or fail to adhere to applicable requirements.

 Dietary
supplements are subject to regulation by the China Food and Drug Administration. China has highly restrictive nutritional supplement
product regulations. Products marketed as "health foods" are subject to extensive laboratory and clinical analysis by government
authorities, and the product registration process in China generally takes one to two years, but may be substantially longer. We market
both "health foods" and "general foods." For products we distribute on behalf of or acquired from others, we
are not in a position to obtain any required license, though we may be held liable if we were to distribute a product which had not been
properly tested and registered with the authorities. There is some risk associated with the common practice in China of marketing a product
as a "general food" while seeking "health food" classification. If government officials feel the categorization
of a product distributed by us is inconsistent with product claims, ingredients or function, this could end or limit our ability to market
such products.

 As
the middle class has grown, the number of manufacturers and distributors of nutritional supplements in China has dramatically increased.
Many of these have often ignored applicable laws and distributed adulterated or inferior products. We believe this has created a marketing
opportunity which we have tried to exploit as a trusted source of products on which our clients can rely. To the extent our reputation
results from reviewing and testing products prior to distributing them, and then distributing only products determined to be safe, it
is incumbent upon us to ensure that the manufacturers and distributors upon which we rely are trustworthy. A failure by any of these
third parties could cause substantial damage to our reputation, business and financial results.

 Direct
selling and multi-level marketing are two forms of marketing regulated by various national, provincial and local government agencies
in China. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, including "pyramid"
schemes, which compensate participants primarily for recruiting additional participants without significant emphasis on product sales
to consumers.

 Under
PRC regulations, "direct selling" refers to a type of business mode in which a company recruits door-to-door salesmen to
sell products directly to ultimate consumers outside the companies' fixed places of business. Businesses engaged in "direct
selling" are required to obtain a license from the PRC government. A direct selling company is required to provide vocational training
for, and conduct an examination of, any sales promoter it recruits, and obtain a certificate for each sales promoter after the sales
promoter has passed the examination. A direct selling company is also required, when commencing operations, to deposit RMB20 million
($2.9 million) in a special account with a designated bank, which deposit is adjusted on a monthly basis to equal 15% of the operator's
sales from direct selling products up to RMB0.1 billion ($14.5 million).

 We
do not engage in direct selling activities subject to regulations prevalent in China since we do not employ sales personnel engaged in
door-to-door sales outside our place of business.

 Under
PRC regulations, "multi-level marketing" refers to marketing, promotional and sales activities whereby organizers or operators
take in new members and compensate each member based upon the number of new members introduced by such member, directly or indirectly,
or based upon the level of sales generated by the members introduced by such member. The regulations also prohibit an organizer from
requiring new members to deposit a sum of money as a condition to membership or requiring that members recruit additional members to
establish a multi-level relationship. PRC regulations distinguish direct selling from multi-level marketing in that all direct sellers
are normally trained by the direct selling company and any direct seller is not allowed to develop new followers or form multiple levels.

 We
are not in the direct selling category or multi-level marketing category since (i) we do not pay salaries or commissions to our member
distributors, who decide as a matter of personal preference whether to introduce our products to relatives or friends based on their
own personal experience of usage and/or trust of our company's products; (ii) we do not require individuals to deposit a sum of
money to become a member; and (iii) we do not pay members to recruit individuals to join in or to form a multi-level relationship.

 Nevertheless,
the laws and regulations governing direct selling and multi-level marketing may be modified or reinterpreted from time to time, which
may cause us to change our business model. Regulations are subject to discretionary interpretation by regulators and governmental authorities.
There is often ambiguity and uncertainty with respect to the implication of direct selling and anti-pyramiding laws and regulations.

 Item
 1A.

 Risk
 Factors

 An
investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with
all of the other information included in this report, before making an investment decision. If any of the following risks actually occurs,
our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline,
and you may lose all or part of your investment.

 Risks
Associated with Our Company

 We
operate in a highly competitive industry and our failure to compete effectively could adversely affect our market share, revenues and
growth prospects.

 The
market for health and wellness products is large, highly fragmented and intensely competitive. Current and prospective participants include
specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, online merchants, mail-order companies
and a variety of other smaller participants. The market is also highly sensitive to the introduction of new products, which may rapidly
gain consumer acceptance. We compete for sales with heavily advertised brands manufactured by large pharmaceutical and food companies,
as well as other brands, some of which have greater market presence, name recognition and financial, marketing and other resources, including
some competitors that may spend more aggressively on advertising and promotional activities than we do. Further, the ability of consumers
to compare prices on a real-time basis through the use of smartphones and digital technology puts additional pressure on us to maintain
competitive pricing. We compete in multiple product categories and sales channels, including pharmaceutical stores, wholesale to specialty
store formats, direct marketing and increasingly internet-based and direct-sell retailers and vendors. Many factors affect the extent
to which competition could affect our results, including as it relates to pricing, quality, assortment, marketing, promotions and advertising,
service, locations, capital expenditures, category share and reputation, any of which could have a material effect on our results of
operations. If we fail to compete effectively, we may lose business to other retailers.

 We
have a limited operating history on which to judge our performance and assess our prospects for future success.

 We
first entered the health and wellness business in December 2017 when we acquired AiXin BVI, which at that time owned all of the equity
of AiXin Zhonghong, then engaged in the distribution of health and wellness foods. Consequently, we have a limited operating history
on which to evaluate our prospects in the health and wellness industry. We may fail to continue our growth. You should not consider our
historical growth and expansion of our business through acquisitions as indicative of our ability to grow in the future.

 Our
acquisition of Yunnan Runcangsheng is subject to uncertainties and risks.

 There
is no assurance that we will realize the benefits anticipated from our acquisition of Yunnan Runcangsheng. The process of combining the
operations of Yunnan Runcangsheng with our existing operations could have a material adverse effect on us and our financial condition.

 Our
future expansion plans are subject to uncertainties and risks.

 We
intend to seek to expand our operations through acquisitions. The implementation of such plan requires us to integrate any newly acquired
business and its management teams. If we fail to effectively and efficiently implement our plan for acquisitions, we may not be successful
in achieving profitable results. Even if we effectively and efficiently implement our future plans, there may be other unexpected events
or factors that prevent us from achieving success. Our management has limited experience in effecting a rapid expansion and in managing
larger operations. Our business, financial condition, results of operations and growth prospects may be materially and adversely affected
if our future expansion plans fail to achieve positive results.

 Failure
to effectively anticipate consumer preferences could negatively impact the demand for our products and our ability to generate revenues
and the market price of our common stock.

 Our
success depends on our ability to anticipate and respond in a timely manner to changing consumer demand, consumer preferences, and shopping
patterns regarding health and wellness products. Consumer preferences cannot be predicted with certainty and are subject to continual
change and evolution. Additionally, our customers may have expectations about how they shop in stores or through online activities or
more generally engage with businesses across different channels or media (through online and other digital or mobile channels or particular
forms of social media), which may change over time which may make it more difficult for us to adapt to rapid changes in consumer preferences.

 Our
sales may decline significantly if we misjudge the market for our new products, which may result in significant inventory markdowns and
lower margins, missed opportunities for other products, or inventory write-downs, and could have a negative impact on our reputation
and profitability.

 Resources
devoted to product innovation may not yield new products that achieve commercial success.

 Our
ability to develop new and innovative products or identify and acquire new and innovative products from third-party vendors, depends
on, among other factors, our ability to understand evolving market trends and translate our insights into identifying, and then designing
and manufacturing or otherwise obtaining, commercially successful new products. If we are unable to do so, our customer relationships
and product sales could be harmed significantly. The health and wellness industry is characterized by rapid and frequent changes in demand
for products. Our failure to accurately predict these trends could harm our customer relationships and cause us to fail to grow our revenues.
The development of new and innovative products requires significant investment in research and development and testing of new ingredients,
formulas and possibly new production processes. The research and development process entails considerable uncertainty. Products may appear
promising in development but fail to reach market within the expected time frame, or at all. Further, products also may fail to achieve
commercial success. There is no guarantee that our development teams will be able to successfully respond to competitive products that
could render some of our offerings obsolete.

 If
we do not successfully develop and maintain a robust omni-channel experience for our customers, our business and results of operations
could be materially and adversely affected.

 Omni-channel
retailing where customers are accessed through various coordinated channels, is rapidly evolving, and we must keep pace with changing
customer expectations and new developments by our competitors. The growing middle class in China is increasingly seeking relevant information
regarding healthy lifestyles and products that promote a healthy life. In addition, customers are increasingly shopping for products
online instead of in traditional brick-and-mortar shopping centers and retail locations. As part of our omni-channel strategy, we anticipate
the need to continue making investments in technology and to provide ready means for our customers to access the information and products
they want in a comfortable environment. If we are unable to make, improve, or develop relevant channels to interact with customers in
a timely manner, our ability to compete and our business and results of operations could be materially and adversely affected. In addition,
if our online activities or our other customer-facing technology systems do not function as designed or we are unable to effectively
blend our digital, online and in-store platforms, we may experience a loss of customer confidence, lost sales, or data security breaches,
any of which could materially and adversely affect our business and results of operations.

 The
operation of our hotel is subject to the business, financial and operating risks inherent to the hospitality industry, any of which could
reduce the revenues derived at our hotel.

 The
operation of a hotel is subject to a number of business, financial and operating risks inherent to the hospitality industry. These include
significant competition from multiple hospitality providers in which compete for the business of our guests; the financial condition
of the owner of the property on which our hotel is situated; decreases in business and leisure travel; changes in operating costs, including
employee compensation and benefits, energy, insurance, food and beverage and other supplies; increases in costs due to inflation or other
factors that may not be fully offset by increases in revenues in our business, as well as increases in overall prices and the prices
of our offerings due to inflation, which could weaken consumer demand for travel and the products and services we offer and adversely
affect our revenues; changes in taxes and governmental regulations that influence or increase our operating costs; the costs and administrative
burdens associated with complying with applicable laws and regulations; significant increases in cost for health care coverage for employees
and potential government regulation with respect to health care coverage; shortages of labor or labor disruptions; changes in the desirability
of the region in which our hotel is located; changes in the supply and demand for hotel services, including rooms, food and beverage
and other products and services; and the costs required for climate change initiatives, including those resulting from regulatory changes
or stakeholder or customer expectations.

 Any
of these factors could increase our costs or limit or reduce the prices we are able to charge hotel customers for hospitality products
and services, or otherwise affect our ability to maintain our hotel. As a result, any of these factors can reduce our revenues and limit
opportunities for growth.

 Our
efforts to utilize our hotel in Chengdu City to conduct marketing events for customers and training sessions for our employees may not
anticipated benefits.

 We
envision using the hotel we acquired in Chengdu City to conduct marketing events for our customers and training sessions for our personnel.
These efforts may not result in increased sales and may not improve our ability to train our personnel.

 The
failure to maintain permits and licenses could adversely impact our operations.

 The
manufacture and distribution of food products, and the sale of food and beverages at our hotel, as well as other aspects of our business,
require that we maintain various permits and licenses and conduct our operations in accordance with applicable safety requirements and
other regulations. Should we be unable to renew any of our licenses and permits, it could have a material adverse effect on our results
of operations and the profitability of our business, even if the disruption is for only a limited period of time.

 We
may incur material product liability claims, or experience product recalls, which could increase our costs and adversely affect our sales
and margin, reputation, revenues and operating income.

 As
a retailer, distributor and manufacturer of products for human consumption, we are subject to product liability claims if the use of
our products is alleged to result in injury. The products that we sell consist of minerals, herbs, supplements and other ingredients
that are classified as foods or dietary supplements. The products that we sell could contain contaminated substances, and some of the
products we sell contain ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting
from human consumption of these ingredients could occur.

 In
addition, third-party manufacturers produce many of the products we sell. We rely on these manufacturers to ensure the integrity of their
ingredients and formulations. As a distributor of products manufactured by third parties, we may also be liable for various product liability
claims for products we do not manufacture. Our ultimate liability for these products that are manufactured by third parties depends on
a number of factors, including our contractual relationship with the vendor, the creditworthiness of the vendor and any insurance that
we have. Therefore, we may be unable to adequately protect ourselves against claims with respect to products manufactured by a third-party.

 We
may be subject to product liability claims, including, among others, that our products include inadequate instructions for use or inadequate
warnings concerning possible side effects and interactions with other substances. Product liability claims could significantly damage
our reputation and consumer confidence in our products, regardless of the merits or outcomes of such claims. Our litigation expenses
could increase as well, which also could have a material adverse effect on our results of operations even if a product liability claim
is unsuccessful or is not fully pursued.

 We
may be subject to product recalls, withdrawals or seizures if any of the products we manufacture or sell are believed to be adulterated,
cause injury or illness or if we are alleged to have violated governmental regulations in the manufacturing, labeling, promotion, sale
or distribution of such products. A significant recall, withdrawal or seizure of any of the products may require significant management
attention, would likely result in substantial and unexpected costs and may materially and adversely affect our business, financial condition
or results of operations. Furthermore, a recall, withdrawal or seizure of any of the products that we sell may adversely affect consumer
confidence in our brands and thus decrease consumer demand for such products.

 If
we fail to develop and protect our brand names and reputation, we may not attract and retain new customers, which could adversely affect
our revenues and financial performance.

 We
will invest significant resources to promote our brand names to obtain favorable public recognition for us and our products. If we do
not achieve the reputation we envision, we may not be able to attract and retain a significant customer base, which could in turn adversely
affect our revenues, profitability and the market price of our common stock.

 Our
ability to adequately protect our trade names and trademarks could have an impact on our brand images and ability to penetrate new markets.

 We
believe that trade names and trademarks will be an important aspect of our business and an essential element of our strategy. We have
applied for the registration of many of our trade names, trademarks and patents in China. Some of these applications have been granted
and some of these registrations are currently pending approval from the corresponding departments. There can be no assurance that we
will obtain such registrations or that the registrations we obtain will prevent the imitation of our products or infringement of our
intellectual property rights by others. In particular, the laws of the PRC may not protect proprietary rights to the same extent as the
laws of the U.S. Claims that others are infringing our intellectual property would be costly and would divert the attention of management
and key personnel. Our failure to successfully protect our trademarks could diminish the value and effectiveness of our past and future
marketing efforts and could cause customer confusion. This could in turn adversely affect our revenues, profitability and the market
price of our common stock.

 Unfavorable
publicity about us or consumer perception of our products,, including the nutritional supplements we distribute, the ingredients they
contain and any similar products distributed by other companies could cause fluctuations in our operating results and could have a material
adverse effect on our reputation, the demand for our products and our ability to generate revenues and the market price of our common
stock.

 We
are highly dependent upon consumer perception of the safety and quality of our products, including our nutritional supplements, and the
ingredients they contain, as well as that of similar products distributed by other companies. Consumer perception of products and the
ingredients they contain can be significantly influenced by scientific research, national media attention and other publicity, including
that generated via social media. A research report or publicity related to our products and the ingredients they contain that is perceived
by our consumers as less favorable or that questions earlier favorable research or publicity could have a material adverse effect on
our ability to generate revenues.. Adverse publicity, in the form of published scientific research or otherwise, whether or not accurate,
that associates consumption of our products or the ingredients they contain or similar products distributed by other companies with illness
or other adverse effects, that questions the benefits of our or similar products, or that claims that such products are ineffective could
have a material adverse effect on our reputation, the demand for our products, our ability to generate revenues and the market price
of our common stock.

 We
may be subject to health or advertising claims related to our customers.

 Our
products do are not medical treatments and we do not provide or medical advice, and we do not engage physicians or nurses to monitor
the progress of our customers. A customer who uses our products and experiences health problems could allege or bring a lawsuit against
us on the basis that those problems were caused or worsened by using our products. Further, customers who allege that they were deceived
by any statements that we made in advertising or labeling could bring a lawsuit against us under consumer protection laws. We may ultimately
be unsuccessful in defending ourselves against such claims. Also, defending ourselves against such claims, regardless of their merit
and ultimate outcome, may be lengthy and costly, and could adversely affect our brand image, customer loyalty and results of operations.

 We
rely on third parties to provide us with nutritional supplements, fulfillment, customer service and Internet and networking services,
the loss of any of which could cause our revenue, earnings or reputation to suffer.

 In
addition to the nutritional supplements we manufacture, we rely on third-parties to supply us with additional manufacturer the nutritional
supplements we sell. We do not know if our vendors vendor directly sells the same product under a different brand or provides their supplements
to other parties under private label brands. In each of these instances, sales of the same product under different brands could cause
us to lose revenues and adversely impact our abilities to market our products. While we believe we could locate replacement suppliers
for all supplements we acquire from third parties, it would likely take time to engage replacement suppliers which could adversely impact
our revenues during such transition period and there are no assurances our costs would not increase to a level which makes the product
unattractive to our customers.

 We
depend on the services of key executives and other skilled professionals and our ability to attract, train and retain highly qualified
associates. Any failure to attract or retain such individuals could affect our business strategy and adversely impact our performance
and results of operations.

 Our
senior executives are instrumental in setting our strategic direction, operating our business, identifying, recruiting and training personnel,
identifying opportunities, designing new products and arranging necessary financing. In addition, other key employees below the executive
level, with deep knowledge of our business, are critical to the execution and success of our strategy. We must attract, train and retain
a growing number of qualified individuals.

 Losing
the services of any of these groups of individuals could adversely affect our business and we may be unable to identify candidates of
sufficient experience and capabilities in a timely fashion or at all, which could negatively impact our business and operations. Further,
our ability to control labor and benefit costs is subject to numerous external factors, including regulatory changes, prevailing wage
rates, and healthcare and other insurance costs. We compete with other retail and non-retail businesses for these store and field associates
and invest significant resources in training and motivating them. There is no assurance that we will be able to attract or retain qualified
store and field associates in the future, which could have a material adverse effect on our business, financial condition and results
of operations.

 Compliance
with new and existing laws and governmental regulations could increase our costs significantly and adversely affect our results of operations.

 The
processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products are subject to numerous
Chinese laws and regulations as well as laws and regulations imposed by provincial and local governments and agencies. Government regulations
may prevent or delay the introduction, or require the reformulation, of our products, which could result in lost revenues and increased
costs to us. Manufacturers and distributors of health and wellness products and dietary supplements and dietary ingredients are prohibited
from marketing products that are adulterated or misbranded, and the governing agencies may take enforcement action against any adulterated
or misbranded health and wellness product or dietary supplement on the market. If we violate applicable regulatory requirements, we may
be subject to enforcement actions against us, which could have a material adverse effect on our business, prospects, financial condition,
and results of operations. The government may not accept the evidence of safety for any new product or ingredient we may wish to market,
may determine that a particular product or ingredient presents an unacceptable health risk based on reported serious adverse events or
other information, and may determine that a particular claim or statement of efficacy or nutritional value that we use to support the
marketing of a product is not substantiated, or is an unauthorized version of a "health claim." Any of these actions could
prevent us from marketing particular products or making certain claims or statements with respect to those products. We could also be
required to remove a particular product from the market. Any future recall or removal would result in costs to us, including lost revenues
from any products that we are required to remove from the market, any of which could be material. Any product recalls or removals could
also lead to an increased risk of litigation and liability, substantial costs, and reduced growth prospects.

 Additional
or more stringent laws and regulations of health and wellness products have been considered from time to time. These developments could
require reformulation of some products to meet new standards, recalls or discontinuance of some products not able to be reformulated,
additional record-keeping requirements, increased documentation of the properties of some products, additional or different labeling,
additional scientific substantiation, or other new requirements. Any of these developments could increase our costs significantly. In
addition, regulators' evolving interpretation of existing laws could have similar effects.

 We
depend upon a limited number of suppliers for certain raw materials and any disruption to our timely receipt of raw materials and inventory
could adversely impact sales and operations or increase our transportation costs, which would decrease our profits.

 We
depend upon a limited number of suppliers for the raw materials necessary to produce certain of our products. Unexpected delays in the
deliveries of raw materials from our vendors or inventories or increases in transportation costs (including through increased fuel costs)
could significantly decrease our ability to make sales and earn profits. We must maintain sufficient levels of raw materials and inventories
to operate our business successfully. However, we also must guard against accumulating excess inventory. If we fail to anticipate accurately
either the market for the merchandise we offer or our customers' purchasing habits, we may be forced to rely on markdowns or promotional
sales to dispose of excess or slow moving inventory, which could have a material adverse effect on our business, financial condition,
and results of operations.

 In
addition, sales of adulterated products received from third parties could result in a product liability judgment or a widespread product
recall that may negatively impact our sales and profitability for a period of time depending on product availability, competition reaction
and consumer attitudes. Even if the product liability claim is unsuccessful or is not fully pursued, the negative publicity surrounding
any assertions could adversely impact our reputation with existing and potential customers and our brand image.

 Natural
disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks and terrorist acts in China
and the response of the Chinese governments to such occurrences, could impair our ability to purchase, receive or replenish inventory
or raw materials or cause customer traffic to decline, all of which could result in lost sales and otherwise adversely affect our financial
performance.

 The
occurrence of one or more natural disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change),
unusually adverse weather conditions, pandemic outbreaks (including the outbreak of the coronavirus, or COVID-19) or terrorist acts in
China and the response of the Chinese government to such occurrences, could adversely affect our operations and financial performance.
To the extent these events result in the closure of one or more of our pharmacies, manufacturing facility or our corporate headquarters,
or impact one or more of our key suppliers, our operations and financial performance could be materially adversely affected through lost
sales. Such events could also cause a disruption in travel making it difficult for consumers to order our products, such as has happened
as a result of recent lock-downs in Chengdu. In addition, these events could result in increases in fuel (or other energy) prices or
a fuel shortage, the temporary lack of an adequate work force in a market, the temporary or long-term disruption in the supply of products
from some suppliers, the temporary disruption in the transport of goods, the temporary reduction in the availability of products in our
stores, expiration of inventory and disruption to our information systems.

 We
rely on third parties for the vast majority of our computing, storage, and other services related to our business. Any disruption of
or interference with our use of the services of these third parties would negatively affect our operations and could seriously harm our
business.

 We
rely upon third parties, including cloud based platforms and services, to process and store information and for online interactions with
our customers. Any transition of the cloud services currently provided by the parties we rely upon to other platforms or to another cloud
provider could be difficult to implement and would cause us to incur significant time and expense. Given this, any significant disruption
of or interference with the cloud based services utilized by us, whether temporary, regular, or prolonged, would negatively impact our
operations and our business would be seriously harmed.

 As
we increase the amount of personal and user data we store and process, we may become subject to complex and evolving laws, regulations,
executive actions, rules, contractual obligations, policies, and other obligations regarding privacy, data protection, content, and other
matters. Many of these obligations are subject to change and uncertain interpretations.

 Currently,
we collect, store, and use limited amounts of personal data and other sensitive information. As our business grows and we increase the
amount of such data collect, store and use, we will become subject to a variety of laws, regulations, industry standards, policies, contractual
requirements, executive actions, and other obligations relating to privacy, security, and data protection which are becoming increasingly
stringent and subject to rapid change and uncertain interpretation. Preparing for and complying with these obligations could require
us to devote significant resources. These obligations may necessitate changes to our services, information technologies, systems, and
practices. In addition, these obligations may require us to change our business model.

 Cyber-attacks
could have a disruptive effect on our business.

 From
time to time we and our third-party service providers experience cyber-attacks, attempted and actual breaches of our or their information
technology systems and networks or similar events, which could result in a loss of sensitive business or customer information, systems
interruption or the disruption of our operations. The techniques that are used to obtain unauthorized access, disable or degrade service
or sabotage systems change frequently and may be difficult to detect for long periods of time, we are accordingly unable to anticipate
and prevent all data security incidents.

 Even
if we are fully compliant with legal standards and contractual or other requirements, we still may not be able to prevent security breaches
involving sensitive data. The sophistication of efforts by hackers to gain unauthorized access to information systems has continued to
increase in recent years and may continue to do so. Breaches, thefts, losses or fraudulent uses of customer, employee or company data
could cause consumers to lose confidence in the security of our websites, mobile applications, point of sale systems and other information
technology systems and, as a result of this loss in confidence, choose not to purchase from us. Such security breaches also could expose
us to risks of data loss, business disruption, litigation, fines, regulatory charges and other costs or liabilities, any of which could
adversely affect our business.

 Our
business may be materially adversely affected by global geopolitical conditions resulting from the ongoing Russia-Ukraine conflict and
the Israel-Hamas conflict.

 Global
markets are experiencing volatility and disruption as a result of the geopolitical instability resulting from the ongoing Russia-Ukraine
conflict and the Israel-Hamas conflict. The invasion of Ukraine by Russia and the Israel-Hamas conflict and the resulting measures that
have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and other
countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length
and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility
in commodity prices, credit and capital markets, as well as supply chain interruptions. Additionally, any resulting sanctions could adversely
affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.

 Any
of the abovementioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting
from the Russian invasion of Ukraine, the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect our
business. The extent and duration of the ongoing conflicts, resulting sanctions and any related market disruptions are impossible to
predict, but could be substantial, particularly if current or new sanctions continue for an extended period of time or if geopolitical
tensions result in expanded military operations on a global scale. Any such disruptions may also have the effect of heightening many
of the other risks described in this section. If these disruptions or other matters of global concern continue for an extensive period
of time, our business may be materially adversely affected.

 We
may be impacted by our ability to attract, develop and retain qualified associates and manage labor-related costs.

 We
believe one of our competitive advantages is providing a positive, engaging and satisfying experience for each customer, which requires
us to have highly trained and engaged associates. Our success depends in part upon our ability to attract, develop and retain a sufficient
number of qualified associates to enable us to grow our customer base. The turnover rate in the health and wellness industry is generally
high, and qualified individuals of the requisite caliber and number needed may be in short supply. Competition for such qualified individuals
or changes in labor laws could require us to incur higher labor costs. Our inability to recruit a sufficient number of qualified individuals
may delay the expansion of our customer base and our growth. Significant increases in associate turnover rates or significant increases
in labor-related costs could have a material adverse effect on our results of operations, financial condition and cash flows.

 Large
and similar sized competitors could steal our market share by offering lower prices.

 We
endeavor to provide high quality service to our clients at the best possible price, however, large and similar sized competitors might
steal some of our market share by offering lower prices, causing us to lose some of our clients which could have a material adverse effect
on our results of operations, financial condition and cash flows.

 Our
insurance may not be sufficient.

 We
carry insurance that we consider adequate in regard to the nature of the covered risks and the costs of coverage. We are not fully insured
against all possible risks, nor are all such risks insurable.

 Our
business depends on the continued contributions made by Mr. Quanzhong Lin, our key executive officer. The loss of his services may result
in a severe impediment to our business.

 Our
success is dependent upon the continued contributions made by our CEO and President, Mr. Quanzhong Lin. The Company has no "Key
Man" insurance to cover the resulting losses in the event that any of our officer or directors should die or resign.

 If
Mr. Lin cannot serve the Company or is no longer willing to do so, the Company may not be able to find alternatives in a timely manner
or at all. This would likely result in a severe damage to our business operations and would have an adverse material impact on our financial
position and operational results. To continue as a viable operation, the Company may have to recruit and train replacement personnel
at a higher cost.

 Our
key executive does not devote his full business time to our operations.

 Our
President and Chief Executive Officer, Mr. Quanzhong Lin, is involved in a number of businesses and does not devote all of his working
time to our business. Our positive reputation in Chengdu is derived from the standing of Mr. Lin in the Chengdu business community. If
Mr. Lin does not devote sufficient time to our business, our operations could suffer which would have an adverse material impact on our
financial position and operational results.

 Some
of the other businesses engaged in by Mr. Lin could be deemed competitive with aspects of our business. Should such other businesses
prove more successful than ours, Mr. Lin could choose to focus his attention on such businesses which could cause him to fail to devote
sufficient attention to our business and our operations could suffer and our financial conditions and results of operations may be materially
and adversely affected

 Our
principal shareholder is not familiar with American business practices.

 Mr.
Quanzhong Lin, our founder and principal shareholder, is a citizen of the PRC and an active entrepreneur in Chengdu. Mr. Lin is not familiar
with American business practices and is heavily influenced by the business culture in the PRC. There is a certain level of respect and
prestige associated with being the Chinese principal of a company which is publicly traded in the U.S. Mr. Lin's motivation for
causing the business of AiXinZhongdong to become a part of a U.S. publicly-traded company may differ from those of American entrepreneurs
and his values may cause him to operate the business differently than would an American entrepreneur which could have a material adverse
effect on our results of operations, financial condition and cash flows

 We
may be adversely impacted by certain compliance or legal matters.

 We,
along with third parties with which we do business, are subject to complex compliance and litigation risks. The cost of defending against
claims that might be brought against us or the ultimate resolution of such claims, whether by settlement or adverse court decision, may
harm our business. Further, potential claimants may be encouraged to bring lawsuits based on a settlement from us or adverse court decisions
against us. We cannot currently assess the likely outcome of such suits, but if the outcome were negative, it could have a material adverse
effect on our reputation, results of operations, financial condition and cash flows.

 In
addition, we may be impacted by litigation trends, including class action lawsuits involving consumers and shareholders, that could have
a material adverse effect on our reputation, the market price of our common stock, results of operations, financial condition and cash
flows.

 Failure
to make adequate contributions to various employee benefits plans as required by PRC regulations may subject us to penalties.

 Companies
operating in China are required to participate in various government sponsored employee benefit plans, including certain social insurance,
housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentage of salaries,
including bonuses and allowances, of employees up to a maximum amount specified by the local government from time to time at locations
where they operate their businesses. The requirement of employee benefit plans has not been implemented consistently by the local governments
in China given the different levels of economic development in different locations. Employers that fail to make adequate social insurance
and housing provident fund contributions may be subject to late payment fees, fines and sanctions. If the relevant PRC authorities determine
that we need to make supplemental contributions or that we are subject to late payment fees, fines or other legal sanctions, such as
order of timely rectification, in relation to our failure to make social insurance and housing fund contributions in full for our employees,
our business and financial condition may be adversely affected.

 Our
common stock may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect our auditors. The
delisting of our common stock or the threat of their being delisted, may materially and adversely affect the value of your investment.

 The
HFCAA was enacted on December 18, 2020. The HFCAA, as amended, states if the SEC determines that a company has filed audit reports issued
by a registered public accounting firm that has not been subject to inspection by the PCAOB for two consecutive years beginning in 2021,
the SEC shall prohibit the securities of such company from being traded on a national securities exchange or in the over the counter
trading market in the U.S. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act which,
if enacted, would amend the HFCAA and require the SEC to prohibit an issuer's securities from trading on any U.S. stock exchange
if its auditor is not subject to PCAOB inspections for two consecutive years instead of three.

 On
March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements
of the HFCAA. A company will be required to comply with these rules if the SEC identifies it as having a "non-inspection"
year under a process to be subsequently established by the SEC. The SEC is assessing how to implement other requirements of the HFCAA,
including the listing and trading prohibition requirements described above. On September 22, 2021, the PCAOB adopted a final rule implementing
the HFCAA, which provides a framework for the PCAOB to use when determining whether the PCAOB is unable to inspect or investigate completely
registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.

 On
December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the HFCAA. The
rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public
accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a
position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued a Determination Report which found that
the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in: (i) China, and (ii) Hong
Kong. On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol, or the Protocol,
governing inspections and investigations of audit firms based in China and Hong Kong. Pursuant to the Protocol, the PCAOB shall have
independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information
to the SEC. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely our auditor's work papers
in China, you may be deprived of the benefits of such inspection which could result in limitation or restriction to our access to the
U.S. capital markets and trading of our securities may be prohibited under the HFCAA and the Nasdaq may determine to delist our securities
if the PCAOB determines that it cannot inspect or investigate completely our auditor under the HFCAA.

 Our
auditor is not headquartered in China or Hong Kong and was not identified in this report as a firm subject to the PCAOB's determination.

 The
SEC may propose additional rules or guidance that could impact us if our auditor is not subject to PCAOB inspection. For example, on
August 6, 2020, the President's Working Group on Financial Markets, or the PWG, issued the Report on Protecting United States Investors
from Significant Risks from Chinese Companies to the then President of the United States. This report recommended the SEC implement five
recommendations to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfil its statutory
mandate. Some of the concepts of these recommendations were implemented with the enactment of the HFCAA. However, some of the recommendations
were more stringent than the HFCAA. For example, if a company's auditor was not subject to PCAOB inspection, the report recommended
that the transition period before a company would be delisted would end on January 1, 2022.

 The
SEC has announced that the SEC staff is preparing a consolidated proposal for the rules regarding the implementation of the HFCAA and
to address the recommendations in the PWG report. The implications of possible additional regulation in addition to the requirements
of the HFCAA and what was recently adopted on December 2, 2021 are uncertain. While we understand that there has been dialogue among
the CSRC, the SEC and the PCAOB regarding the inspection of PCAOB-registered accounting firms in China, there can be no assurance that
we will be able to comply with requirements imposed by U.S. regulators. Such uncertainty could cause the market price of our common stock
to be materially and adversely affected.

 A
joint statement by the SEC and the Public Company Accounting Oversight Board (United States), or the "PCAOB," the newly enacted
"Holding Foreign Companies Accountable Act" and the " Accelerating Holding Foreign Companies Accountable Act "
 all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of
their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to the
market for our common stock.

 On
April 21, 2020, the SEC and the PCAOB released a joint statement highlighting the risks associated with investing in companies based
in or having substantial operations in emerging markets including China. The joint statement emphasized the risks associated with lack
of access for the PCAOB to inspect auditors and audit work papers in China and higher risks of fraud in emerging markets.

 On
December 18, 2020, the HFCAA was signed and became law. This legislation requires certain issuers of securities to establish that they
are not owned or controlled by a foreign government. Specifically, an issuer must make this certification if the PCAOB is unable to audit
specified reports because the issuer has retained a foreign public accounting firm not subject to inspection by the PCAOB. Furthermore,
if the PCAOB is unable to inspect the issuer's public accounting firm for three consecutive years, the issuer's securities
are banned from trading on a national exchange or through other methods. On December 29, 2022, the AHFCAA was enacted, which amended
the HFCAA by decreasing the number of non-inspection years from three years to two, thus reducing the time period before our common stock
may be prohibited from trading or delisted if the PCAOB were to determine that it could not inspect our auditor.

 On
March 24, 2021, the SEC announced that it had adopted interim final amendments to implement congressionally mandated submission and disclosure
requirements of the HFCAA. The interim final amendments will apply to registrants that the SEC identifies as having filed an annual report
on Forms 10-K, 20-F, 40-F or N-CSR with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction
and that the PCAOB has determined it is unable to inspect or investigate completely because of a position taken by an authority in that
jurisdiction. The SEC will implement a process for identifying such a registrant and any such identified registrant will be required
to submit documentation to the SEC establishing that it is not owned or controlled by a governmental entity in that foreign jurisdiction,
and will also require disclosure in the registrant's annual report regarding the audit arrangements of, and governmental influence
on, such a registrant.

 On
September 22, 2021, the PCAOB adopted rules to create a framework for the PCAOB to use when determining, as contemplated under the HFCAA,
whether it is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because
of a position taken by one or more authorities in that jurisdiction.

 On
December 2, 2021, the SEC issued amendments to finalize the interim final rules previously adopted in March 2021 to implement the submission
and disclosure requirements in the HFCAA. The rules apply to registrants that the SEC identifies as having filed an annual report with
an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable
to inspect or investigate completely because of a position taken by an authority in a foreign jurisdiction.

 On
December 16, 2021, the PCAOB issued a Determination Report which found that the PCAOB was then unable to inspect or investigate completely
registered public accounting firms headquartered in: (1) mainland China of the People's Republic of China, because of a position
taken by one or more authorities in mainland China; and (2) Hong Kong, a Special Administrative Region and dependency of the PRC, because
of a position taken by one or more authorities in Hong Kong. The PCAOB has made such designations as mandated under the HFCAA. Pursuant
to each annual determination by the PCAOB, the SEC will, on an annual basis, identify issuers that have used non-inspected audit firms
and thus are at risk of such suspensions in the future.

 On
August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol, or the Protocol, governing
inspections and investigations of audit firms based in China and Hong Kong. Pursuant to the Protocol, the PCAOB shall have independent
discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the
SEC. On December 15, 2022, the PCAOB determined that the PCAOB was able to secure complete access to inspect and investigate registered
public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary.
However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB's access in the future, the PCAOB will consider
the need to issue a new determination. Notwithstanding the foregoing, if the PCAOB is not able to inspect and investigate completely
our auditor's work papers in China, you may be deprived of the benefits of such inspection which could result in limitation or
restriction to our access to the U.S. capital markets and trading of our securities may be prohibited under the HFCAA.

 Our
auditor, KCCW Accountancy Corp. ("KCCW CPA"), an independent public accounting firm registered with the PCAOB, and an auditor
of publicly traded companies in the U.S., is subject to laws in the U.S. pursuant to which the PCAOB conducts regular inspections to
assess its compliance with the applicable professional standards. Our auditor is based in the United States and has been inspected by
the PCAOB on a regular basis, with the last inspection in 2022. Our auditor is not headquartered in mainland China or Hong Kong and was
not identified as a firm subject to the determinations announced by the PCAOB on December 16, 2021. Nevertheless, should the PCAOB be
unable to fully conduct inspection of our auditor's work papers in China, it will make it difficult to evaluate the effectiveness
of our auditor's audit procedures or equity control procedures. Investors may consequently lose confidence in our reported financial
information and procedures or quality of the financial statements, which would adversely affect us and our securities. Moreover, if trading
in our securities is prohibited under the HFCAA in the future because the PCAOB determines that it cannot inspect or fully investigate
our auditor at such future time, if our securities were then traded on an exchange, that exchange may determine to delist our securities.

 There
are uncertainties under the PRC Securities Law relating to the procedures and requisite timing for the U.S. securities regulatory agencies
to conduct investigations and collect evidence within the territory of the PRC.

 On
December 28, 2019, the newly amended Securities Law of the PRC (the "PRC Securities Law") was promulgated, which became effective
on March 1, 2020. According to Article 177 of the PRC Securities Law ("Article 177"), the securities regulatory authority
of the State Council may establish a regulatory cooperation mechanism with securities regulatory authorities of another country or region
for the implementation of cross-border supervision and administration. Article 177 further provides that overseas securities regulatory
authorities shall not engage in activities pertaining to investigations or evidence collection directly conducted within the territories
of the PRC, and that no Chinese entities or individuals shall provide documents and information in connection with securities business
activities to any organizations and/or persons aboard without the prior consent of the securities regulatory authority of the State Council
and the competent departments of the State Council. As of the date of this prospectus, we are not aware of any implementing rules or
regulations which have been published regarding application of Article 177.

 Article
177 is only applicable where the activities of overseas authorities constitute a direct investigation or evidence collection by such
authorities within the territory of the PRC. Our principal business operation is conducted in the PRC. In the event that the U.S. securities
regulatory agencies carry out an investigation on us such as an enforcement action by the Department of Justice, the SEC or other authorities,
such agencies' activities will constitute conducting an investigation or collecting evidence directly within the territory of the
PRC and accordingly fall within the scope of Article 177. In that case, the U.S. securities regulatory agencies may have to consider
establishing cross-border cooperation with the securities regulatory authority of the PRC by way of judicial assistance, diplomatic channels
or establishing a regulatory cooperation mechanism with the securities regulatory authority of the PRC. However, there is no assurance
that the U.S. securities regulatory agencies will succeed in establishing such cross-border cooperation in this particular case and/or
establish such cooperation in a timely manner.

 Furthermore,
there have not been implementing rules or regulations regarding the application of Article 177, and it remains unclear as to how it will
be interpreted, implemented or applied by the Chinese Securities Regulatory Commission or other relevant government authorities. As such,
there are uncertainties as to the procedures and requisite timing for the U.S. securities regulatory agencies to conduct investigations
and collect evidence within the territory of the PRC. If the U.S. securities regulatory agencies are unable to conduct such investigations,
there exists a risk that they may determine to suspend or de-register our registration with the SEC and may also delist our securities
from any applicable trading market within the US.

 We
could be subject to conflicting demands placed upon us by regulatory authorities in the United States and the PRC which could result
in disciplinary actions if not resolved.

 Article
26 of the Trial Measures issued by the CSRC on February 17, 2023 came into effect on March 31, 2023. Article 26 provides that if an overseas
securities regulatory agency intends to conduct an investigation and collect evidence regarding an overseas offering or listing activities
by a domestic company, and request assistance of the CSRC under relevant cross-border securities regulatory cooperation agreements, the
CSRC may provide necessary assistance in accordance with the laws of the PRC. Any domestic entity or individual intending to provide
documents and materials requested by an overseas securities regulatory agency in connection with an investigation may not provide such
information without prior approval from the CSRC and competent authorities under the State Council. In addition, Article 11 of the Provisions
on Strengthening Confidentiality and Archives Administration in Respect of Overseas Issuance and Listing of Securities by Domestic Enterprises
which was jointly issued by the CSRC, the Ministry of Finance, the State Secrecy Administration and the State Archives Bureau on February
24, 2023 came into effect on March 31, 2023, and provides that, when an overseas securities regulator and the relevant competent authorities
intends to conduct inspections or investigations to collect evidence from a domestic enterprise and any domestic securities firms and
securities service agencies providing services regarding the overseas offering and listing activities of the domestic enterprise, the
inspection or investigation shall be carried out under the appropriate cross-border regulatory cooperation agreement, and the CSRC or
the relevant authorities shall provide the requisite assistance pursuant to the bilateral and multilateral cooperation mechanism. Further,
any domestic company, securities firm and securities service agency shall obtain the consent of the CSRC or the relevant administrative
authorities prior to cooperating in an inspection or investigation carried out by an overseas securities regulator or relevant administrative
authorities or providing documents and materials for cooperating in the inspection or investigation.

 As
this regulation has recently been adopted, clarifying regulations have not been issued and companies in China and their counsel generally
have little experience in assessing when permission must be obtained before releasing information to a foreign regulatory agency. If
the Company were to provide information to any securities regulatory agency in violation of Article 26 or Article 11, it would be subject
to fines and, if the information were deemed a state secret, government work secret or might jeopardize the national security of China
or the public interest, as provided in the Confidentiality and Archives Provisions, it could cause the Company or the individuals responsible
for the disclosure to be subject to criminal investigation. Likewise, if the Company refuses to provide information requested by any
U.S. securities regulatory agency in circumstances that the Company believes would have caused it to violate Article 26 or Article 11,
it will be subject in the United States to fines, penalties. While detailed interpretation of or implementation rules under Article 177,
of Article 26 and Article 11 have yet to be promulgated, the inability of an overseas securities regulator to directly conduct an investigation
or evidence collection activities within China may further increase difficulties that you may face in protecting your interests.

 We
are exposed to liabilities relating to environmental protection and safety laws and regulations.

 Our
operations are subject to comprehensive and frequently changing laws and regulations relating to environmental protection and health
and safety. The discharge of waste and pollutants from our manufacturing operations into the environment may give rise to liabilities
that may require us to incur costs to remedy such discharge. If we violate such laws or regulations, we may be required to implement
corrective actions and could be subject to civil or criminal fines or penalties or other sanctions.

 However,
we cannot assure you that any environmental laws adopted in the future will not materially increase our operating costs and other expenses.
We cannot assure you that we will not have to make significant capital or operating expenditures in the future in order to comply with
existing or new laws and regulations or that we will comply with applicable environmental laws at all times. Such violations or liability
could have a material adverse effect on our business, financial condition and results of operations.

 We
may require additional financing and our operations could be curtailed if we are unable to obtain required additional financing when
needed.

 We
may need to obtain additional debt or equity financing to fund the immediate development of Yunnan Runcangsheng and future capital expenditures.
While we do not anticipate seeking additional financing in the immediate future, any the issuance of additional equity securities may
result in dilution to the holders of our outstanding shares of capital stock. Additional debt financing may include conditions that would
restrict our freedom to operate our business, such as conditions that:

 limit
 our ability to pay dividends or require us to seek consent for the payment of dividends;

 increase
 our vulnerability to general adverse economic and industry conditions;

 require
 us to dedicate a portion of our cash flow from operations to payments on our debt, thereby reducing the availability of our cash
 flow to fund capital expenditures, working capital and other general corporate purposes; and

 limit
 our flexibility in planning for, or reacting to, changes in our business and our industry.

 We
cannot guarantee that we will be able to obtain any additional financing on terms that are acceptable to us, or at all.

 General
Risks Associated with Business Operations in China

 The
PRC government has significant oversight and discretion over the conduct of a PRC company's business operations or to exert control
over any offering of securities conducted overseas and/or foreign investment in China-based issuers, and may intervene with or influence
our operations, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value
of such securities to significantly decline or become worthless, as the government deems appropriate to further regulatory, political
and societal goals.

 The
PRC government may intervene or influence our operations at any time, which could result in a material change in our operations and/or
the value of our common stock. For example, the PRC government has recently published new policies that significantly affected certain
industries such as the education and internet industries, and we cannot rule out the possibility that the PRC government will release
regulations or policies regarding any industry that could adversely affect the business, financial condition and results of operations
of our company. Furthermore, the PRC government has also recently indicated an intent to exert more oversight and control over securities
offerings and other capital markets activities that are conducted overseas and foreign investment in China-based companies. Any such
action, once taken by the PRC government, could significantly limit or completely hinder our ability to offer or continue to offer securities
to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless.

 The
PRC government initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice,
including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas
using variable interest entity ("VIE") structures, adopting new measures to extend the scope of cybersecurity reviews and
expanding anti-monopoly enforcement efforts. These statements and regulatory actions have yet to have an impact on our daily business
operations, the ability to accept foreign investments or list our securities on a U.S. or other foreign exchange. Since these statements
and regulatory actions are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and
what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and
the potential impact such modified or new laws and regulations will have on our daily business operation, the ability to accept foreign
investments and list our securities on an U.S. or other foreign exchange.

 The
CSRC has released draft rules for China-based companies seeking to conduct initial public offerings in foreign markets. The Chinese government
may exert more oversight and control over offerings that are conducted overseas and foreign investment in China-based issuers, which
could significantly limit or completely hinder our ability to offer or continue to offer our common stock to investors and could cause
the value of our common stock to significantly decline or become worthless.

 On
December 24, 2021, the CSRC released the Administrative Provisions of the State Council Regarding the Overseas Issuance and Listing of
Securities by Domestic Enterprises (Draft for Comments) (the "Administrative Provisions") and the Measures for the Overseas
Issuance of Securities and Listing Record-Filings by Domestic Enterprises (Draft for Comments) (the "Measures"). The Administrative
Provisions and Measures lay out the filing regulation arrangement for both direct and indirect overseas listing and clarify the determination
criteria for indirect overseas listing in overseas markets. The Administrative Provisions and Measures, if enacted, may subject us to
additional compliance requirement in the future. Any failure of us to fully comply with new regulatory requirements may significantly
limit or completely hinder our ability to offer or continue to offer our common stock, cause significant disruption to our business operations,
and severely damage our reputation, which would materially and adversely affect our financial condition and results of operations and
cause our common stock shares to significantly decline in value or become worthless.

 The
CSRC has released the Trial Measures requiring Chinese domestic companies to complete filings with the CSRC if they complete an overseas
offering and listing of their securities.

 The
Trial Measures, regulations for the filing-based administration of direct and indirect overseas securities offerings and listings by
domestic companies incorporated in Mainland China went into effect on March 31, 2023. We anticipate that as a domestic Chinese operating
company with securities listed in the U. S., we will be required to make filings pursuant to the Trial Measures. Any
filings we make in accordance with the Trial Measures will provide the Chinese Government with information regarding our operations.
Reviewing information we provide may cause the PRC government to exert oversight and control over our operations, securities offerings
and other capital markets activities. Any such action could significantly limit or completely hinder our ability to offer or continue
to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless.

 The
CSRC has released Provisions on Strengthening the Confidentiality and Archives Administration Related to the Overseas Securities Offering
and Listing by Domestic Enterprises which may limit the activities of or disclosures made by companies in the PRC which, directly or
indirectly, list their securities overseas.

 The
Confidentiality and Archives Provisions, which went into effect March 31, 2023, require, among other items, that PRC domestic enterprises
seeking to offer and list securities in overseas markets, establish an archival system which will maintain the confidentiality of information
in accordance with applicable laws and regulations. Further, if a PRC domestic enterprise plans, directly or indirectly, to release documents
or provide material that contain state secrets or government work secrets, or that will jeopardize national security or the public interest,
it must strictly comply with all relevant governmental procedures and obtain approval of the appropriate regulatory before doing so.
Although we are subject to the Confidentiality and Archives Provisions, we believe that none of the documents or materials we intend
to provide to parties outside of the PRC contains materials that would require us to make any filing or obtain any approval of a Chinese
regulatory authority. Nevertheless, the determination of whether information contains state secrets, government work secrets or jeopardizes
national security or the public interest is subjective and any failure or perceived failure by us or our subsidiaries to comply with
the confidentiality and archive administration requirements under the Confidentiality and Archives Provisions could cause us to be referred
for criminal investigation and held liable for such violations by the authorities in China. Further, PRC regulatory authorities could
use these regulations to limit our disclosures or interfere with our operations. Any determination that we have violated the Confidentiality
and Archives Provisions or use of these provisions to limit our disclosures could cause the value of our common stock to significantly
decline in value or become worthless.

 You
may have difficulty in effecting service of legal process or bringing actions in China against us or our management based on foreign
laws.

 We
are a Colorado holding company which conducts our operations in China through wholly owned subsidiaries with direct equity ownership
and most of our assets are and will be located outside the United States. Almost all of our operations will be conducted in China. In
addition, nearly all of our officers and directors, including Quanzhong Lin, Huiliang Jiao and Tianfeng Li are PRC nationals and residents
of China and all of their assets are located outside the United States. In addition, Yao-Te Wang is a resident of Taiwan and resides
in Taiwan. Christopher Lee, our remaining director, resides outside of the United States for a significant portion of time. As a result,
it may be difficult for you to effect service of process upon us or our directors and officers inside China or to bring actions against
us or our management in China.

 Shareholder
claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue
as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining information
needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities
in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to
implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the
Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article 177 of the
PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct an investigation
or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators
and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities
to overseas parties outside of the PRC.

 You
may have difficulty in enforcing foreign judgements in China against us or our management.

 China
does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States and many
other countries and regions. Even judgements from countries that have an enforcement treaty with China are often not enforceable in China.
Therefore, recognition and enforcement in China of judgments of a court in any non-PRC jurisdiction in relation to any matter not subject
to a binding arbitration provision may be difficult or impossible. It may also be difficult for you to enforce U.S. courts judgments
based on violations of the civil liability provisions of the U.S. federal securities laws against us and our officers and directors,
since most of them are residents of the PRC and those who are not residents of the PRC reside outside of the United States for all or
a significant portion of time. In addition, there is uncertainty as to whether the courts of China would recognize or enforce judgments
of U.S. courts.

 Foreign
exchange fluctuations may affect our business.

 The
functional currency utilized by our PRC Subsidiaries is the RMB and we accept payment for our products in RMB. Therefore, foreign exchange
fluctuations may influence our business in unpredictable ways.

 The
value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political
and economic conditions and the foreign exchange policy adopted by the PRC government. For instance, in August 2015, the People's
Bank of China, or PBOC, changed the way it calculates the mid-point price of Renminbi against the U.S. dollar, requiring the market-makers
who submit for reference rates to consider the previous day's closing spot rate, foreign-exchange demand and supply as well as
changes in major currency rates. In fiscal year 2019 and 2020, the value of the Renminbi depreciated by approximately 6.9% and 5.5% against
the U.S. dollar, respectively. In fiscal year 2021 and 2022 the value of the Renminbi appreciated by approximately 7.4% and 3.2% against
the U.S. dollar. It is difficult to predict how market forces or PRC or U.S. government policy, including any interest rate increases
by the Federal Reserve, may impact the exchange rate between the Renminbi and the U.S. dollar in the future. There remains significant
international pressure on the PRC government to adopt a more flexible currency policy, including from the U.S. government, which has
threatened to label China as a "currency manipulator," which could result in greater fluctuation of the Renminbi against
the U.S. dollar.

 A
substantial percentage of our revenues and costs are denominated in Renminbi, and a significant portion of our assets are also denominated
in Renminbi. We are a holding company and we rely on dividends, loans and other distributions on equity paid by our operating subsidiaries
in China. Any significant fluctuations in the value of the Renminbi may materially and adversely affect our liquidity and cash flows.
Appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount we would receive. Conversely,
to the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar
would have an adverse effect on the Renminbi amount we would receive.

 Inflation
could pose a risk to our business.

 Inflation
is an important factor that must be considered as we move forward. A change in the rate of inflation could influence the profits that
we generate from our business. When the rate of inflation rises, the operational costs of running our company would increase, such as
labor costs, raw materials and public utilities, affecting our ability to provide our services at competitive prices. An increase in
the rate of inflation would force our clients to search for other service providers, causing us to lose business and revenue.

 Changes
in the policies, regulations, rules and the enforcement of laws of the PRC government may be quick with little advance notice and could
have a significant impact upon the business we may be able to conduct in the PRC and the profitability of such business.

 The
PRC's economy is in a transition from a planned economy to a market oriented economy subject to five-year and annual plans adopted
by the central government that set national economic development goals. Policies of the PRC government can have significant effects on
the economic conditions of the PRC. The PRC government has confirmed that economic development will follow the model of a market economy.
Under this direction, we believe that the PRC will continue to strengthen its economic and trading relationships with foreign countries
and business development in the PRC will follow market forces. While we believe that this trend will continue, we cannot assure you that
this will be the case. Changes in policies, regulations, rules and the enforcement of laws by the PRC government, which changes may be
quick with little advance notice, could adversely affect our interests by. Although the PRC government has been pursuing economic reform
policies for more than two decades, we cannot assure you that the government will continue to pursue such policies or that such policies
may not be significantly altered, especially in the event of a change in leadership, social or political disruption, or other circumstances
affecting the PRC's political, economic and social environment.

 There
are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.

 Most
of our operations are conducted in the PRC and are governed by PRC laws, rules and regulations. Our PRC Subsidiaries are subject to laws,
rules and regulations applicable to foreign investment in China. The PRC legal system is a civil law system based on written statutes.
Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value.

 In
1979, the PRC government began to promulgate a comprehensive system of laws, rules and regulations governing economic matters in general.
However, China has not developed a fully integrated legal system, and recently enacted laws, rules and regulations may not sufficiently
cover all aspects of economic activities in China or may be subject to significant degree of interpretation by PRC regulatory agencies
and courts. In particular, because these laws, rules and regulations are relatively new, and because of the limited number of published
decisions and the non-precedential nature of these decisions, and because the laws, rules and regulations often give the relevant regulator
significant discretion in how to enforce them, the interpretation and enforcement of these laws, rules and regulations involve uncertainties
and can be inconsistent and unpredictable. Therefore, it is possible that our existing operations may be found not to be in full compliance
with relevant laws and regulations. In addition, the PRC legal system is based in part on government policies and internal rules, some
of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of
our violation of these policies and rules until after the occurrence of the violation.

 Any
administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management
attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and
contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection
we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce the contracts we have entered into
and could materially and adversely affect our business, financial condition and results of operations.

 PRC
regulations regarding acquisitions impose significant regulatory approval and review requirements, which could make it more difficult
for us to pursue growth through acquisitions.

 Under
the PRC Anti-Monopoly Law, companies undertaking acquisitions relating to businesses in China must notify the anti-monopoly enforcement
agency in advance of any transaction where the parties' revenues in the China market exceed certain thresholds and the buyer would
obtain control of, or decisive influence over, the other party. In addition, on August 8, 2006, six PRC regulatory agencies, including
the MOFCOM, the State-Owned Assets Supervision and Administration Commission, the State Administration of Taxation, the SAIC, the China
Securities Regulatory Commission, or the CSRC, and the State Administration of Foreign Exchange, or SAFE, jointly adopted Regulations
on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&A Rules, which came into effect on September 8,
2006 and was amended on June 22, 2009. Under the M&A Rules, the approval of MOFCOM must be obtained in circumstances where overseas
companies established or controlled by PRC enterprises or residents acquire domestic companies affiliated with such PRC enterprises or
residents. Applicable PRC laws, rules and regulations also require certain merger and acquisition transactions to be subject to security
review.

 Our
business may be subject to a variety of PRC laws and other obligations regarding cybersecurity and data protection.

 Our
business may be subject to PRC laws relating to the collection, use, sharing, retention, security, and transfer of confidential and private
information, such as personal information and other data. These laws continue to develop, and the PRC government may adopt other rules
and regulations in the future. Non-compliance could result in penalties or other significant legal liabilities.

 Pursuant
to the PRC Cybersecurity Law, which was promulgated by the Standing Committee of the National People's Congress on November 7,
2016 and took effect on June 1, 2017, personal information and important data collected and generated by a critical information infrastructure
operator in the course of its operations in China must be stored in China, and if a critical information infrastructure operator purchases
internet products and services that affects or may affect national security, it should be subject to cybersecurity review by the Cyberspace
Administration of China ("CAC"). Due to the lack of further interpretations, the exact scope of "critical information
infrastructure operator" remains unclear.

 On
December 28, 2021, twelve Chinese government agencies jointly promulgated the Measures for Cybersecurity Review, which became effective
February 15, 2022, set forth the cybersecurity review mechanism for critical information infrastructure operators, and provided that
critical information infrastructure operators who intend to purchase internet products and services that affect or may affect national
security shall be subject to a cybersecurity review. On June 10, 2021, the Standing Committee of the National People's Congress
promulgated the PRC Data Security Law, which took effect in September 2021. The Data Security Law provides for a security review procedure
for data activities that may affect national security. Moreover, the State Internet Information Office issued the Measures of Cybersecurity
Review (Revised Draft for Comments, not yet effective) on July 10, 2021, which requires operators with personal information of more than
1 million users who want to list abroad to file a cybersecurity review with the CAC. Furthermore, the General Office of the Central Committee
of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Severe and Lawful Crackdown
on Illegal Securities Activities, which was available to the public on July 6, 2021. These opinions emphasized the need to strengthen
the administration over illegal securities activities and the supervision of overseas listings by China-based companies. These opinions
proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents
facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. As these laws, opinions and
the draft measures were recently issued, official guidance and interpretation of these remain unclear in several respects at this time,
and the PRC government authorities have wide discretion in the interpretation and enforcement of these laws, opinions and draft measures.
Therefore, it is uncertain whether the future regulatory changes would impose additional restrictions on our business

 The
Data Security Law also sets forth the data security protection obligations for entities and individuals handling personal data, including
that no entity or individual may acquire such data by stealing or other illegal means, and the collection and use of such data should
not exceed the necessary limits. The costs of compliance with, and other burdens imposed by, PRC Cybersecurity Law and any other cybersecurity
and related laws may limit the utility of our internet sales channel of distribution and could have an adverse impact on our business.
Further, if the enacted version of the Measures for Cybersecurity Review mandates clearance of cybersecurity review and other specific
actions to be completed by companies like us, we face uncertainties as to whether such clearance can be timely obtained, or at all.

 There
remains uncertainty as to how the Draft Measures will be interpreted or implemented and whether the PRC regulatory agencies, including
the CAC, may adopt new laws, regulations, rules, or detailed implementation and interpretation related to the Draft Measures. If any
such new laws, regulations, rules, or implementation and interpretation comes into effect, we will take all reasonable measures and actions
to comply and to minimize the adverse effect of such laws on us.

 We
cannot assure you that PRC regulatory agencies, including the CAC, would take the same view as we do, and there is no assurance that
we can fully or timely comply with such laws. In the event that we are subject to any mandatory cybersecurity review and other specific
actions required by the CAC, we face uncertainty as to whether any clearance or other required actions can be timely completed, or at
all. Given such uncertainty, we may be further required to shut down our website, or face other penalties, which could materially and
adversely affect our business, financial condition, and results of operations.

 PRC
regulations relating to investments in offshore companies by PRC residents may subject our PRC-resident beneficial owners or our PRC
Subsidiaries to liability or penalties, limit our ability to inject capital into our PRC Subsidiaries or limit our PRC Subsidiaries'
ability to increase their registered capital or distribute profits.

 SAFE
promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment and
Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37, on July 4, 2014, which replaced the former
circular commonly known as "SAFE Circular 75." SAFE Circular 37 requires PRC residents to register with local branches of
SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment
and financing, with such PRC residents' legally owned assets or equity interests in domestic enterprises or offshore assets or
interests, referred to in SAFE Circular 37 as a "special purpose vehicle." SAFE Circular 37 further requires amendment to
the registration in the event of any significant changes with respect to the special purpose vehicle, such as changes in capital contributed
by PRC individuals, share transfers or exchanges, mergers, divisions or other material events. In the event that a PRC shareholder holding
interests in a special purpose vehicle fails to fulfill the required SAFE registration, the PRC Subsidiaries of that special purpose
vehicle may be prohibited from making profit distributions to the offshore parent and from carrying out subsequent cross-border foreign
exchange activities, and the special purpose vehicle may be restricted in its ability to contribute additional capital into its PRC Subsidiaries.
Moreover, failure to comply with the various SAFE registration requirements could result in liability under PRC law for evasion of foreign
exchange controls.

 As
we have little control over the registration procedures, we cannot assure you of the outcome of such registration, and we cannot assure
you that any of our shareholders who are PRC residents will submit the required registration or amend or update their registration as
required under Circular 37 and the Notice of the State Administration of Foreign Exchange on Further Simplifying and Improving the Foreign
Exchange Administration Policies for Direct Investment [Hui Fa (2015) No.13] issued by SAFE with effect from June 1, 2015, or SAFE Notice
13, in a timely manner or at all. In addition, we may not be aware of the identities of all of our beneficial owners who are PRC residents.
We do not have control over our beneficial owners and cannot assure you that all of our PRC-resident beneficial owners will comply with
SAFE Circular 37 and subsequent implementation rules. The failure of our current and future beneficial owners who are PRC residents to
register or amend their SAFE registrations in a timely manner pursuant to SAFE Circular 37 and subsequent implementation rules, may subject
the beneficial owners or our PRC Subsidiaries to fines and legal sanctions. On February 13, 2015, SAFE promulgated a Notice on Further
Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June
1, 2015. Pursuant to SAFE Notice 13, entities and individuals are required to apply for foreign exchange registration of foreign direct
investment and overseas direct investment, including those required under the SAFE Circular 37, with designated domestic banks, instead
of SAFE. The designated domestic banks will directly review the applications and conduct the registration.

 Furthermore,
since it is unclear how the new SAFE regulations, and any future regulation concerning offshore or cross-border transactions, will be
interpreted, amended and implemented by the relevant PRC government authorities, we cannot predict how these regulations will affect
our business operations or future strategy. Failure to register or comply with relevant requirements may also limit our ability to contribute
additional capital to our PRC Subsidiaries and limit our PRC Subsidiaries' ability to distribute dividends to our company. These
risks may have a material adverse effect on our business, financial condition and results of operations.

 We
may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law, and we may therefore be subject
to PRC income tax on our global income.

 Under
the PRC Enterprise Income Tax Law and its implementing rules, both of which came into effect on January 1, 2008, enterprises established
under the laws of jurisdictions outside of China with "de facto management bodies" located in China may be considered PRC
tax resident enterprises for tax purposes and may be subject to the PRC enterprise income tax at the rate of 25% on their global income.
"De facto management body" refers to a managing body that exercises substantive and overall management and control over the
production and business, personnel, accounting books and assets of an enterprise. The State Administration of Taxation issued the Notice
Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as PRC Tax Resident Enterprises on the basis of de
facto management bodies, or Circular 82, on April 22, 2009. Circular 82 provides certain specific criteria for determining whether the
"de facto management body" of a Chinese-controlled offshore-incorporated enterprise is located in China. Although Circular
82 only applies to offshore enterprises controlled by PRC enterprises, not those controlled by foreign enterprises or individuals, the
determining criteria set forth in Circular 82 may reflect the State Administration of Taxation's general position on how the "de
facto management body" test should be applied in determining the tax resident status of offshore enterprises, regardless of whether
they are controlled by PRC enterprises. If we, AiXin Colorado and AiXin BVI, were to be considered a PRC resident enterprise, we would
be subject to PRC enterprise income tax at the rate of 25% on our global income. In such case, our profitability and cash flow may be
materially reduced as a result of our global income being taxed under the Enterprise Income Tax Law. We believe that none of our entities
outside of China is a PRC resident enterprise for PRC tax purposes. However, the tax resident status of an enterprise is subject to determination
by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term "de facto management body."

 Restrictions
on currency exchange may limit our ability to utilize our PRC revenue effectively.

 We
are a holding company with no material operations of our own. We conduct substantially all of our operations through the operating companies
established in the PRC. Substantially all of our revenue is denominated in Renminbi. The Renminbi is currently convertible under the
"current account," which includes dividends, trade and service-related foreign exchange transactions, but requires approval
from or registration with appropriate government authorities or designated banks under the "capital account," which includes
foreign direct investment and loans, including loans we may secure from our onshore subsidiaries. The relevant PRC governmental authorities
or the local bank may limit or eliminate our ability to purchase foreign currencies in the future for current account transactions.

 Since
2016, PRC governmental authorities have imposed more stringent restrictions on outbound capital flows, including heightened scrutiny
over "irrational" overseas investments for certain industries, as well as over four kinds of "abnormal" offshore
investments, which are:

investments through enterprises established for only a few months without substantive operation;

investments with amounts far exceeding the registered capital of the onshore parent and not supported by its business performance shown
on financial statements;

investments in targets which are unrelated to an onshore parent's main business; and

investments with abnormal sources of Renminbi funding suspected to be involved in illegal transfer of assets or illegal operation of
underground banking.

 On
January 26, 2017, SAFE promulgated the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness
and Compliance Verification, which tightened the authenticity and compliance verification of cross-border transactions and cross-border
capital flow, including requiring banks to verify board resolutions, tax filing forms and audited financial statements before wiring
foreign invested enterprises' foreign exchange dividend distribution of over US$50,000. In addition, the Outbound Investment Sensitive
Industry Catalogue (2018) lists certain sensitive industries that are subject to NDRC pre-approval requirements prior to remitting investment
funds offshore, which subjects us to increased approval requirements and restrictions should we have overseas investments. Since a significant
amount of our PRC revenue is denominated in Renminbi, any existing and future restrictions on currency exchange may limit our ability
to utilize revenue generated in Renminbi to fund our business activities outside of the PRC, make investments, service any debt we may
incur outside of China or pay dividends in foreign currencies to our shareholders.

 Fluctuations
in foreign exchange rates will impact our reported results.

 The
functional currency utilized by our PRC Subsidiaries is the RMB. Our financial results are reported in U.S. Dollars. Therefore, foreign
exchange fluctuations will impact the reporting of our financial results and significant fluctuations in the value of the RMB relative
to the U.S. Dollar may materially and adversely affect our financial results as reported in our filings with the SEC. Such variations
in our perceived operating results may increase the volatility in the market for our common stock.

 The
disclosures in our reports and other filings with the SEC and our other public pronouncements are not subject to the scrutiny of any
regulatory bodies in the PRC.

 We
are subject to the regulations of the SEC and our reports and other filings with the SEC are subject to SEC review in accordance with
the rules and regulations promulgated by the SEC under the Securities Act and the Exchange Act. Our SEC reports and other disclosure
and public pronouncements are not subject to the review or scrutiny of any PRC regulatory authority. For example, the disclosure in our
SEC reports and other filings are not subject to the review by China Securities Regulatory Commission, a PRC regulator that is responsible
for oversight of the capital markets in China. Accordingly, you should review our SEC reports, filings and our other public pronouncements
with the understanding that no local regulator has done any review of us, our SEC reports, other filings or any of our other public pronouncements.

 Introduction
of new laws or changes to existing laws by the PRC government may adversely affect our business.

 The
PRC legal system is a codified legal system made up of written laws, regulations, circulars, administrative directives and internal guidelines.
Unlike common law jurisdictions like the U.S., decided cases (which may be taken as reference) do not form part of the legal structure
of the PRC and thus have no binding effect on subsequent cases with similar issues and fact patterns. Furthermore, in line with its transformation
from a centrally-planned economy to a more free market-oriented economy, the PRC government is still in the process of developing a comprehensive
set of laws and regulations. As the legal system in the PRC is still evolving, laws and regulations or the interpretation of the same
may be subject to further changes. For example, the PRC government may impose more stringent environmental regulations which would affect
our ability to comply with, or our costs to comply with, such regulations. Such changes, if implemented, may adversely affect our business
operations and may reduce our profitability.

 Risks
Relating to Our Holding Company Structure

 Substantial
uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may
impact the viability of our current corporate structure, corporate governance and business operations.

 On
March 15, 2019, the PRC National People's Congress approved the Foreign Investment Law, which came into effect on January 1, 2020
and replaced existing laws regulating foreign investment in the PRC and become the legal foundation for foreign investment in the PRC.
Meanwhile, the Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment
 came into effect as of January 1, 2020, which clarified and elaborated the relevant provisions of the Foreign Investment Law.
The Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry
national treatment with a restricted list for foreign investments, pursuant to which (i) foreign entities and individuals are prohibited
from investing in the areas that are not open to foreign investments, (ii) foreign investments in the restricted industries must satisfy
certain requirements under the law, and (iii) foreign investments in business sectors outside of the restricted list will be treated
equally with domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage
foreign investments and proposes to establish a foreign investment information reporting system, through which foreign investors or foreign-invested
enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their investments
to the Ministry of Commerce, or MOFCOM, or its local branches.

 Although
our operating structure is legal and permissible under the current Chinese law and regulations, including the Foreign Investment Law,
Chinese regulatory authorities could disallow our operating structure, which would likely result in a material change in our operations
and/or could cause the value of our common stock to significantly decline or become worthless.

 We
may rely on dividends and other distributions on equity paid by our PRC Subsidiaries to fund any cash and financing requirements we may
have, and any limitation on the ability of our PRC Subsidiaries to make payments to us could have a material and adverse effect on our
ability to conduct our business.

 We
are a Colorado holding company and we rely on dividends and other distributions on equity paid by our PRC Subsidiaries and loans between
us and our PRC Subsidiaries to fund any cash and financing requirements we or any of our PRC Subsidiaries may have, including for the
payment of dividends to our investors, the shareholders of AiXin Colorado. Any limitation on the ability of our PRC Subsidiaries to make
payments to or transfer funds to us or our other PRC Subsidiaries could have a material and adverse effect on our ability to conduct
our business and the ability of our PRC Subsidiaries to conduct their respective businesses. If our PRC Subsidiaries incur debt, the
instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations,
our PRC Subsidiaries may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting
standards and regulations. In addition each of our PRC Subsidiaries is required to set aside at least 10% of its accumulated after-tax
profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered
capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, each of our PRC Subsidiaries may allocate a
portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund.

 We
have had no transactions that involved the transfer of cash or assets throughout our corporate structure. None of our Chinese Operating
Companies has distributed any cash or other assets to AiXin HK, including by way of dividends or interest payments and AiXin Colorado
has not transferred any cash or other assets to any of our PRC Subsidiaries. No transfers, dividends or distributions have been made
to our investors. To the extent our cash or other assets is in one of our Chinese Operating Companies or AiXin HK, the funds or assets
may not be available to fund operations or for use outside of mainland China or Hong Kong including for the payment of dividends to the
shareholders of AiXin Life, due to interventions by the governments of PRC or Hong Kong, or the imposition of restrictions and limitations
on the ability of the PRC Subsidiaries to use such cash or assets imposed by the government of mainland China or Hong Kong.

 The
PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting processes may be put forward
by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of
our PRC Subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow,
make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.

 Except
for such limitations on our Company's ability to transfer cash and other assets among our entities currently or hereafter imposed
by the governments of the PRC and Hong Kong, there are no limitations on our Company's ability to transfer cash and other assets
through our corporate structure. Our Company does not have any cash management policies with respect to the transfer of cash among our
entities other than requirements for the approval of management for transfers in excess of specified amounts and none of our entities
is currently party to any debenture, loan or other agreement which imposes restrictions or otherwise limits our Company's ability
to transfer our cash and other assets and we have not adopted any policies that dictate how funds are transferred other than as necessary
to comply with applicable laws.

 In
addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable
to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties
or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises
are incorporated.

 PRC
regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion
may delay or prevent us from making loans or additional capital contributions to our PRC Subsidiaries, which could materially and adversely
affect our liquidity and our ability to fund and expand our business.

 We
are an offshore holding company conducting our operations in China through our PRC Subsidiaries. We may make loans or provide guarantees
for the benefit of our PRC Subsidiaries subject to the approval of or registration with governmental authorities and limitations of the
amount, or we may make additional capital contributions to our PRC Subsidiaries. Any loans to our PRC Subsidiaries, which are treated
as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a foreign-invested enterprise,
or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE
shall not be used for the following purposes: (i) directly or indirectly for payments beyond the business scope of the enterprise or
payments prohibited by relevant laws and regulations; (ii) directly or indirectly for investments in securities or investments other
than in banks' principal-secured products unless otherwise provided by relevant laws and regulations; (iii) the granting of loans
to non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv) paying the expenses related to
the purchase of real estate that is not for self-use (except for foreign-invested real estate enterprises).

 In
light of the requirements imposed by PRC regulations on loans to and direct investments in PRC entities by offshore holding companies,
we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals
on a timely basis, if at all, with respect to future loans by us to our PRC Subsidiaries or with respect to future capital contributions
by us to our PRC Subsidiaries. If we fail to complete such registrations or obtain such approvals, our ability to capitalize or otherwise
fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund
and expand our business.

 Risks
Related to our Common Stock

 There
is a limited public market for our common stock and you may not be able to resell our shares at or above the price you paid or at all.

 There
is a limited public market for our common stock in the OTCQB. On many days during the years ended December 31, 2022, and 2023, and to
date in 2024, no shares were traded. We cannot assure you that an active public market for our common stock will develop or that you
will be able to resell our shares at or above the price you paid or at all.

 The
market price of our shares is likely to be highly volatile, which could result in substantial losses to investors.

 The
trading price of our common stock may be volatile and could fluctuate widely due to factors beyond our control. The trading price for
our common stock varied during the twelve-month period ended December 31, 2023, between a high of $11.00 on April 13, 2023 and a low
of $1.00 on November 20, 2023. The last reported trade in our common stock on March 21, 2024, was $0.27. Our stock price is likely to
continue to be volatile and subject to significant price and volume fluctuations. This may happen because of the broad market and industry
factors, like the performance and fluctuation of the market prices of other companies with business operations located mainly in China
that have securities publicly traded in the United States. The securities of some companies with operations in China and securities publicly
traded in the United States have experienced significant volatility, including price declines in connection with their initial public
offerings. The trading performance of these Chinese companies' securities after their offerings may affect the attitudes of investors
toward Chinese companies publicly traded in the United States, including those of investors based in China, in general and consequently
may impact the trading performance of our common stock, regardless of our actual operating performance. Such volatility in the price
of our common stock including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition
or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

 In
addition to market and industry factors, the trading price and volume of our common stock may be highly volatile due to factors specific
to our operations, including the following:

 variations
 in our actual and perceived operating results;

 news
 regarding gains or losses of customers or partners by us or our competitors;

 news
 regarding gains or losses of key personnel by us or our competitors;

 announcements
 of competitive developments, acquisitions or strategic alliances in our industry by us or our competitors;

 changes
 in earnings estimates or buy/sell recommendations by financial analysts;

 potential
 litigation;

 the
 imposition of fines or penalties related to our activities in the PRC and failure to comply with applicable rules and regulations;

 general
 market conditions or other developments affecting us or our industry; and

 the
 operating and stock price performance of other companies, other industries and other events or factors beyond our control.

 In
addition, the stock market has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of particular companies. Securities class action litigation has often been instituted against companies following
periods of volatility in the overall market and in the market price of a company's securities. This litigation, if instituted against
us, could result in very substantial costs, divert our management's attention and resources, and harm our business, operating results
and financial condition. In addition, recent fluctuations in the financial and capital markets have resulted in volatility in securities
prices.

 Military
or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities
which could adversely impact the price of our common stock.

 Military
or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities,
or affect the operations or financial condition of companies, and lead to national, regional or international economic disruptions and
economic uncertainty, any of which could adversely impact the price of our common stock.

 The
sale or availability for sale of substantial amounts of our common stock could adversely affect its market price.

 Sales
of substantial amounts of our common stock in the public market or the perception that these sales could occur, could adversely affect
the market price of our common stock and could materially impair our ability to raise capital through equity offerings in the future.
Shares held by our existing shareholders may be sold in the public market in the future subject to the restrictions in Rule 144 under
the Securities Act. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other
shareholder or the availability of these securities for future sale will have on the market price of our common stock.

 If
securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations
regarding our common stock, the market price for our common stock and trading volume could decline.

 The
trading market for our common stock will be influenced by research or reports that industry or securities analysts publish about our
business. If one or more analysts who cover us downgrade our common stock, the market price for our common stock would likely decline.
If one or more of these analysts cease to cover us or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the market price or trading volume for our common stock to decline.

 Because
we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our common stock for return on your
investment.

 To
date, we have not paid dividends on our common stock. We currently intend to retain all of our available funds and any future earnings
to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future.
Therefore, you should not rely on an investment in our common stock as a source for dividend income.

 Our
board of directors has complete discretion as to whether to distribute dividends. The timing, amount and form of future dividends, if
any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount
of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed
relevant by our board of directors. Accordingly, the return on your investment in our common stock will likely depend entirely upon any
future price appreciation of our common stock. There is no guarantee that our common stock will appreciate in value or even maintain
the price at which you purchased our common stock and you may even lose your entire investment.

 Our
CEO has substantial influence over our company. His interests may not be aligned with the interests of our other shareholders, and he
could prevent or cause a change of control or other transactions.

Lin, our Chairman of the Board of Directors and Chief Executive Officer, beneficially owns an aggregate of approximately 58% of our outstanding
common stock. Accordingly, Mr. Lin could have significant influence in determining the outcome of any corporate transaction or other
matter submitted to the shareholders for approval, including mergers, consolidations, the appointment of directors and other significant
corporate actions. Mr. Lin will also have the power to prevent or cause a change in control. Without the consent of Mr. Lin, we may be
prevented from entering into transactions that could be beneficial to us or our minority shareholders. In addition, Mr. Lin could violate
his fiduciary duties by diverting business opportunities from us to himself or others. The interests of Mr. Lin may differ from the interests
of our other shareholders. The concentration in the ownership of our common stock shares may cause a material decline in the value of
our common stock.

 Item
 1B.

 Unresolved
 Staff Comments

 No
disclosure is required pursuant to this item.

 Item
 1C.

 Cybersecurity
 Policy

 We regularly review our cybersecurity defenses to assess our vulnerability to cybersecurity attacks from viruses, malware and more sophisticated and targeted cyber-related attacks such as hackers looking to demand ransomware or access our systems to obtain information and data, as well as our vulnerability to cybersecurity failures resulting from human error and technological errors. We rely upon internal IT personnel working in conjunction with specialized outside security consultants on a day to day basis to conduct reviews and upgrade our systems when determined to be necessary.

 Our
overall strategy in combatting cybersecurity risks includes a variety of measures, including:

 the
 use of antivirus software, virtual private networks, email security, as well as other software and system-wide measures such as multi-factor
 authorization to prevent and detect data intrusions;

 deployment
 of updates and patches as they become available from our software suppliers and consultants and maintaining the current versions
 of major software to reduce the exposure to vulnerabilities;

 the
 use of third-party services to conduct mandatory online training for all employees regarding identifying and avoiding cyber-security
 risks;

 the
 review of the security procedures used by third parties that may host or otherwise have access to our systems;

 the
 deployment of third-party cyber-security experts to perform penetration testing on our internal and external networks and systems
 in an effort to identify potential vulnerabilities; and

 consideration
 of the cybersecurity risks posed by interacting with current and potential third-party service providers, suppliers and customers..

 We
are not aware of any existent weakness in our systems or malware embedded in our systems that are likely to would materially affect,
or are reasonably likely to materially affect, our operations.

 Day-to
day management of cybersecurity threats is conducted by our Information Technology department in conjunction with outside service providers,
which is charged with identifying and reporting threats to senior management. On a quarterly basis, cybersecurity is reviewed by our
Chief Executive Officer and Chief Financial Officer, who are expected to report to the Audit Committee.

 Board
Oversight

 The
Audit Committee of our Board of Directors, which is composed of all non-employee directors, is responsible for oversight of our efforts
to eliminate cybersecurity risks. The Audit Committee meets regularly with our Chief Executive Officer and Chief Financial Officer and,
in turn, reports its finding to the Board of Directors.

 Item
 2.

 Properties.

 We
currently operate 25 retail pharmacies in Chengdu. The pharmacies are operated subject to short term leases at market rate rents. In
addition to the pharmacies, we maintain our administrative offices in Chengdu.

 Yunnan
Runcangsheng operates a 13,000 square meter production facility, including, R&D centers, extraction facilities, preparation workshops
and a warehouse. Yunnan Runcangsheng operates planting facilities where it grows some of the key ingredients used in its products. Runcangsheng
acquired the right to use the production facility pursuant to a Development Agreement with the People's Government of Luquan Li
and Miao Autonomous County. The Development Agreement grants Ruuncangsheng the rights to use the facility for a period of five years
ending November 25, 2025, provided Runcangsheng invests certain amounts in the development of the property and its business, including
the construction of office space, manufacturing facilities and workshops. The governmental authorities appear to be satisfied with the
progress Runcangsheng has made in the development of the property to date and have not expressed any intent to terminate the Agreement.

 Effective March 31, 2024, we terminated our lease
for t he Shangyan Hotel. In the termination agreement we and the landlord agreed to release each other from any claims and the landlord
agreed to return the security deposit.

 On
February 6, 2024, w e entered into a lease with respect to
a hotel located in Bandzhuyuan Town, Xindu District, Chengdu City. The term of the lease commenced February 29, 2024 and expires
April 15, 2034. The lease provides for an annual rent of 1.2 million RMB and an annual property management fee of 400,000 RMB, which
remains unchanged for the initial five-year term and are subject to a 5% annual increase thereafter. We have remitted to the
landlord a deposit equal to two months' rent and property management fee, refundable upon lease expiration or termination,
less deductions for any outstanding payments, damages, or breaches of contract. The Lease grants us the right to occupy various
areas within the hotel, covering approximately 18,000 square meters, including the first-floor lobby, external shops (subject to the
rights of the current occupants), second to fourth floors, fifth to eighteenth floors (inclusive of meeting rooms and part of the
dining rooms), underground and ground parking lots, and all hotel facilities and equipment.

 Item

 Legal
 Proceedings.

 From
time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However,
litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may
harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect
on our business, financial condition or operating results.

 In
December 2020, Jian Yiao (the "Plaintiff") filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. ("Aixintang
Pharmacy") in Zhangjiagang People's Court in Jiangsu Province. The complaint alleges that Mr. Yiao is entitled to $392,305
(RMB2,500,000) from Aixintang Pharmacy for breaching a purchase agreement entered in March 2020 (the "Purchase Agreement").
Aixintang Pharmacy claimed that the Purchase Agreement was the result of a forgery by an employee, and that Aixintang Pharmacy did not
enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products
ordered and ordered Aixintang Pharmacy to pay $392,305 (RMB2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a
motion in the Jiangsu Suzhou Intermediate People's Court against the verdict.

 In
February 2021, the judge in the Jiangsu Suzhou Intermediate People's Court denied Aixintang Pharmacy's motion and upheld
the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion to the Jiangsu High People's Court on
the basis that the Purchase Agreement was forged. In February 2022, Aixintang Pharmacy filed an appeal in Jiangsu High People's
Court against the judgment reached by Jiangsu Suzhou Intermediate People's Court in February 2021. To date, this legal proceeding
remains pending.

 The
incident which is the subject to the above lawsuit occurred before Aixintang Pharmacy was acquired by the Company. In November 2021,
Mr. Lin agreed to indemnify the Company against any losses arising from this legal proceeding.

 The
Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results
of operations or cash flows.

 Item

 Mine
 Safety Disclosures.

 Not
applicable

 PART
II

 Item

 Market
 For Registrant's Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities.

 Market
Information

 Our
common stock is quoted on OTCQB under the symbol "AIXN." From January 22, 2021 until June 5, 2023,
our common stock was quoted on OTCQX under the symbol "AIXN."

 Trading
in stocks on the OTCQX and OTCQB is often thin and is characterized by wide fluctuations in trading prices due to many factors that may
have little to do with a company's operations or business prospects. We cannot assure you that there will be a market for our common
stock in the future.

 The
following table sets forth the high and low trading prices of one share of our common stock for each fiscal quarter during the two most
recent fiscal years. Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission
and may not necessarily represent actual transactions. Our common stock trades on a limited, sporadic and volatile basis. These high
and low bid prices per share of common stock have been adjusted to give effect to the 1-for-2 reverse stock split of our common stock effected on February 17, 2023.

 Year ended December 31, 2023

 Low

 High

 First Quarter

 $
 1.60

 $
 6.86

 Second Quarter

 1.17

 11.01

 Third Quarter

 2.25

 4.50

 Fourth Quarter

 1.00

 2.25

 Year
 ended December 31, 2022

 Low

 High

 First
 Quarter

 $

 3.22

 $

 6.98

 Second
 Quarter

 3.32

 5.49

 Third
 Quarter

 3.32

 4.00

 Fourth
 Quarter

 3.35

 6.80

 Holders

 As
of March 29, 2024, there were approximately 635 record holders of our common stock.

 Dividends

 Since
inception we have not paid any dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable
future on our common stock. Although we intend to retain our earnings, if any, to finance the exploration and growth of our business,
our board of directors will have the discretion to declare and pay dividends in the future.

 Payment
of dividends in the future will depend upon our earnings, growth, capital requirements, and other factors, which our board of directors
may deem relevant.

 Issuer
Purchases of Equity Securities

 None.

 Securities
Authorized for Issuance under Equity Compensation Plans

 The
following table sets forth information about the common stock available for issuance under compensatory plans and arrangements as of
December 31, 2023.

 Plan Category

 (a)
 Number of securities to be issued upon exercise of outstanding options

 (b)
 Weighted-average exercise price of outstanding options under equity compensation plans

 (c)
 Number of securities remaining available for future issuance under equity Compensation plans (excluding securities reflected in
 column (a))

 Equity compensation plan approved by security holders

 None

 —

 662,500

 Equity compensation plans not approved by security holders

 None

 —

 None

 Total

 None

 —

 662,500

 On
January 10, 2019, we adopted the 2019 Equity Incentive Plan (the "2019 Plan") pursuant to which we registered up to 625,000
shares of our common stock for issuance and delivery to employees, directors and consultants of the Company as additional incentives
to attract and retain the best available personnel.

 Penny
Stock Regulations

 The
SEC has regulations which generally define so-called "penny stocks" to be equity securities that have a market price less
than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. Our common stock is a "penny
stock" and is subject to Rule 15g-9 under the Exchange Act, or the Penny Stock Rule. This rule imposes additional sales practice
requirements on broker-dealers that sell such securities to persons other than established customers and "accredited investors"
(generally, individuals with a net worth in excess of $1,000,000 or annual incomes exceeding $200,000, or $300,000 together with their
spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and
have received the purchaser's written consent to the transaction prior to sale. As a result, this rule may affect the ability of
broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market,
thus possibly making it more difficult for us to raise additional capital.

 For
any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in penny stock, of a disclosure
schedule required by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable
to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are
required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market
in penny stock.

 There
can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock
were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority
to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the
public interest.

 Recent
Sales of Unregistered Equity Securities

the fourth quarter of 2023, we did not have any sales of equity securities in transactions that were not registered under the
Securities Act of 1933, as amended, that have not been previously reported in a report filed pursuant to the Exchange
Act.

 Item

 Management's
 Discussion And Analysis Of Financial Condition And Results Of Operations.

 The
following discussion should be read in conjunction with our consolidated audited financial statements and related notes thereto and other
financial information appearing elsewhere in this report. In addition to historical information, the following discussion contains forward-looking
statements. Where possible, we have tried to identify these forward-looking statements by using words such as "anticipate,"
"believe," "intends," or similar expressions. Although we believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot assure you that these expectations will prove to be correct. As a result of many factors, including
those factors set forth in the " Risk Factors " section of this report, our actual results could differ materially from
the results described in or implied by the forward-looking statements contained in this report.

 Overview

 In
December 2017, we completed a "reverse" acquisition whereby we acquired all of the outstanding shares of AiXin (BVI) International
Group Co., Ltd. a British Virgin Islands corporation ("AiXin BVI"). As a result, AiXin BVI became our wholly-owned subsidiary,
and through AiXin BVI we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company
("AiXin HK"), which in turn owns all of the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd.,
a Chinese limited company ("AiXinZhonghong"), which began distributing nutritional products in 2013.

 In
September 2021, we completed the acquisition of nine pharmacies located in Chengdu by acquiring the entities which owned the pharmacies
for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million. Since
that time, the number of our pharmacies has increased to 13.

 Pursuant to an Equity Transfer Agreement (the "Transfer Agreement"),
on September 30, 2022, we acquired all of the outstanding equity of Yunnan Runcangsheng Technology Co., Ltd ("Runcangsheng")
for RMB 31,557,820 (approximately USD$4.4 million), reduced by $116,802 the excess of the estimated net worth of Runcangsheng over its
audited net worth as of December 31, 2021. In addition to transferring their respective equity interest in Runcangsheng, both Sellers
agreed to forgive any loans due to them from Runcangsheng. Runcangsheng operates a 13,000 square meter production facility, which houses R&D centers,
extraction facilities, preparation workshops and a warehouse. Runcangsheng has more than 30 sub brands and operates planting facilities
where it grows some of the key ingredients used in its products. Many of the products it has developed are specifically targeted to alleviate
symptoms associated with the increasingly competitive and pressured lifestyle of the Chinese middle class.

 Runcangsheng. was established in April 2020, and is headquartered in Luquan Yi and Miao Autonomous County, Kunming
City, Yunnan Province. It is focused on promoting a healthy lifestyle through the use of foods believed to promote well-being, health
foods, modernized versions of traditional Chinese medical products and plant extracts. Runcangsheng cultivates many of the raw materials
used in its products, compounds the materials into easy to transport and use pre-packaged foods and distributes the products at the wholesale
level. As life-styles in China evolve, work pressures increase and the ingestion of meats and other western style foods increases, Runcangsheng
seeks to design and market products intended to combat the increase in obesity, hypertension, insomnia and physical ailments associated
with such changes. The acquisition of Runcangsheng will enable us to operate as a vertically integrated company, capable of formulating
the kinds of health foods and other nutritional products and supplements suitable for our clients and marketing those products through
our distribution channels.

 In
addition to our acquisitions in the health and nutritional sector, in July 2021, we completed the acquisition of Aixin Shangyan Hotel
through which we owned and operated a hotel located in the Jinniu District, Chengdu City. Effective March 31, 2024, we terminated our lease for the Shangyan Hotel. In the termination agreement we and the
landlord agreed to release each other from any claims and the landlord agreed to return the security deposit.

 On February 6, 2024, we entered into a lease with respect to a hotel located in Bandzhuyuan Town, Xindu District,
Chengdu City. The term of the lease commenced February 29, 2024 and expires April 15, 2034. The Lease grants us the right to occupy various
areas within the hotel, covering approximately 18,000 square meters, including the first-floor lobby, external shops (subject to the rights
of the current occupants), second to fourth floors, fifth to eighteenth floors (inclusive of meeting rooms and part of the dining rooms),
underground and ground parking lots, and all hotel facilities and equipment. References to hotel revenues and operating costs below are
with respect to the hotel we previously occupied in the Jinniu District of Chengdu.

 We
intend to look for additional opportunities to profit from the growing healthcare market in China. Though currently we are not party
to any agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary
products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics
which provide medical care to clients.

 Our
Business

 We
are focused on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market
and sell premium-quality healthcare, nutritional products and wellness supplements, including herbs and greens, traditional Chinese remedies,
functional products, such as weight management tools, probiotics, foods and drinks. We also offer products purchased from third parties
and provide advertising and marketing services to clients which engage us to market and distribute their products. We offer our products
and those of clients for which we provide marketing services, through a diversified, omni-channel business model which generates revenues
through retail and wholesale product sales, through company-owned pharmacies, direct marketing and e-commerce. Our marketing approach
emphasizes proactively approaching customers such as by hosting marketing events for clients, which we believe is ideally suited to marketing
the products we offer because sales of healthcare, nutritional products and supplements are strengthened by ongoing personal contact
and support, coaching and education among the Company and our clients towards how to achieve a healthy and active lifestyle.

 We
believe the competitive strengths that will enable us to grow in the health and wellness market include our ability to design and manufacture
products that are responsive to consumers' needs as the life style of China's middle class evolves, our coordinated omni-channel
distribution network where we enable consumers to obtain the information they need to improve their lifestyle on our website, at our
pharmacies and through individual meetings with our team members.

 Our
ability to operate profitably and generate positive cash flow will be determined by our ability to attract a large and loyal customer
base and provide the information and products they need cost effectively. Our revenue will largely be determined by our ability to achieve
and maintain a strong brand name and company image, the volume of products we sell and the prices we can charge for such products, which
will require that we compete effectively. Our costs will largely be determined by the cost of raw materials and acquired inventory, the
labor used to design and manufacture products, and the costs incurred to deliver these products to the consumer.

 We
intend to build a reputation as a provider of premium health and wellness products that seeks to improve our customers health and well-being.
Our objective is to offer a broad and deep mix of products for consumers interested in living well, whether they are looking to treat
a health-related issue or simply maintain their overall wellness, Our premium, value-added offerings include both proprietary products
developed and manufactured by us as well as products acquired from or sold on behalf of third parties. We believe our range of products
and ability to develop new products, combined with the customer support and service we offer, differentiate us and allow us to effectively
compete against food, drug and mass channel players, specialty stores, independent vitamin, supplement and natural food shops and online
retailers. There is no assurance that we will achieve our business objectives.

 Results
of Operations

 Years
ended December 31, 2023 and 2022

 The following table sets forth the results of our operations for the periods indicated as a percentage of net revenue.
Certain columns may not add due to rounding:

 2023

 2022

 $

 % of

 $

 % of

 $
 4,089,799

 %

 $
 2,708,560

 %

 6,588,606

 %

 5,278,019

 %

 (2,498,807
)

 (61
)%

 (2,569,459
)

 (95
)%

 Non-operating income (expense), net

 427,632

 %

 (3,798,689
)

 (140
)%

 Loss before income tax

 (2,071,175
)

 (51
)%

 (6,368,148
)

 (235
)%

 Income tax expense

 19,519

 0.5
 %

 1,097

 0.04
 %

 $
 (2,090,694
)

 (51
)%

 $
 (6,369,245
)

 (235
)%

 The
following table shows our operations by business segment for the years ended December 31, 2023 and 2022.

 For the Years Ended December 31,

 2023

 2022

 Net revenue

 $
 1,159,134

 $
 823,930

 937,655

 789,347

 Hotel

 1,194,829

 856,884

 798,181

 238,399

 Total revenues, net

 $
 4,089,799

 $
 2,708,560

 $
 393,862

 $
 171,345

 1,790,747

 1,526,246

 531,890

 578,092

 455,906

 622,835

 Hotel

 Hotel operating costs

 1,811,065

 1,739,948

 192,963

 310,902

 688,198

 353,723

 723,975

 (25,072
)

 Total operating costs and expenses

 $
 6,588,606

 $
 5,278,019

 $
 (1,025,475
)

 $
 (873,661
)

 (50,141
)

 (411,580
)

 Hotel

 (809,199
)

 (1,193,966
)

 (613,992
)

 (90,252
)

 $
 (2,498,807
)

 $
 (2,569,459
)

was $4,089,799 in the year ending December 31, 2023, compared to $2,708,560 for 2022, an increase of $1,381,239 or
51%. The increase in revenue was mainly due to increases in direct sales of our nutritional products, increases in revenues from our
hotel and pharmacies, and the generation of revenue by Runcangsheng which we acquired in September 2022. For the year ended December
31, 2023, we had $2,894,970 in product revenues (of which $1,159,134 were from direct sales, $937,655 were from sales at our pharmacies
and $798,181 from sales by Runcangsheng) and hotel revenue of $1,194,829. For 2022, we had $1,851,676
product revenues (of which $823,930 were from direct sales, $789,347 represented sales at our pharmacies, $238,399 represented sales
from Runcangsheng), and hotel revenue of $856,884.

 Direct
products sales

 Our
direct products sales revenue was $1,159,134 for the year ended December 31, 2023, compared with $823,930 for 2022, representing an increase of $335,204 or 41%. Our direct products sales revenue as a percentage to total revenue was 28% for
the year ended December 31, 2023, compared to 30% for 2022. The increase in direct sales revenue was mainly
due to our heightened promotional activities in 2023 and the cessation of the Covid-19 policy in China.

 Our
pharmacies revenue was $937,655 for the year ended December 31, 2023, compared with $789,347 for 2022,
representing an increase of $148,308 or 19%. Our pharmacies revenue as a percentage to total revenue was 23% for the year ended
December 31, 2023, compared to 29% for 2022. The increase in pharmacies revenue was a result of our introduction of new products in
the second half year of 2022. Specifically, we started to sell Chinese medicinal herbs, considered by some to be a treatment and
prevention supplements for Covid-19.

 Hotel

 Our
hotel revenue was $1,194,829 for the year ended December 31, 2023, compared with $856,884 for 2022, representing
an increase of $337,945 or 39%. Our hotel revenue as a percentage of total revenue was 29% for the year ended December 31, 2023, compared
to 32% for 2022. The increase in hotel revenue was a result of increased travel and consumption activities
in China after the pandemic.

 Manufacture
and sales

 Our
manufacture and sales revenues were $798,181 for the year ended December 31, 2023, compared with $238,399 for 2022, representing an
increase of $559,782 or 235%. Our manufacture and sales revenue as a percentage of total revenue was 20% for the year ended December
31, 2023, compared to 9% for 2022. The primary reason for the increase in manufacture and sales revenue was the inclusion of revenue from Runcangsheng. which we acquired in September 202 2.

 Operation
Costs and Expenses

 Cost
of Goods Sold

 Cost
of goods sold was $1,613,950 for the year ended December 31, 2023, compared to $1,103,160 for 2022, an increase
of $510,790 or 46%. The increase in our cost of goods sold is attributable to the increase in our sales.

 Direct
products sales

 The
cost of goods sold for our direct products was $393,862 for the year ended December 31, 2023, compared with $171,345 for 2022,
representing an increase of $222,517 or 130%. The cost of goods sold for our direct product sales as a percentage of sales was 34%
in 2023, compared to 21% for 2022. The increase in cost of goods sold was primarily driven by the increased commission payouts to
our sales personnel in 2023.

 The
cost of goods sold at our pharmacies was $531,890 for the year ended December 31, 2023, compared with $578,092 for 2022,
representing a decrease of $46,202 or 8%. The cost of goods sold at our pharmacies as a percentage of pharmacy product sales was 57%
in 2023, compared to 73% in 2022. The decrease in cost of goods sold was mainly due to the low cost of Chinese medicinal herbs which
were acquired by subsidiary Runcangsheng and distributed by our pharmacies; our coordination of activities at our pharmacies, such
as the implementation of bulk inventory purchasing which reduced our purchasing costs; and cost reduction measures undertaken in
2023, including reviewing our list of vendors and replacing those vendors with higher purchasing costs.

 Manufacture
and sales

 The
cost of goods sold for our manufacture and sales was $688,198 for the year ended December 31, 2023, compared with $353,723 for, representing an increase of $334,475 or 95%. The cost of goods sold as a percentage of sales by our manufacture and sales
was 86% in 2023, compared to 148% in 2022. The primary reason for the increase in cost of goods sold was due to our acquisition of Runcangsheng
in September 2022, which resulted in our recording twelve months of revenues and costs in 2023 compared with three months in 2022.

 Hotel
Operating Costs

 Hotel
operating costs were $1,811,065 and $1,739,948 for the years ended December 31, 2023 and 2022, representing an increase of $71,117 or
4%. The increase in hotel operating costs was mainly due to the increase in hotel sales but was partly offset by decreases in the cost
of foods and fruits.

 Operating
Expenses

 Operating
expenses were $3,163,591 for the year ended December 31, 2023, compared to $2,434,911 for the same period of 2022, an increase of
$728,680 or 30%. The increase in operating expenses was mainly due to the increase in operating expenses reported for Runcangsheng which was
acquired on September 30, 2022.

 Loss
from Operations

 Loss
from operations was $2,498,807 in the year ended December 31, 2023, compared to $2,569,459 in 2022, a decrease of
$70,652 or 3%. The decrease in our loss from operations for 2023 was due to the increases in our revenues at our pharmacies and hotel segments, partly offset by the losses incurred by direct sales activities and our new subsidiary, Runcangsheng.

 Non-operating

 Non-operating income was $427,632 for the year ended December 31, 2023,
compared to non-operating expenses of $3,798,689 for the year ended December 31, 2022. For 2023, we had interest income of $838 and other
income $438,348, partly offset by other expenses of $11,554. For 2023, other income mainly consisted of a government grant of $369,857.
For 2022, we had an impairment loss of goodwill of $3,823,770 arising from the acquisition of Runcangsheng, and other expenses of $31,651,
partly offset by interest income of $4,876 and other income of $51,856.

Tax Expense

tax expense was $19,519 and $1,097 for the years ended December 31, 2023 and 2022, respectively, an increase of $18,422 or 1,679% for
the year ended December 31, 2023 compared with 2022.

 Net
Loss

 Our
net loss for the year ended December 31, 2023 was $2,090,694, compared to a net loss of $6,369,245 for 2022, a decrease
of $4,278,551 or 61%. The decrease in our net loss was mainly due to increased sales and the absence of an impairment
loss, partly offset by increased operating costs and expenses as explained above.

 Liquidity
and Capital Resources

the year ended December 31, 2023, we used $1,392,259 in operations. As of December 31, 2023, cash and cash equivalents were $443,758
(excluding $23,208 of restricted cash), compared to $510,128 (excluding $109,772 of restricted cash) as of December 31, 2022. At December
31, 2023, we had a working capital deficit of $4,467,006 compared to $3,346,358 at December 31, 2022.

 The
following is a summary of cash provided by or used in each of the indicated types of activities during years ended December 31, 2023
and 2022, respectively.

 Net cash used in operating activities

 $
 (1,392,259
)

 $
 (1,624,565
)

 Net cash (used in) provided by investing activities

 $
 (302,838
)

 $
 (3,522,369
)

 Net cash provided by (used in) financing activities

 $
 1,560,466

 $
 (2,389,593
)

 Net
cash used in operating activities

 For
the year ended December 31, 2023, net cash used in operating activities was $1,392,259. This reflects our net loss of $2,090,694,
adjusted by non-cash related expenses including depreciation and amortization expense of $410,690, a change in deferred tax of
$15,152, a bad debt reversal of $47,762, an inventory impairment of $7,770, operating lease expenses of $817,179, government grant
income of $369,857 and stock-based compensation of $371,540, and then decreased by changes in working capital of $506,639. The cash
outflow from changes in working capital mainly resulted from increases in other receivables and prepaid expense, including related
party receivables of $11,649, in accounts payable from related party of $159,843, in accrued liabilities and other payables of
$161,393, in taxes payable of $52,010 and payments of lease liabilities of $779,599, partly offset by cash inflows from accounts
receivable, including from related parties in the amount of $477,951, cash inflows from advances to suppliers of $133,513, cash inflows from inventory of $36,240, cash inflows from accounts payable of $93,682, and cash inflow from
unearned revenue of $37,275.

 For
the year ended December 31, 2022, net cash used in operating activities was $1,624,565. This reflects our net loss of $6,369,245, increased
by non-cash related expenses including depreciation and amortization expense of $185,565, the change in deferred tax of $1,858, operating
lease expense of $837,425, stock-based compensation of $371,540, inventory impairment of $54,899 and an impairment loss of goodwill of
$3,823,770, less changes in working capital of $576,330. The cash outflow from changes in working capital mainly resulted from an increase
in outstanding accounts receivable of $425,961, payments of lease liabilities of $710,865, a change in accounts payable of $71,153, unearned
revenue of $24,401 and taxes payable of $137,711, which was partly offset by cash inflows from accrued liabilities and other payables
of $289,868, other receivable and prepaid expense of $109,439, inventory of $150,872, accounts payable to related party of $140,608,
and advances to suppliers of $103,016.

 Net
cash used in investing activities

 For
the year ended December 31, 2023 and 2022, net cash used in investing activities was $302,838 including $295,487 for the purchase of fixed
assets, $4,032 for the purchase of intangible assets, and $3,319 cash disposed of at the termination of a non-operating subsidiary. For
the year ended December 31, 2022, net cash used in investing activities was $3,522,369, mainly as a result of $3,812,027 paid for the
acquisition of Runcangsheng, and purchases of property and equipment of $156,723, partly offset by cash acquired in connection with the
acquisition of Runcangsheng of $446,381.

 Net
cash provided by financing activities

 For
the year ended December 31, 2023, net cash provided by financing activities were the result of capital contributions of $142,200 and
proceeds from a government grant of $369,857, and proceeds from advances from related parties of $1,048,409. For the year ended
December 31, 2022, net cash used in financing activities was $2,389,593 as a result of payments made against advances from related
parties of $2,389,593.

 We
substantially depleted our available cash and working capital during 2023 supporting our operations which generated a $2,498,807
loss in 2023 and completing the acquisition of Runcangsheng. It is
likely that Runcangsheng will require additional capital to achieve its short term operational goals and long range business plans.
Further, we may need additional capital to maintain our other businesses. We may also have to raise additional financing as our
working capital requirements are expected to increase in line with the growth of our business. In the past we have funded our
operations through proceeds from private placements of equity and advances from our principal shareholder. Should we require capital
to fund our business, we intend to finance our business by raising additional capital or, when available, borrowing additional
funds. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders and could
cause the price of our common stock to decrease. Further, such securities might have rights, preferences or privileges senior to our
common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are
not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities,
which could significantly and materially restrict our business operations.

 We
are subject to all of the substantial risks inherent in the development of a new business enterprise within an extremely competitive
industry. Due to the absence of a long-standing operating history and the emerging nature of the markets in which we compete, we anticipate
operating losses until we can successfully implement our business strategy. Our revenue model is new and evolving, and we cannot be certain
that it will be successful. The potential profitability of our business model is unproven. We may never achieve profitable operations.
Our future operating results depend on many factors, including demand for our products, the level of competition, and the ability of
our officers to manage our business and growth. As a result of the emerging nature of the market in which we compete, we may incur operating
losses until such time as we can develop a substantial and stable revenue base. Additional development expenses may delay or negatively
impact our ability to generate profits. Accordingly, we cannot assure you that our business model will be successful or that we can sustain
revenue growth, achieve or sustain profitability, or continue as a going concern.

 Our
ability to obtain funds through the issuance of debt or equity is dependent upon the state of the financial markets at such time as we
may seek to raise funds. The state of the capital market markets may be adversely impacted by various risks and uncertainties, including,
but not limited to future and current impacts of global events such as COVID-19, the war in the Ukraine and the conflict in Palestine,
increases in inflation and other risks detailed herein.

 Impact
of Inflation

 Our
results of operations may be affected by inflation, particularly rising prices for products and other operating costs if we cannot pass
such increases along to our customers in the form of higher prices for our products and services. Generally, we are not party to long
term contracts and our inventory turns multiple times per year and we anticipate that we will be able to increase prices on products
to reflect increases in the cost of inventory.

 Contractual
Obligations

 We
have no long-term fixed contractual obligations or commitments other than leases that are disclosed in Note 12 in the notes to our consolidated
financial statements.

 Contingencies

 Our
operations are conducted in the PRC and are subject to specific considerations and significant risks not typically associated with companies
in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments
in China and foreign currency exchange rates. Our results may be adversely affected by changes in PRC government policies with respect
to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad and rates and methods of taxation, among
other things.

 Our
sales, purchases and expense transactions in China are denominated in RMB and all of our assets and liabilities in China are also denominated
in RMB. The RMB is not freely convertible into foreign currencies under the current PRC law. In China, foreign exchange transactions
are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require
certain supporting documentation in order to affect the remittance.

 Significant
Accounting Policies

 Our
management's discussion and analysis of our financial condition and results of operations are based on our consolidated financial
statements, which were prepared in accordance with accounting principles generally accepted in the United States of America ("US
GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as
the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We
base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions.

 While
our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe the following
accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

 Basis
of Presentation

 The
accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles ("US GAAP").
The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi ("RMB").
The accompanying financial statements are translated from RMB and presented in U.S. dollars ("USD").

 Use
of Estimates

 In
preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the
reported amounts of revenues and expenses during the reporting period.

 Significant
estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve
for obsolete and slow-moving inventories. Actual results could differ from those estimates.

Receivable

 We
maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and
analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment
patterns to evaluate the adequacy of these reserves. As of December 31, 2023 and 2022, the bad debt allowance was $80,640 and $272,550,
respectively.

Recognition

from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of our products and services
to customers in return for expected consideration and includes the following elements:

 executed contract(s) with
 customers that we believe are legally enforceable;

 identification of performance
 obligation in the respective contract;

 determination of the transaction
 price for each performance obligation in the respective contract;

 allocation of the transaction
 price to each performance obligation; and

 recognition of revenue
 only when we satisfy each performance obligation.

 Our
revenue recognition policies for our operating segments are as follows:

 Our
revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists. We do not provide
unconditional return or other concessions to customers. Our sales policy allows for the return of unopened products for cash after deducting
certain service and transaction fees. As an alternative to returning a product, customers may request an exchange for products with the
same value.

 Product
sales revenue represents the invoiced value of goods, net of value-added taxes ("VAT"). All of our products sold in China
are subject to the PRC VAT of 17% of the gross sales price prior to May 1, 2018, 16% since May 1, 2018 and 13% since April 1, 2019. This
VAT may be offset by VAT paid by for raw materials and other materials purchased in China. We record VAT payables and VAT receivables
net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases
are recorded net of VAT collected and paid as we act as an agent for the government.

 Our
retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription
claim is its own arrangement with the customer and is a performance obligation. We generally receive payment from pharmacy customers
we satisfy our performance obligations. We record a receivable when we have an unconditional right to receive payment and only the passage
of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the products sold
in our pharmacies are exempt from VAT as the pharmacies qualify for a small business exemption.

 Manufacture
and Sale

 The
Company's new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation.
The Company records a receivable for the sales when it has an unconditional right to receive payment and only the passage of time is
required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the Company's products
sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

 Hotel

 Hotel
revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but
not limited to souvenir, parking and conference reservations. Each of these products and services represents a distinct performance obligation
and, in exchange for these services, we receive fixed amounts based on published rates or negotiated contracts. Payment is due in full
at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are
occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to
the guests as the respective performance obligations are satisfied. All of the hotel's goods sold in China are subject to the PRC
VAT of 6%. This VAT may be offset by VAT paid by on raw materials and other materials purchased in China.

 Item
 7A

 Quantitative
 And Qualitative Disclosures About Market Risk.

 This
item does not apply to smaller reporting companies.

 Item

 Financial
 Statements And Supplementary Data.

 Our
financial statements appear beginning on page F-1, immediately following the signature page of this report.

 Item

 Changes
 In And Disagreements With Accountants On Accounting And Financial Disclosure.

 Not
applicable.

 Item
 9A

 Controls
 And Procedures.

 Disclosure
Controls and Procedures

 Management
of AiXin Life International, Inc. is responsible for maintaining disclosure controls and procedures that are designed to ensure that
information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 (the
"Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange
Commission's rules and forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated
and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate,
to allow timely decisions regarding required financial and other required disclosures.

 At
December 31, 2023, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and
15(d)-15(e) of the Securities Exchange Act of 1934 (the "Exchange Act")) was carried out under the supervision and with the
participation of our Chief Executive Officer and our Chief Financial Officer. Based on their evaluation of our disclosure controls and
procedures, they concluded that at December 31, 2023, such disclosure controls and procedures were not effective. This was due to our
limited resources, including the absence of a financial staff with accounting and financial expertise and knowledge of the regulations
of the Securities and Exchange Commission, and deficiencies in the design or operation of our internal control over financial reporting
that adversely affected our disclosure controls and that may be considered to be "material weaknesses."

 We
plan, if our revenues continue to increase, to seek to recruit individuals responsible for identifying reportable developments and to
implement procedures designed to remediate the material weakness by focusing additional attention and resources in our internal accounting
functions. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient
period of time and management has concluded, through testing, that these controls are operating effectively.

 Management's
Annual Report on Internal Control over Financial Reporting

 Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting
principles.

 Our
internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that
in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded
as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company
assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use
or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely
basis.

 Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions
may occur or the degree of compliance with the policies or procedures may deteriorate.

 Our
management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial
Officer of the effectiveness of our internal control over financial reporting as of December 31, 2023. This evaluation was based on criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based
upon such assessment, our Chief Executive Officer and Chief Financial Officer have concluded that due to the absence of a financial staff
with accounting and financial expertise and certain deficiencies in the design or operation of our internal control over financial reporting,
our internal controls over financial reporting were not effective as of December 31, 2023.

 This
report shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the
liabilities of that section, and is not incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.

 This
annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting. The rules of the SEC do not require an attestation of the Management's report by our registered public accounting firm
in this annual report.

 Changes
in Internal Controls

 There
have been no changes in our internal control over financial reporting that occurred during our fiscal quarter ended December 31, 2023
that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting. Given the
limitations of our accounting personnel, we need to take additional steps to ensure that our financial statements are in accordance with
US GAAP.

 Item
 9B.

 Other
 Information

 Not
applicable

 Item
 9C.

 Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 Not
applicable

 PART
III

 Item

 Directors
 And Executive Officers And Corporate Governance.

 The
following table sets forth the names and ages of all directors and executive officers as of the end of the last fiscal year and on the
date of this report:

 Name

 Age

 Position

 Lin

 Director,
 Chairman, President and Chief Executive Officer

 Yao-Te
 Wang (1) (2) (3)

 and Secretary

 Christopher
 Lee (1) (2) (3)

 Huiliang
 Jiao (1) (2) (3)

 Tianfeng
 Li

 Chief
 Financial Officer

 (1)

 Member
 of the Audit Committee

 (2)

 Member
 of the Compensation Committee

 (3)

 Member
 of the Nominating and Corporate Governance Committee

Lin has served as a director, President and Chief Executive Officer of our company since February 2, 2017. Mr. Lin is a highly active
entrepreneur in China, and currently serves as Chairman of AiXin Company Group, a diversified company which he founded in 2008. In addition
to AiXin Company Group, Mr. Lin has founded a number of companies located in Chengdu City, Sichuan Province, China, engaged in various
types of business, including pharmacies, retail outlets, hotel management services and global tourism.

 In
2009, Mr. Lin founded QingBaiJiangJinWanXiang Daily Necessities store, predecessor to AixinZhonghong Biotechnology Co., Ltd. From 2010
to 2013, Mr. Lin opened branches in Xindu and Xinjin district, officially entering the Chengdu market.

 In
September 2013, Mr. Lin founded Chengdu AiXin E-Commerce Company Ltd., which in the following twelve months opened branches in cities
and counties including Huayuan and Wenjiang district, and Mianyang and Jianyang city. In April 2015, AiXin E-commerce Co., Ltd. changed
its name to Chengdu AixinZhonghong Biotechnology Co., Ltd., whose shares became listed on the Shanghai Stock Exchange (Ticker Symbol:
207448) in October 2015; and during 2015, AixinZhonghong opened branches in Dujiangyan City, and Chongzhou City.

 Yao-Te
Wang has served as a director of our company since December 12, 2017. He became our Secretary on June 20, 2023. Mr. Wang has been
the Chief Executive Officer of Ivy Service Group (China), which is a transnational consultant company in China, since 2015. From January
2016 to June 2016, Mr. Wang participated in the overall operation planning for Chongqing Cultural Assets and Equity Exchange. From June
2015 to January 2016, Mr. Wang helped with the overall brand strategy development for Swire Group, who merged the biggest baking brand
in Southwest China within more than 150 million RMB. From September 2014 to February 2015, Mr. Wang was the chairman special assistant
for JECUI Health Science Company. From July 2012 to August 2014, Mr. Wang was the Chief Executive Officer of Ivy Service Group (Taipei).
From August 2007 to June 2012, Mr. Wang was an instructor of National Defense University (Taipei), taught International Politics and
Economic Analysis.

 Christopher
Lee was appointed as a Member of the Board of Directors of the Company on February 5, 2021. Mr. Lee has served as Chief Financial
Officer of Semileds Corporation since September 2015. Mr. Lee joined Semileds Corporation in September 2014 and from November 2014 until
his appointment as Chief Financial Officer, Mr. Lee was the interim Chief Financial Officer of Semileds Corporation. Semileds develops,
manufactures and sells high performance light emitting diodes and is currently listed on The Nasdaq Stock Market. Mr. Lee has over 20
years of experience in accounting and finance, including US GAAP, PCAOB standards and SEC rules and regulations. Mr. Lee was a partner
of KEDP CPA Group from August 2009 to June 2011 and a self-employed accountant from July 2011 to August 2014. Mr. Lee holds a BS degree
in accounting from Ohio State University and a MS degree in business taxation from Golden Gate University and is licensed as a Certified
Public Accountant (CPA) in the United States.

 Huiliang
Jiao was elected to the Board of Directors of our company on December 1, 2022. Mr. Jiao received his degree from China Pharmaceutical
University in 1997 where he majored in Pharmacy. Mr. Jiao joined Yunnan Runcangsheng Technology Co., Ltd. in April 2020, most recently
serving as Chief Executive Officer. Mr. Jiao served as the general manager of Yunnan Shengshengyuan Technology Co., Ltd. from June 2016
until he joined Runcangsheng. From January 2007 until May 2016, Mr. Jiao was the general manager of Yunnan Shengcaofeng Biotechnology
Co., Ltd. Throughout his career Mr. Jiao has been involved in the research and development of new products intended to improve individuals'
health and well-being, with an emphasis on functional products comprised of natural plants, foods and supplements intended to address
obesity and other chronic conditions. He was named as an inventor on more than forty patents relating to the composition and manufacture
of health foods. In addition to the development of health foods, Mr. Jiao has participated in the design and maintenance of production
systems intended to meet the latest manufacturing standards.

 Tianfeng
Li, became our Chief Financial Officer on December 1, 2022. Ms. Li also serves as Chief Financial Officer of the Company's
subsidiaries. Ms. Li has held various positions, most recently, Finance Manager, within the Finance Department of our subsidiary, Chengdu
AiXin Pharmacy Co., Ltd., which she joined in May 2019. While serving at AiXin Pharmacy Ms. Li helped build the company's finance
team and established the development of its financial reporting and risk management systems. In addition, she presided over the preparation
of the company's financial statements, the completion of its annual audit, daily cash management, the preparation of the annual
budget and the integration of newly acquired pharmacies. From May 2013 until joining AiXin Pharmacy in May 2019, Ms. Li served as the
Finance Manager of Sichuan Jinxin Clean Energy Equipment Co., Ltd., where she was responsible for developing the company's financial
systems, preparing its budget and managing all aspects of cash management. At Sichuan Jinxin Clean Energy Equipment Co Ms. Li supervised
a staff of five assistants. Ms. Li received a bachelor's degree from The Open University of China in 2017, and has received a Certificate
of Honor as an Intermediate Accountant.

 There
are no family relationships among any of our officers and directors.

 Directors
hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Officers are
elected by the board of directors and hold office until the earliest of their death, resignation or removal from office.

 Board
Meetings; Leadership Structure and Risk Oversight

 Mr.
Quanzhong Lin holds the positions of chief executive officer and chairman of the board of the Company. The board believes that Mr. Lin's
services as both chief executive officer and chairman of the board is in the best interest of the Company and its shareholders. Mr. Lin
is a well-recognized successful entrepreneur in Chengdu. He possesses detailed and in-depth knowledge of the issues, opportunities and
challenges facing the Company in its business and is thus best positioned to develop agendas that ensure that the Board's time
and attention are focused on the most critical matters relating to the business of the Company. His combined role enables decisive leadership,
ensures clear accountability, and enhances the Company's ability to communicate its message and strategy clearly and consistently
to the Company's shareholders, employees and customers.

 The
board has not designated a lead director. Given the limited number of directors comprising the Board, the independent directors call
and plan their executive sessions collaboratively and, between meetings of the Board, communicate with management and one another directly.
Under these circumstances, the directors believe designating a lead director to take on responsibility for functions in which they all
currently participate might detract from rather than enhance performance of their responsibilities as directors.

 Management
is responsible for assessing and managing risk, subject to oversight by the board of directors. The board oversees our risk management
policies and risk appetite, including operational risks and risks relating to our business strategy and transactions. Various committees
of the board assist the board in this oversight responsibility in their respective areas of expertise.

of Directors

 The
following table sets forth certain information regarding the compensation paid to, earned by or accrued for, our directors during the
fiscal year ended December 31, 2023.

 DIRECTOR COMPENSATION

 Name

 Fees Earned
 or Paid
 In Cash
 ($)

 Stock
 Awards
 ($)

 Option
 Awards
 ($)

 Non-Equity
 Incentive Plan
 ($)

 Non-Qualified
 Deferred
 Earnings ($)

 All Other
 ($)

 Total ($)

 Yao-Te Wang

 $
 37,000

 —

 —

 —

 —

 $
 37,000

 Quanzhong Lin

 $

 —

 —

 —

 —

 $

 Christopher Lee

 9,600

 —

 —

 —

 $
 9,600

 Huiliang Jiao

 12,000

 —

 —

 —

 —

 —

 $
 12,000

 Our
Board of Directors has determined that Yao-Te Wang,, Christopher Lee and Huiliang Jiao are "independent directors" within
the meaning of NASDAQ Marketplace Rule 5605(a)(2) and Section 10(A)(m)(3) of the Exchange Act.

 Board
Meetings; Committees and Membership

 Our
Board of Directors did not meet in formal session during 2023, though it regularly took action by written consent after the directors
consulted with each other as to the actions to be taken.

 We
maintain the following committees of the Board of Directors: the Audit Committee, the Compensation Committee and the Nominating and Corporate
Governance Committee. Each committee is comprised entirely of directors who are "independent" within the meaning of NASDAQ
Marketplace Rule 5605(a)(2). Each committee acts pursuant to a separate written charter, and each such charter has been adopted and approved
by the Board of Directors. Copies of the committee charters were filed as Exhibits to our Report on Form 8-K filed on September 25, 2020.

 Audit
Committee

 Our
Audit Committee consists of Messrs. Lee, Jiao and Wang, each of whom is independent. The Audit Committee assists the Board of Directors
oversight of (i) the integrity of financial statements, (ii) our compliance with legal and regulatory requirements, (iii) the independent
auditor's qualifications and independence, and (iv) the performance of our internal audit function and independent auditor and
prepares the report that the SEC requires to be included in our annual proxy statement. The Audit Committee operates under a written
charter. Mr. Lee is the Chairman of our Audit Committee.

 The
Board of Directors determined that Mr. Lee possesses accounting or related financial management experience that qualifies him as financially
sophisticated within the meaning of Rule 4350(d)(2)(A) of the Nasdaq Marketplace Rules and that he is an "audit committee financial
expert" as defined by the rules and regulations of the SEC.

 Nominating
and Corporate Governance Committee

 The
purpose of the Nominating and Corporate Governance Committee is to assist the Board of Directors in identifying qualified individuals
to become members of our Board of Directors, in determining the composition of the Board of Directors and in monitoring the process to
assess Board effectiveness. Each of Messrs. Lee, Jiao and Wang are members of the Nominating and Corporate Governance Committee. Mr.
Wang serves as Chairman of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee operates
under a written charter.

 Our
 Nominating and Corporate Governance Committee has, among the others, the following authority and responsibilities:

 To
 determine and recommend to the Board, the criteria to be considered in selecting nominees for the director;

 To
 identify and screen candidate consistent with such criteria and consider any candidates recommended by our stockholders pursuant
 to the procedures described in our proxy statement or in accordance with applicable laws, rules and regulations and provisions of
 our charter documents.

 To
 select and approve the nominees for director to be submitted to a stockholder vote at the annual meeting of stockholders.

Committee

 The
Compensation Committee is responsible for overseeing and, as appropriate, making recommendations to the Board of Directors regarding
the annual salaries and other compensation of our executive officers and general employees and other policies, and for providing assistance
and recommendations with respect to our compensation policies and practices. Each of Messrs. Lee, Jiao and Wang are members of the Compensation
Committee. The Compensation Committee operates under a written charter. Mr. Jiao is the Chairman of Compensation Committee.

 Our
Compensation Committee has, among the others, the following responsibilities and authority.

 The
 compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other
 adviser.

 The
 compensation committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation
 consultant, legal counsel and other adviser retained by the compensation committee or said group.

 The
 Company must provide for appropriate funding, as determined by the compensation committee, for payment of reasonable compensation
 to a compensation consultant, legal counsel or any other adviser retained by the compensation committee or said group.

 The
 compensation committee select, or receive advice from, a compensation consultant, legal counsel or other adviser to the compensation
 committee or said group, other than in-house legal counsel, only after conducting an independence assessment with respect to the
 adviser as provided for in the Exchange Act.

 Code
of Business Conduct and Ethics

 We
have adopted a Code of Business Conduct and Ethics that applies to, among other persons, members of our board of directors, our Company's
officers including our Chief Executive Officer, employees, consultants and advisors. A copy of the Code of Business Conduct and Ethics
was filed as an exhibit to our report on Form 8-K filed on September 25, 2020, and is available on the SEC's website, www.sec.gov.

 Shareholder
Communications

 Shareholders
may communicate with the board of directors and individual directors by submitting their communications in writing to the Company's
Corporate Secretary at Hongxing International Business Building 2, 14 th FL, No. 69 Qingyun South Ave., Jinjiang District,
Chengdu City, Sichuan Province, China. Any communications received that are directed to the board of directors will be processed by the
Corporate Secretary and distributed promptly to the board of directors or individual directors, as appropriate. If it is unclear from
the communication received whether it was intended or appropriate for the Board, the Corporate Secretary will (subject to any applicable
regulatory requirements) use his business judgment to determine whether such communications should be conveyed to the board of directors.

 Item

 Executive
 Compensation.

 The
following table sets forth certain information about compensation paid, earned or accrued for services by each individual who served
as our chief executive officer and chief financial officer for services rendered in all capacities during the year ended December 31,
2023. No other executive officer of our Company or other individual received total annual salary and bonus compensation in excess of
$100,000 for the year ended December 31, 2023.

 Summary
Compensation Table

 Name and Principal Position

 Year

 Salary ($)

 Bonus ($)

 Total ($)

 Quanzhong Lin, President(1)

 2023

 $
 20,100

 $

 $
 20,100

 2022

 20,822

 20,822

 Tiangfeng Li, Chief Financial Officer (2)

 2023

 $
 26,500

 $

 $
 26,500

 2022

 $
 20,533

 $

 $
 20,533

 (1)
Amounts attributed to Mr. Lin represent amounts paid as President and CEO of AiXinZhonghong.

 (2)
Amounts attributed to Ms. Li represent amounts paid as CFO of AiXinZhonghong.

 Neither
Mr. Lin nor Ms. Li has an employment agreement with the Company.

 Stock
Option Plan; Pension, Profit-Sharing and Retirement Benefits

 In
2019 we adopted the 2019 Equity Incentive Plan (the "2019 Plan"), which authorizes the issuance of shares of common stock
for grants of stock options, stock appreciation rights, restricted stock, stock units, bonus stock, dividend equivalents, other stock
related awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan authorizes the issuance of
up to 625,000 shares. In October 2019, we issued an aggregate of 293,750 shares to employees and
contractors under the 2019 Equity Incentive Plan.

 We
adopted the 2019 Plan to provide a means by which employees, directors, and consultants of our Company and those of our subsidiaries
and other designated affiliates, which we refer to together as our affiliates, may be given an opportunity to purchase our common stock,
to assist in retaining the services of such persons, to secure and retain the services of persons capable of filling such positions,
and to provide incentives for such persons to exert maximum efforts for our success and the success of our affiliates. The material features
of the 2019 Plan are outlined below. This summary is qualified in its entirety by reference to the complete text of the 2019 Plan which
has been filed with the SEC.

 None
of our executive officers or directors was granted any options or equity awards during 2023 or held any options or other equity awards
at December 31, 2023.

 There
are no annuity, pension or retirement benefits proposed to be paid to our officers, directors or employees in the event of retirement
at normal retirement date pursuant to any presently existing plan provided or contributed to by the Company or any of its subsidiaries.

 Outstanding
Equity Awards

 At
December 31, 2023, there were no outstanding equity awards granted pursuant to the 2019 Equity Incentive Plan.

 Item
 12.

 Security
 Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 The following table sets forth, as of March 29, 2024, certain information
concerning the beneficial ownership of our common stock by (i) each stockholder known by us to own beneficially five percent or more of
our outstanding common stock; (ii) each director; (iii) each named executive officer; and (iv) all of our executive officers and directors
as a group, and their percentage ownership and voting power. There were 24,999,945 shares of our common stock outstanding as of March
29, 2024.

 The
information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of
the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person
is deemed to be a "beneficial owner" of a security if that person has or shares the power to vote or direct the voting of
the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security which
such person has the right to acquire sole or shared voting or investment power within sixty (60) days through the conversion or exercise
of any convertible security, warrant, option, or other right. More than one (1) person may be deemed to be a beneficial owner of the
same securities. The percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of
shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting
or investment power within sixty (60) days, by the sum of the number of shares outstanding as of such date including the number of such
shares which such person has the right to acquire. Consequently, the denominator used for calculating such percentage may be different
for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the beneficial
owners of our common stock listed below have sole voting and investment power with respect to the shares shown.

 Name of Shareholder (1)

 Amount and Nature of Beneficial Ownership

 Percent of Common Stock

 Directors and Executive Officers:

 Quanzhong Lin, Chairman and CEO

 14,534,676

 58.14
 %

 Yao-Te Wang, Director

 1,884,336

 7.54
 %

 Christopher Lee, Director

 -

 Huiliang Jiao, Director

 -

 Tianfeng Li, CFO

 -

 All directors and executive officers as a group (five persons)

 16,419,012

 65.68
 %

 (1)

 The
 address of each beneficial owner is c/o AiXin Life International, Inc., Hongxing International Business Building 2, 14 th FL,
 No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China

 Item

 Certain
 Relationships And Related Transactions, And Director Independence.

 Transactions
with Related Persons

 The
following includes a summary of transactions since January 1, 2023, or any currently proposed transaction, in which we were or are to
be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets
at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest
(other than compensation described under "Executive Compensation"). We believe the terms obtained or consideration that we
paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts
that would be paid or received, as applicable, in arm's-length transactions.

 Advance
to/from related parties

 As
of December 31, 2022, the Company had accounts payable in the amount of $165,958 due to Luquan Shengcaofeng Biotechnology Co., Ltd.,
an affiliate of Runcangsheng, for the purchase of raw materials. This payable was satisfied during 2023.

 From
time to time, we have advanced certain amounts to pharmacies owned by Quanzhong Lin. The amount due from each of such entities as of
December 31, 2023 and 2022 were as follows:

 2023

 2022

 Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.

 $

 $
 9,708

 Chengdu Fuxiang Tang Pharmacy Co., Ltd.

 26,125

 Chengdu Zhiweibing Pharmacy Co., Ltd.

 1,738

 -

 Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd

 34,622

 Sichuan Aixin Investment Co. Ltd

 9,310

 Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.

 -

 12,502

 Total

 $
 12,400

 $
 83,102

 From
time to time, we have received advances from certain affiliates. The amounts due to such affiliates as of December 31, 2023 and 2022
were as follows:

2023

2022

 Quanzhong Lin

 $
 1,051,429

 $
 140,644

 Yirong Shen

 87,325

 89,892

 Huiliang Jiao

 82,152

 -

 Tianfeng Li

 -

 Mianyang Aixin Cunshan Pharmacy Co. Ltd

 -

 Chengdu Aixin International travel service Co, Ltd

 5,087

 6,346

 Total

 $
 1,226,885

 $
 236,882

 All
the entities in the above list are controlled by Quanzhong Lin. These advances to and from related parties were for working capital purposes,
payable on demand, and bear no interest. Yirong Shen was a shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase
Agreement and serves as the supervisor of Aixin Shangyan Hotel.

 Forgiveness
of Loan; Contribution of Shares

 On
December 31, 2021, Mr. Lin forgave a loan previously made to the Company in the amount of $6,912,513. This was treated as a contribution
to capital. On March 1, 2023, for no consideration other than the expenses to be incurred by the Company in connection with this offering,
Mr. Lin agreed to contribute to the capital of the Company seven million shares of the common stock of the Company.

 In
May 2014, we entered into a lease with Mr. Lin for use of an office. We have renewed the lease until April 30, 2024, with monthly
rent of RMB5,000 ($[ ]), payable quarterly.

 Other
than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own
beneficially more than 5% of the Company's outstanding shares of its Common Stock, nor any associate or affiliate of such persons
or companies, had any material interest, direct or indirect, in any transaction that occurred since January 1, 2023, or in any proposed
transaction, which has materially affected or will affect the Company.

 Item

 Principal
 Accountant Fees And Services.

 The
following is a summary of the fees billed to us for professional services rendered by our registered independent public accountants for
the fiscal years ended December 31, 2023 and December 31, 2022:

 Fiscal year ended December 31,

 2023

 2022

 Audit Fees

 $
 310,000

 $
 310,000

 Audit Related Fees

 -

 -

 Tax Fees

 -

 -

 All Other Fees

 -

 -

 $
 310,000

 $
 310,000

 Audit
Fees. Consists of fees billed for professional services rendered for the audit of our financial statements and review of interim financial
statements included in quarterly reports and services that are normally provided in connection with statutory and regulatory filings
or engagements.

 Audit
Related Fees. Consists of fees billed for assurance and related services that are reasonably related to the performance of the audit
or review of our financial statements and are not reported under "Audit Fees".

 Tax
Fees. Consists of fees billed for professional services for tax compliance, tax advice and tax planning. These services include preparation
of federal and state income tax returns.

 All
Other Fees. Consists of fees for product and services other than the services reported above.

 Board
of Directors' Pre-Approval Policies

 Our
Board of Directors' policy is to pre-approve all audit and permissible non-audit services provided by the independent auditors.
These services may include audit services, audit related services, tax services, and other services. Pre-approval is generally provided
for up to one year, and any pre-approval is detailed as to the particular service or category of services and is generally subject to
a specific budget. The independent auditors and management are required to periodically report to the board of directors regarding the
extent of services provided by the independent auditors in accordance with this pre-approval and the fees for the services performed
to date. The board of directors may also pre-approve particular services on a case-by-case basis.

 Our
Board of Directors reviewed our audited financial statements contained in our Annual Report on Form 10-K for the 2023 fiscal year. The
board of directors also has been advised of the matters required to be discussed pursuant to PCAOB Rule 3526 (Communication with Audit
Committees Concerning Independence), which includes, among other items, matters related to the conduct of the audit of our financial
statements.

 Our
Board of Directors considered whether the provision of services other than audit services is compatible with maintaining auditor independence.
Based on the review and discussions referred to above, the board of directors has determined that the audited financial statements be
included in our Annual Report on Form 10-K for our 2023 fiscal year for filing with the SEC.

 PART
IV

 ITEM

 EXHIBITS
 AND FINANCIAL STATEMENT SCHEDULES.

 (a)

 The
 following documents have been filed as a part of this Annual Report on Form 10-K.

 1.

 Financial
 Statements

 Years
Ended December 31, 2023 and 2022

 Page

 Report of Independent Registered Public Accounting Firm (PCAOB ID 2851)

 Financial
 Statements:

 Consolidated Balance Sheets as of December 31, 2023 and 2022

 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022

 Consolidated Statements of Stockholders' Equity (Deficit) for the Years Ended December 31, 2023 and 2022

 Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022

 Notes to Consolidated Financial Statements

 2.

 Financial
 Statement Schedules.

 All
schedules are omitted because they are not applicable or not required or because the required information is included in the Financial
Statements or the Notes thereto.

 3.

 Exhibits.
 The following exhibits are filed as part of, or incorporated by reference into, this Annual Report:

 Exhibit

Number

 Description of Document

 3.1

 Articles of Incorporation (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2006 as filed with the SEC on March 7, 2007).

 3.2

 Articles of Amendment to Articles of Incorporation (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on June 3, 2008).

 3.3

 Articles of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.3 the Company's Quarterly Report on Form 10-Q for the quarterly period ended November 30, 2017 as filed with the SEC on January 16, 2018).

 3.4

 Articles of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the 14C Information Schedule filed with the SEC on August 24, 2020).

 3.5

 Articles of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to Current Report on Form 8-K filed with the SEC on January 12, 2023)

 3.6

 Statement of Correction (incorporated by reference to Current Report on Form 8-K filed with the SEC on February 15, 2023)

 3.7

 Bylaws of the Company (incorporated by reference to Exhibit 3.6 of Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-268190) filed January 17, 2023).

 4.1

 Description of Securities (incorporated by reference to the Company's Annual Report on Form 10-K filed with the SEC on May 14, 2020).

 10.1

 2019 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Company's Registration Statement on Form S-8 filed on January 10, 2019).

 10.2

 English Translation of Equity Transfer Agreement with Respect to Shangyan Hotel Company (incorporated by reference to Current Report on Form 8-K dated May 25, 2021).

 10.3

 English Translation of Equity Transfer Agreement with respect to Chengdu AiXin Pharmacy Co., Ltd. and affiliated entities (incorporated by reference to Current Report on Form 8-K dated June 2, 2021).

 10.4

 English Translation of Equity Transfer Agreement among the Company, Chen Yun and Yunnan Sheng Shengyuan Technology Co., Ltd. (incorporated by reference to Current Report on Form 8-K dated July 7, 2022)

 10.5

 English Translation of Supplementary Agreement to Equity Transfer Agreement among the Company, Yunnan Sheng Shengyuan Technology Co., Ltd. and Chen Yun. (incorporated by reference to Current Report on Form 8-K/A filed October 10, 2022).

 10.6

 English Translation of Supplementary 2 Agreement to Equity Transfer Agreement among the Company, Yunnan Sheng Shengyuan Technology Co., Ltd. And Chen Yun. (incorporated by reference to Report on Form 8-K/A filed October 27, 2022).

 10.7

 English translation of Framework Agreement for Project Cooperation in Intelligent Deep Processing of Agricultural Products with Plateau Characteristics (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-268190) filed March 7, 2023).

 10.8

 Contribution Agreement dated March 1, 2023, by Mr. Quanzhong Lin in favor of the Company(incorporated by reference to Exhibit 10.8 to Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-268190) filed March 7, 2023).

 14.1

 Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed September 25, 2020).

 19.1

 Insider Trading Policy

 21.1

 List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Amendment No. 7 to Registration Statement on Form S-1 (File No. 333-268190) filed February 9, 2024).

 23.1

 Consent of Independent Registered Public Accounting Firm

 31.1

 Certification of Chief Executive Officer pursuant to Rule 13a-14 or Rule 15d-14 of Securities Exchange Act of 1934.

 31.2

 Certification of Chief Financial Officer pursuant to Rule 13a-14 of 15d-14 of Securities Exchange Act of 1934.

 32.1

 Certification of Chief Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).

 32.2

 Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).

 99.1

 Executive Compensation Clawback Policy.

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 Date:
 April 8, 2024

 By:

 /s/ Quanzhong
 Lin

 Lin

 Chief
 Executive Officer

 (Principal
 Executive Officer

 By:

 /s/ Tianfeng
 Li

 Chief
 Financial Officer

 (Principal
 Financial Officer)

 In
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities
indicated on April 8, 2024.

 Signature

 Title

 /s/
 Lin

 Chief
 Executive Officer and a Director

 Lin

 (Principal
 Executive Officer)

 /s/
Tianfeng Li

 Chief
 Financial Officer

 Tianfeng
 Li

 (Principal
 Financial Officer)

 /s/ Yao-Te
 Wang

 Yao-Te
 Wang

 /s/
 Huiliang
 Jiao

 Huiliang
 Jiao

 /s/
 Christopher Lee

 Christopher
 Lee

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To
the Board of Directors and Stockholders of

 AiXin
Life International, Inc.

 Opinion
on the Financial Statements

 We
have audited the accompanying consolidated balance sheets of AiXin Life International, Inc. (the "Company") as of December
31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and
cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements").
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years ended December 31, 2023 and 2022,
in conformity with generally accepted accounting principles in the United States of America.

 Consideration
of the Company's Ability to Continue as a Going Concern

 The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As described
in Note 2 to the financial statements, the Company incurred recurring losses from operations and has an accumulated deficit, which raises
substantial doubt about its ability to continue as a going concern. Management's plans with regard to these matters are described
in Note 2. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this
uncertainty.

 Basis
for Opinion

 These
consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.

 Critical
Audit Matter

 The
critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 F- 1

 Critical
Audit Matter Description

 As
described in Note 2 to the consolidated financial statements, the Company's products revenue is derived from the delivery of its
products. The sale of products by the Company is considered complete when the products are delivered at that time the ownership and risk
of loss have been transferred to the customer.

 The
Company considers the contracts with its customer contain one performance obligation, and the Company is entitled to the consideration
when performance obligation is satisfied at a point in time. The amount of revenue to be recognized is determined by the contracts between
the Company and its customer. The Company recognizes revenue when the product is delivered.

 The
principal considerations for our determination that performing procedures relating to revenue recognition, specifically the identification
and evaluation of the timing and amount of revenue recognition, is a critical audit matter, involved judgment exercised by management
in identifying and evaluating the performance obligation. Auditor judgement is involved in performing our audit procedures to evaluate
whether the timing and amount of revenue recognition was appropriately stated.

 How
the Critical Audit Matter Will Be Addressed in the Audit

 Our
audit procedures over determining the timing and amount of revenue recognition involved, among others, evaluation of management's
assessment in regard to the identification of performance obligation of revenue. We selected sales transactions and performed the following
procedures:

 -
Evaluated the terms and conditions of each selected transaction and the appropriateness of the accounting treatment within the context
of the five-step model prescribed by ASC 606, Revenue from Contracts with Customers, and evaluated whether management's conclusions
were appropriate.

 -
Tested the accuracy of management's recognition of revenue for the performance obligation.

 /s/
 KCCW Accountancy Corp.

 We
have served as the Company's auditor since 2019.

 Diamond
Bar, California

 April
5, 2024

 F- 2

 AIXIN

 CONSOLIDATED
BALANCE SHEETS

 2023

 2022

 Assets

 Current assets

 Cash and cash equivalents

 $
 443,758

 $
 510,128

 Restricted cash

 23,208

 109,772

 Accounts receivable, including related parties, net

 253,586

 562,581

 Other receivables and prepaid expenses

 170,831

 42,631

 Advances to suppliers

 152,563

 168,523

 Inventory, net

 441,098

 499,252

 Due from related parties

 12,400

 83,102

 Total current assets

 1,497,444

 1,975,989

 Property and equipment, net

 1,679,675

 1,971,793

 Intangible assets, net

 3,917

 1,269

 Deferred tax asset

 -

 15,556

 Security deposit

 84,508

 86,992

 Operating lease right-of-use assets

 1,576,814

 999,285

 Goodwill, net

 -

 -

 Total assets

 $
 4,842,358

 $
 5,050,884

 Liabilities and stockholders' equity

 Current liabilities

 $
 478,456

 $
 398,469

 Accounts payable - related party

 1,776

 165,958

 $
 478,456

 $
 398,469

 Unearned revenue

 172,753

 139,502

 Taxes payable

 49,249

 104,100

 Accrued liabilities and other payables

 2,163,066

 2,356,490

 Government grant

 923,238

 950,371

 Loan from third parties

 84,508

 86,992

 Operating lease liabilities

 864,519

 883,583

 Due to related parties

 1,226,885

 236,882

 Total current liabilities

 5,964,450

 5,322,347

 Operating lease liabilities - non-current

 789,489

 194,725

 Total liabilities

 6,753,939

 5,517,072

 Stockholders' deficit

 Undesignated preferred stock, $ 0.001 par value, 20,000,000 shares authorized, none
 issued and outstanding

 -

 -

 Common stock, par value $ 0.00001 per share, 500,000,000 shares authorized; 24,999,834 shares issued
 and outstanding as of December 31, 2023 and December 31, 2022

 Additional paid in capital

 14,975,423

 14,458,583

 Statutory reserve

 Accumulated deficit

 ( 17,220,392
)

 ( 15,249,858
)

 Accumulated other comprehensive income

 181,150

 172,849

 Total stockholders' deficit

 ( 1,911,581
)

 ( 466,188
)

 Total liabilities and stockholders' deficit

 $
 4,842,358

 $
 5,050,884

 The
accompanying notes are an integral part of these financial statements

 F- 3

 AIXIN

 CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 2023

 2022

 2023

 2022

 Sales revenue:

 $
 2,894,970

 $
 1,851,676

 Room revenues

 598,252

 262,605

 Food and beverage revenues

 498,029

 475,746

 Others

 98,548

 118,533

 Total revenue, net

 4,089,799

 2,708,560

 1,613,950

 1,103,160

 Hotel operating costs

 1,811,065

 1,739,948

 Selling

 888,745

 787,637

 General and administrative

 1,947,294

 1,395,008

 (Reversal of) provision for bad debts

 ( 43,988
)

 ( 119,274
)

 Stock-based compensation

 Total operating costs and expenses

 6,588,606

 5,278,019

 ( 2,498,807
)

 ( 2,569,459
)

 Non-operating income (expenses)

 Interest income

 4,876

 Impairment loss

 -

 ( 3,823,770
)

 Other income

 438,348

 51,856

 Other expenses

 ( 11,554
)

 ( 31,651
)

 Total non-operating income (loss), net

 427,632

 ( 3,798,689
)

 Loss before income tax

 ( 2,071,175
)

 ( 6,368,148
)

 Income tax expense

 19,519

 1,097

 ( 2,090,694
)

 ( 6,369,245
)

 Other comprehensive items

 Foreign currency translation gain (loss)

 8,301

 ( 537,974
)

 Comprehensive loss

 $
 ( 2,082,393
)

 $
 ( 6,907,219
)

 Income per share - basic and diluted

 $
 ( 0.084
)

 $
 ( 0.255
)

 Weighted average shares outstanding

 24,999,834

 24,999,842

 The
accompanying notes are an integral part of these financial statements

 F- 4

 AIXIN

 CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' DEFICIT

 Shares

 Amount

 paid in capital

 reserves

 deficit

 income

 Total

 Common Stock

 Additional

 Statutory

 Accumulated

 Accumulated

 other
comprehensive

 Shares

 Amount

 paid in capital

 reserves

 deficit

 income

 Total

 Balance at December 31, 2021

 24,999,842

 $

 $
 14,087,043

 $

 $
 ( 8,880,613
)

 $
 710,823

 $
 6,069,491

 Stock-based compensation

 -

 -

 -

 -

 -

 -

 -

 -

 -

 ( 6,369,245
)

 -

 ( 6,369,245
)

 Foreign currency translation

 -

 -

 -

 -

 -

 ( 537,974
)

 ( 537,974
)

 Balance at December 31, 2022

 24,999,842

 14,458,583

 ( 15,249,858
)

 172,849

 ( 466,188
)

 Balance

 24,999,842

 14,458,583

 ( 15,249,858
)

 172,849

 ( 466,188
)

 Stock-based compensation

 -

 -

 -

 -

 -

 Disposal of subsidiary

 -

 -

 -

 -

 120,160

 -

 120,160

 Shareholder contribution

 -

 -

 145,300

 -

 -

 -

 145,300

 Reverse stock split adjustment

 ( 8
)

 -

 -

 -

 -

 -

 -

 -

 -

 -

 -

 ( 2,090,694
)

 -

 ( 2,090,694
)

 Foreign currency translation

 -

 -

 -

 -

 -

 8,301

 8,301

 Balance at December 31, 2023

 24,999,834

 $

 $
 14,975,423

 $

 $
 ( 17,220,392
)

 $
 181,150

 $
 ( 1,911,581
)

 Balance

 24,999,834

 $

 $
 14,975,423

 $

 $
 ( 17,220,392
)

 $
 181,150

 $
 ( 1,911,581
)

 The
accompanying notes are an integral part of these financial statements

 F- 5

 AIXIN

 CONSOLIDATED
STATEMENTS OF CASH FLOWS

 2023

 2022

 2023

 2022

 CASH FLOWS FROM OPERATING ACTIVITIES:

 $
 ( 2,090,694
)

 $
 ( 6,369,245
)

 Adjustments required to reconcile net loss to net cash used in operating activities:

 Depreciation and amortization

 410,690

 185,565

 Loss on disposal of fixed assets

 -

 (Reversal of) provision for bad debts

 ( 47,762
)

 45,953

 Provision for inventory reserve

 7,770

 54,899

 Operating lease expense

 817,179

 837,425

 Stock-based compensation

 Deferred tax

 15,152

 1,858

 Impairment loss

 -

 3,823,770

 Government grant income

 ( 369,857
)

 -

 Changes in assets and liabilities:

 Accounts receivable

 564,502

 ( 425,961
)

 Accounts receivable - related parties

 ( 86,551
)

 ( 42
)

 Accounts receivable

 564,502

 ( 425,961
)

 Other receivables and prepaid expenses

 ( 132,455
)

 109,439

 Advances to suppliers

 133,513

 103,016

 Inventory

 36,240

 150,872

 93,682

 ( 71,153
)

 Accounts payable - related parties

 ( 159,843
)

 140,608

 93,682

 ( 71,153
)

 Unearned revenue

 37,275

 ( 24,401
)

 Taxes payable

 ( 52,010
)

 ( 137,711
)

 Payment of operating lease liabilities

 ( 779,599
)

 ( 710,865
)

 Accrued liabilities and other payables

 ( 161,393
)

 289,868

 Net cash used in operating activities

 ( 1,392,259
)

 ( 1,624,565
)

 CASH FLOWS FROM INVESTING ACTIVITIES:

 Cash disposed at disposal of subsidiary

 ( 3,319
)

 -

 Cash acquired at acquisition of subsidiary

 -

 446,381

 Purchase of property and equipment

 ( 295,487
)

 ( 156,723
)

 Purchase of intangible asset

 ( 4,032
)

 -

 Payment for acquisition of subsidiary

 -

 ( 3,812,027
)

 Net cash used in investing activities

 ( 302,838
)

 ( 3,522,369
)

 CASH FLOWS FROM FINANCING ACTIVITIES:

 Change in advance from related parties

 1,048,409

 ( 2,389,593
)

 Proceeds from government grant

 369,857

 -

 Capital contribution

 142,200

 -

 Net cash provided by (used in) financing activities

 1,560,466

 ( 2,389,593
)

 EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

 ( 18,303
)

 ( 444,426
)

 NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

 ( 152,934
)

 ( 7,980,953
)

 CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR

 619,900

 8,600,853

 CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR

 $
 466,966

 $
 619,900

 Supplemental Cash flow data:

 Income tax paid

 $
 4,367

 $
 71,163

 Interest paid

 $
 -

 $
 -

 The
accompanying notes are an integral part of these financial statements

 F- 6

 AIXIN

 NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS

 1.
 ORGANIZATION AND DESCRIPTION OF BUSINESS

 Aixin
Life International, Inc. (the "Company" or "Aixin Life" or "we") was incorporated under the laws
of the State of Colorado on December 30, 1987. On February 2, 2017, Mr. Quanzhong Lin (Mr. Lin) purchased 65.0 % of the Company's
outstanding shares from China Concentric Capital Group for $ 300,000, pursuant to a Stock Purchase Agreement dated December 21, 2016,
which resulted in a change in control of the Company.

 On
December 12, 2017, pursuant to a Share Exchange Agreement, in consideration for all of the outstanding shares of AiXin (BVI) International
Group Co., Ltd. a British Virgin Islands corporation ("AiXin BVI"), the Company issued to Mr. Lin, the sole stockholder of
AiXin BVI, shares of common stock then representing 71 % of the outstanding of common stock of the Company.

 As
a result of the Share Exchange, AiXin BVI became the Company's wholly-owned subsidiary, and the Company now owns all of the outstanding
shares of HK AiXin International Group Co., Limited, a Hong Kong limited company ("AiXin HK"), which in turn owns all of
the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company ("AiXinZhonghong"),
which markets and sells premium-quality nutritional products in China.

 AiXin
BVI was incorporated on September 21, 2017 as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 as an
intermediate holding company. AiXinZhonghong was established in the People's Republic of China ("PRC") on March 4,
2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXinZhonghong
by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 For
accounting purposes, the acquisition of AiXin BVI was accounted for as a reverse acquisition and treated as a recapitalization of the
Company effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations
prior to December 12, 2017, the historical consolidated financial statements of AiXinZhonghong are now the historical consolidated financial
statements of the Company. The assets and liabilities of AiXinZhonghong were brought forward at their book value and no goodwill was
recognized.

 Effective
February 1, 2018, the Company changed its name to AiXin Life International, Inc. ("Aixin Life").

 The
Company, through its indirectly owned AiXinZhonghong subsidiary, develops and distributes consumer products by offering a line of nutritional
products. The Company sells the products through exhibition events, conferences, and person-to-person marketing. Beginning in 2019, the
Company began to provide advertising services to clients who engaged the Company to help distribute their products. The Company's
business mainly focuses on a proactive approach to its customers such as hosting events for clients, which it believes is ideally suited
to marketing its products because sales of nutrition products are strengthened by ongoing personal contact and support, coaching and
education of its clients, as to the benefits of a healthy and active lifestyle.

 On
May 25, 2021, AiXin HK entered into an Equity Transfer Agreement (the "Hotel Purchase Agreement") with Chengdu Aixin Shangyan
Hotel Management Co., Ltd ("Aixin Shangyan Hotel"), and its two shareholders Quanzhong Lin and Yirong Shen ("Transferor").
Pursuant to the Hotel Purchase Agreement, Aixin Life purchased 100 % ownership of Aixin Shangyan Hotel from Transferor. Eighty percent
of the equity of Aixin Shangyan Hotel was owned by Mr. Lin, and the remaining balance was owned by Ms. Shen. Under the terms of the Hotel
Purchase Agreement, Aixin Life purchased all of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887,
or approximately $ 1.16 million (the "Transfer Price"). The Transfer Price will be reduced by an amount equal to any amounts
paid or distributed by Aixin Shangyan Hotel to the Transferor after December 31, 2020 and will be increased by an amount equal to any
amounts contributed to Aixin Shangyan Hotel by the Transferor after December 31, 2020. The acquisition was completed in July 2021.

 F- 7

 On
June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the "Pharmacies Purchase Agreement") with Chengdu Aixintang
Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, "Aixintang Pharmacies")
and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li ("Transferor"). Mr. Lin owned in excess of 95% of the
outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling Li. Pursuant to the Pharmacies
Purchase Agreement, AiXin HK purchased all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845,
or approximately US$ 5.31 million (the "Transfer Price"). The Transfer Price will be reduced by an amount equal to any amounts
paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by an amount contributed
to any of the Aixintang Pharmacies by the Transferor after such date. The acquisition was completed in September 2021.

 On
July 19, 2022, AiXin HK entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, ("Yunnan Shengshengyuan")
and Yun Chen (together, the "Sellers"), the shareholders of Yunnan Runcangsheng Technology Company Ltd. ("Runcangsheng").
Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun
Chen. Pursuant to the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Runcangsheng for an aggregate
purchase price of $ 4,418,095 (RMB 31,557,820), adjusted by $ 116,802 the amount equal to the initial net worth minus the audited net worth.
In addition to transferring their respective equity interest in Runcangsheng by the Sellers, both Sellers agree to forgive any loans
Runcangsheng due to them. The acquisition was completed on September 30, 2022 (see Note 19).

 On
February 17, 2023, the Company effected a 1 for 2 reverse stock split. As a result of the reverse split, every two shares of the Company's
issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock,
par value $ 0.00001 per share. The Company has approximately 24,999,834 shares of outstanding common stock after the effect of reverse
stock split and the elimination of fractional shares. All share and earnings per share information has been retroactively adjusted to
reflect the reverse stock split.

 2.
 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Basis
of Presentation and Consolidation

 The
accompanying consolidated financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles ("US
GAAP"). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese
Renminbi ("RMB"). The accompanying consolidated financial statements are translated from RMB and presented in U.S. dollars
("USD").

 The
consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, AiXin HK, AiXinZhonghong,
Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng. Intercompany transactions and accounts were eliminated in consolidation.

 Going
Concern

 The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. The realization of assets and the satisfaction of liabilities in
the normal course of business are dependent on, among other things, the Company's ability to operate profitably, to generate cash
flows from operations, and to pursue financing arrangements to support its working capital requirements.

 The
Company has suffered net losses of $ 2,090,694 and $ 6,369,245 for the years ended December 31, 2023 and 2022, respectively, and used net
cash in operating activities of $ 1,392,259 and $ 1,624,565 for the years ended December 31, 2023 and 2022, respectively, and has an accumulated
deficit of $ 17,220,392 as of December 31, 2023. These facts and conditions raise substantial doubt about the Company's ability
to continue as a going concern. From January 1, 2023 through December 31, 2023, the Company's cash and cash equivalents decreased
from $ 510,128 to $ 443,758 mainly due to operating losses, and the use of cash to support operating activities.

 F- 8

 Management
believes that it has developed a liquidity plan, summarized below, that, if executed successfully, should provide sufficient liquidity
to meet the Company's obligations as they become due for a reasonable period of time, and allow the development of its core business.
The plan includes:

Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

Raising cash through loans from related parties and potential equity offerings.

 While
the Company's management believes that the measures in its liquidity plan including those described above will be adequate to satisfy
its liquidity requirements for the twelve months after the date that these financial statements are issued, there is no assurance that
the liquidity plan will be successfully implemented. Failure to successfully implement the liquidity plan may have a material adverse
effect on its business, results of operations and financial position, and may adversely affect its ability to continue as a going concern.
These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded assets
or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue
as a going concern.

 Global
Uncertainties

 The
Company's liquidity may be adversely impacted by various risks and uncertainties, including, but not limited to future and current
impacts of global events such as a widespread health crisis, the continuation of the war in the Ukraine or the conflict in Palestine,
the outbreak of another conflict or the expansion of the conflict in Palestine to other countries, the ongoing tensions between the United
States and China, the Russian Federation and certain countries in the Middle East, increases in inflation, and other risks detailed in
in the Company's Annual Report on Form 10-K or other reports filed with the Securities and Exchange Commission.

 While
the invasion of Ukraine, the conflict in Palestine and responses thereto have not interrupted the Company's operations, these or
future developments which disrupt the international financial markets could make it difficult to access debt and equity capital on attractive
terms, if at all, and impact the Company's ability to fund business activities, including proposed acquisitions.

 Use
of Estimates

 In
preparing consolidated financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements,
as well as the reported amounts of revenues and expenses during the reporting period.

 Significant
estimates required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for
obsolete and slow-moving inventories. Actual results could differ from those estimates.

 Reclassification

 Certain
prior period amounts have been reclassified to conform to the current period presentation and had no effect on previously reported consolidated
net income (loss) or accumulated deficit.

 Cash
and Cash Equivalents

 For
financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to
be cash and cash equivalents.

 F- 9

 Restricted
Cash

 The
restricted cash was cash maintained in temporarily frozen bank accounts held by Aixintang Pharmacy and its branches by the court for
a judgement against Aixintang Pharmacy (see Note 18 – litigation).

Receivable

 The
Company's policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition
of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends
and changes in customer payment patterns to evaluate the adequacy of these reserves. As of December 31, 2023 and 2022, the bad debt allowance
was $ 80,640 and $ 272,550 respectively.

 The
following table summarizes the activity related to the Company's accounts receivable allowance for doubtful accounts for the years
ended December 31, 2023 and 2022:

OF ACCOUNTS RECEIVABLE ALLOWANCE FOR DOUBTFUL ACCOUNTS

 2023

 2022

 For the years ended December 31,

 2023

 2022

 Beginning balance

 $
 272,550

 $
 213,787

 (Reversal of) provision for bad debts

 ( 47,762
)

 45,953

 Acquisition of subsidiary

 -

 196,164

 Recoveries/Write offs

 ( 135,589
)

 ( 165,227
)

 Effect of translation

 ( 8,559
)

 ( 18,127
)

 Ending balance

 $
 80,640

 $
 272,550

 Inventories

 Inventories
mainly consists of health supplements, drugs, pharmaceutical and nutritional products, food and beverage, hotel supplies and consumables.
Inventories are valued at the lower of average cost or market, cost being determined on a moving weighted average method at the end of
the month. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories
to market value, if lower. The Company recorded provision for inventory reserve of $ 7,770 and $ 54,899 for the years ended December 31,
2023 and 2022, respectively.

 Property
and Equipment

 Property
and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly
extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs
are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided
using the straight-line method for substantially all assets with 5 % salvage value and estimated lives as follows:

OF PROPERTY AND EQUIPMENT ESTIMATED LIVES

 Office furniture

 5 years

 Electronic equipment

 2 - 3 years

 Machinery

 3 years

 Leasehold improvements

 3 years

 Vehicles

 5 years

 Impairment
of Long-Lived Assets

 Long-lived
assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable, but at least annually.

 F- 10

 Recoverability
of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future
cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an
impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally
determined using the asset's expected future discounted cash flows or market value, if readily determinable. Based on its review,
the Company believes that, as of December 31, 2023 and 2022, there were no significant impairments of its long-lived assets.

 Goodwill

 The
Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the
carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment
to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative
assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests
goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting
units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not
that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair
value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts
of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category
expansion, pricing, market segment share, and general economic conditions.

 The
Company completed the required testing of goodwill for impairment as of December 31, 2022, and determined that goodwill was impaired
because of the current financial condition of the Company and the Company's inability to generate future operating income without
substantial sales volume increases, which are highly uncertain. Furthermore, the uncertainty of the future cash flows indicates that
the recoverability of goodwill is not reasonably assured.

 The
goodwill write-down was reflected as an impairment loss, $ 3,823,770, in non-operating expenses in the statement of operations and comprehensive
income (loss) during the year ended December 31, 2022.

Taxes

taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences
in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end
based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 The
Company follows Accounting Standards Codification ("ASC") Topic 740, which prescribes a more-likely-than-not threshold for
financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides
guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities,
accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 Under
ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities,
while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately
sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on
all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including
the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax
positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than
50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions
taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying
balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest
associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative
expenses in the statement of income.

 F- 11

 At
December 31, 2023 and 2022, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

Recognition

from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company's products
and services to customers in return for expected consideration and includes the following elements:

 executed
 contract(s) with customers that the Company believes is legally enforceable;

 identification
 of performance obligation in the respective contract;

 determination
 of the transaction price for each performance obligation in the respective contract;

 allocation
 of the transaction price to each performance obligation; and

 recognition
 of revenue only when the Company satisfies each performance obligation.

 The
Company's revenue recognition policies for its various operating segments are as follows:

 The
Company's revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists.
The Company does not provide unconditional return or other concessions to the customer. The Company's sales policy allows for the
return of unopened products for cash after deducting certain service and transaction fees. As an alternative to the product return option,
the customers have the option of asking for an exchange for products with the same value.

 Sales
revenue of AiXin Zhonghong represents the invoiced value of goods, net of value-added taxes ("VAT"). All of the Company's
products sold in China are subject to the PRC VAT of 13 % since April 1, 2019. This VAT may be offset by VAT paid by the Company on raw
materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial
statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT
collected and paid as the Company acts as an agent for the government.

 Hotel

 Hotel
revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but
not limited to souvenir, parking and conference reservation. Each of these products and services represents a distinct performance obligation
and, in exchange for these services, the Company receives fixed amounts based on published rates or negotiated contracts. Payment is
due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis
when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered
or rendered to the guests as the respective performance obligations are satisfied. All of the hotel's goods sold in China are subject
to the PRC VAT of 6 %. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China.

 The
Company's retail drugstores (Aixintang Pharmacies) recognize revenue at the time the customer takes possession of the merchandise.
For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. Aixintang Pharmacies
generally receives payments from customers as it satisfies its performance obligations. The Company records a receivable when it has
an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the
invoiced value of goods, net of VAT. All of Aixintang Pharmacies' products sold in China are eligible for the PRC VAT of 0 % as
it qualifies as a small business.

 F- 12

 Manufacture
and Sale

 The
Company's new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation.
The Company records a receivable for its sales when it has an unconditional right to receive payment and only the passage of time is
required before payment is due. Sales revenue represents the invoiced value of goods, net of value-added taxes ("VAT"). All
of the Company's products sold in China are subject to the PRC VAT of 13 % unless it is a qualified small business subject to exemption.

 Unearned

 The
Company's unearned revenue primarily consists of advances received from customers for the purchase of products prior to the delivery
of goods, and for the rental of hotel rooms prior to the delivery of service. The delivery of products and room rental services is based upon contract terms and customer demand, normally within one year.

 Concentration
of Credit Risk

 The
operations of the Company are in the PRC. Accordingly, the Company's business, financial condition, and results of operations may
be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 The
Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks
is covered by insurance up to RMB 500,000 ($ 72,500) per bank. The Company has not experienced any losses in such accounts and believes
they are not exposed to any risks on its cash in these bank accounts.

the years ended December 31, 2023 and 2022, the Company had no customer that accounted for over 10 % of its total revenue.

the year ended December 31, 2023, the Company had two suppliers that accounted for over 10% of its total purchases.

OF CONCENTRATION OF RISK BY RISK FACTORS

 Supplier

 Net purchases for the
 year ended

 % of total purchase

 A

 $
 250,999

 %

 B

 195,202

 %

the year ended December 31, 2022, the Company had two major suppliers that accounted for over 10% of its total purchases.

 Supplier

 Net
 purchases for the

 year ended

 %
 of total purchase

 B

 $

 189,150

 %

 C
 (1)

 149,806

 %

 (1)

 The
 Company purchased inventory from this supplier, Runcansheng, in the year ended December 31, 2022. The Company acquired all of the
 outstanding equity of Runcangsheng on September 30, 2022 (see Note 19).

 F- 13

 Leases

 The
Company determines if an arrangement is a lease at inception under FASB ASC Topic 842, Right of Use Assets ("ROU") and lease
liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this
purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of its leases do not
provide an implicit rate, it uses its incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding
of what its credit rating would be. The ROU assets include adjustments for prepayments and accrued lease payments. The ROU asset also
includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company's lease
terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise such options.

 ROU
assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject
to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets.

 ROU
assets are tested for impairment individually or as part of an asset group if the cash flows related to the ROU asset are not independent
from the cash flows of other assets and liabilities. An asset group is the unit of accounting for long-lived assets to be held and used,
which represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets
and liabilities. The Company recognized no impairment of ROU assets as of December 31, 2023 and 2022. Operating leases are included in
operating lease ROU and operating lease liabilities (current and non-current), on the consolidated balance sheets.

 Statement
of Cash Flows

 In
accordance with ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated
based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on
the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.

 Fair
Value of Financial Instruments

 The
carrying amounts of certain of the Company's financial instruments, including cash and cash equivalents, accrued liabilities and
accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, "Financial Instruments,"
requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the consolidated
balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because
of the short period of time between the origination of such instruments and their expected realization and the current market rate of
interest.

 Fair
Value Measurements and Disclosures

 ASC
Topic 820, "Fair Value Measurements and Disclosures," defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined
as follow:

 Level
 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 Level
 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
 are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 Level
 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 F- 14

 As
of December 31, 2023 and 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance
sheet at fair value.

 Foreign
Currency Translation and Comprehensive Income (Loss)

 The
functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets
and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the
average rate of exchange prevailing during the reporting period.

 Translation
adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders'
equity as "Accumulated other comprehensive income". Gains and losses resulting from foreign currency transactions are included
in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 The
Company uses FASB ASC Topic 220, "Comprehensive Income". Comprehensive loss is comprised of net loss and all changes to the
statements of stockholders' equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. Comprehensive income (loss) for the year ended December 31, 2023 and 2022 consisted of net income (loss) and foreign
currency translation adjustments.

 Earnings
per Share

 Basic
income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.

 Dilution
is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be
exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase
common stock at the average market price during the period.

 As
of December 31, 2023 and 2022, the Company did not have any potentially dilutive instruments.

 Stock-Based

 The
Company periodically grants stock options, warrants and awards to employees and non-employees in non-capital raising transactions as
compensation for services rendered. The Company accounts for stock option, stock warrant and stock award grants to employees based on
the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the
vesting period. The Company accounts for stock option, stock warrant and stock award grants to non-employees in accordance with the authoritative
guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at
which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.
Stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where
there are no future performance requirements by the employees and non-employees, option, warrant and award grants are immediately vested
and the total stock-based compensation charge is recorded in the period of the measurement date.

 Segment
Reporting

 ASC
Topic 280, "Segment Reporting," requires use of the "management approach" model for segment reporting. The management
approach model is based on the way a company's chief operating decision maker organizes segments within the Company for making
operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography,
legal structure, management structure, or any other manner in which management disaggregates a company.

 The
Company manages its business as four operating segments, products, pharmacies, hotel, and manufacture and sales, all of which are located
in the PRC. All of its revenues are derived in the PRC. All long-lived assets are located in PRC.

 F- 15

 The
following table shows the Company's operations by business segment for the years ended December 31, 2023 and 2022.

OF SEGMENTS INFORMATION

 2023

 2022

 For the Years Ended December 31,

 2023

 2022

 Net revenue

 $
 1,159,134

 $
 823,930

 937,655

 789,347

 Hotel

 1,194,829

 856,884

 798,181

 238,399

 Total revenues, net

 $
 4,089,799

 $
 2,708,560

 $
 393,862

 $
 171,345

 1,790,747

 1,526,246

 531,890

 578,092

 455,906

 622,835

 Hotel

 Hotel operating costs

 1,811,065

 1,739,948

 192,963

 310,902

 688,198

 353,723

 723,975

 ( 25,072
)

 Total operating costs and expenses

 $
 6,588,606

 $
 5,278,019

 $
 ( 1,025,475
)

 $
 ( 873,661
)

 ( 50,141
)

 ( 411,580
)

 Hotel

 ( 809,199
)

 ( 1,193,966
)

 ( 613,992
)

 ( 90,252
)

 $
 ( 2,498,807
)

 $
 ( 2,569,459
)

 Segment assets

 As of

 As of

 $
 270,932

 $
 410,754

 425,546

 758,675

 Hotel

 1,654,165

 970,385

 2,491,715

 2,911,070

 Total assets

 $
 4,842,358

 $
 5,050,884

 As
the acquisition of Runcangsheng was consummated as of September 30, 2022 (see Note 19), the revenues and operating results of the manufacture
and sale segment were included in the financial statements of the Company beginning on October 1, 2022.

 New
Accounting Pronouncements

 In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The adoption of ASU 2016-13 did not have any impact on the Company's consolidated financial
statements presentation or disclosures.

 F- 16

 In
January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill
impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting
unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective
basis. As a smaller reporting company, the standard will be effective for the Company for interim and annual reporting periods beginning
after December 15, 2022, with early adoption permitted. The adoption of ASU 2017-04 did not have any impact on the Company's consolidated
financial statements presentation or disclosures.

 In
August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
- Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's
Own Equity ("ASU 2020-06"), which simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing
guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features
and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception
from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer's
own stock and classified in stockholders' equity, by removing certain criteria required for equity classification; and (3) revises
the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments
by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an
instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal
years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the
fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The adoption of ASU 2020-06 is not expected to
have any impact on the Company's consolidated financial statements presentation or disclosures.

 The
Company's management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently
adopted, would have a material impact on the Company's financial statement presentation or disclosures.

 3.
 OTHER RECEIVABLES AND PREPAID EXPENSES

 Other
receivables and prepaid expenses consisted of the following at December 31, 2023 and 2022:

OF OTHER RECEIVABLES AND PREPAID EXPENSES

 Deposits

 $
 8,978

 $
 15,546

 Prepaid expenses including related party (see Note 13)

 128,378

 9,490

 Employees' social insurance

 8,667

 10,124

 Others

 24,808

 7,471

 Total

 $
 170,831

 $
 42,631

 4.
 ADVANCES TO SUPPLIERS

 The
Company had advances to suppliers of $ 152,563 and $ 168,523 as of December 31, 2023 and 2022, respectively. Advances to suppliers primarily
include prepayments for products and equipment expected to be delivered subsequent to balance sheet dates.

 F- 17

 5.
 INVENTORIES

 Inventories
consisted of the following at December 31, 2023 and 2022:

OF INVENTORIES

 Raw material

 $
 114,005

 $
 62,462

 Work in process

 -

 15,315

 Finished goods-health supplements

 -

 Drugs, pharmaceutical and nutritional products

 324,588

 412,129

 Food and beverage, hotel supplies and consumables

 81,969

 82,646

 Total

 $
 520,562

 $
 573,073

 Less: reserve for inventory

 79,464

 73,821

 Total inventories, net

 $
 441,098

 $
 499,252

 6.
 PROPERTY AND EQUIPMENT, NET

 Property
and equipment consisted of the following at December 31, 2023 and 2022:

 SCHEDULE OF PROPERTY AND EQUIPMENT

 Vehicles

 $
 451,381

 $
 426,836

 Office furniture

 80,612

 82,549

 Electronic equipment

 25,899

 20,607

 Machinery

 1,314,902

 1,241,778

 Leasehold improvements

 1,125,581

 1,139,087

 Other

 11,997

 17,485

 Total

 3,010,372

 2,928,342

 Less: Accumulated depreciation

 ( 1,330,697
)

 ( 956,549
)

 Property and equipment, net

 $
 1,679,675

 $
 1,971,793

 Depreciation
expense for the years ended December 31, 2023 and 2022 was $ 409,351 and $ 183,542, respectively

 7.
 INTANGIBLE ASSET, NET

 Intangible
asset consisted of the following at December 31, 2023 and 2022:

 SCHEDULE OF INTANGIBLE ASSET

 Software

 $
 12,516

 $
 8,564

 Less: Accumulated amortization

 ( 8,599
)

 ( 7,295
)

 Intangible asset, net

 $
 3,917

 $
 1,269

 Amortization
expense for the years ended December 31, 2023 and 2022 was $ 1,339 and $ 2,023, respectively.

 8.
 TAXES PAYABLE

 Taxes
payable consisted of the following at December 31, 2023 and 2022:

 SCHEDULE OF TAX PAYABLE

 Value-added

 $
 6,439

 $
 56,806

 29,998

 30,919

 City construction

 1,423

 3,746

 Education

 1,024

 2,184

 Other

 10,365

 10,445

 Taxes payable

 $
 49,249

 $
 104,100

 F- 18

 9.
 ACCRUED LIABILITIES AND OTHER PAYABLES

 Accrued
liabilities and other payables consisted of the following at December 31, 2023 and 2022:

 SCHEDULE OF ACCRUED LIABILITIES AND OTHER PAYABLES

 Accrued employees' social insurance

 $
 231,983

 $
 270,349

 Accrued payroll and commission

 308,768

 307,331

 Accrued rent expense

 -

 32,746

 Construction payable

 1,229,775

 1,384,674

 Payable for equipment purchase

 30,307

 32,278

 Accrued professional fees

 250,505

 233,894

 Deposit

 10,986

 11,308

 Other payables

 100,742

 83,910

 Total

 $
 2,163,066

 $
 2,356,490

 10.
 GOVERNMENT GRANT

 On
December 1, 2021, The Company and Luquan Yizu Miaozu Autonomous County People's Government ("the People's Government")
entered a cooperation agreement for a cooperation term of 10 years. According to the agreement, the People's Government will contribute
RMB 8,000,000 ($ 1,194,400) as a one-time payment to the Company for supporting them on deep processing of Chinese herbs. The Company
can retain the contributed amount at the end of the cooperation term if it passes the performance assessment by People's Government;
otherwise, it will return the full proceeds they received plus 20% penalty. As of December 31, 2023, the Company only received $ 923,238
from People's Government, the Company plans to return the funds to the People's Government as it is not the full amount the Peoples'
Government promised to contribute.

 11.
 LOAN FROM THIRD PARTIES

 As
of December 31, 2023 and 2022, the Company had advances from unrelated third parties of Aixin Shangyan Hotel in an aggregate amount $ 84,508
and $ 86,992, respectively. There was no written agreement, and these loans are payable on demand and bear no interest.

 12.
 LEASE

 AiXinZhonghong
leases its office on a monthly basis. AiXinZhonghong also has operating leases for other sales locations under various operating lease
arrangements. The leases have remaining lease terms of approximately 0.33 to 4.41 years.

 Aixin
Shangyan Hotel leases its hotel premises under an operating lease arrangement. The lease has a remaining lease term of approximately
 2 years.

 Aixintang
Pharmacies lease retail pharmacy stores under operating lease arrangements, with remaining lease terms of 0.96 to 2.67 years.

 Runcangsheng
leases its office under an operating lease arrangement. The lease was expired as of December 31, 2023. In January 2024, the lease was renewed with the expiration date on December 31, 2024.

 Balance
sheet information related to the Company's leases is presented below:

 SCHEDULE OF OPERATING LEASE LIABILITIES

 Operating Leases

 Operating lease right-of-use assets

 $
 1,576,814

 $
 999,285

 Operating lease liabilities – current

 $
 864,519

 $
 883,583

 Operating lease liability – non-current

 789,489

 194,725

 Total operating lease liabilities

 $
 1,654,008

 $
 1,078,308

 F- 19

 The
following provides details of the Company's lease expenses:

 SCHEDULE OF OPERATING LEASE EXPENSES

 2023

 2022

 2023

 2022

 Operating lease expenses

 $
 817,179

 $
 837,425

 Other
information related to leases is presented below:

 SCHEDULE OF OTHER INFORMATION RELATED LEASES

 2023

 2022

 Cash Paid for Amounts Included In Measurement of Liabilities:

 Operating cash flows from operating leases

 $
 779,599

 710,865

 Weighted Average Remaining Lease Term:

 Operating leases

 1.99 years

 1.45 years

 Weighted Average Discount Rate:

 Operating leases

 4.75
 %

 4.75
 %

 Maturities
of lease liabilities were as follows:

 SCHEDULE OF MATURITIES OF LEASE LIABILITIES

 For the year ending December 31:

 2024

 $
 921,869

 2025

 759,052

 2026

 37,370

 2027

 8,451

 2028

 3,521

 Total lease payments

 1,730,263

 Less: imputed interest

 ( 76,255
)

 Total lease liabilities

 1,654,008

 Less: current portion

 ( 864,519
)

 Lease liabilities – non-current portion

 $
 789,489

 13.
 RELATED PARTY TRANSACTIONS

receivable – related party

receivable – related party consisted of the following as of the periods indicated:

OF ACCOUNTS RECEIVABLE RELATED PARTY

 Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.

 $
 2,451

 $
 -

 Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.

 4,309

 -

 Chengdu Fuxiang Tang Pharmacy Co., Ltd.

 2,028

 -

 Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd

 2,028

 -

 Xiaoyan Zhou

 32,493

 -

 Chengdu Aixin International Travel Service Co., Ltd

 43,083

 -

 Other

 -

 Total

 $
 86,392

 $

receivable – related party

 $
 86,392

 $

 The
related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life).
Xiaoyan Zhou is the wife of Huiliang Jiao, the Company's Director.

 Prepaid
expense – related party

 Prepaid
expense – related party consisted of the following as of the periods indicated:

OF PREPAID EXPENSE AND ACCOUNTS PAYABLE TO RELATED PARTY

 Chengdu Aixin International Travel Service Co., Ltd

 $
 120,483

 $
 -

 Chengdu
Aixin International Travel Service Co., Ltd is an entity owned by the Company's CEO.

 F- 20

payable – related party

payable – related party consisted of the following as of the periods indicated:

 Luquan Shengcaofeng Biotechnology Co., Ltd.

 $
 -

 $
 165,958

 Sichuan Aixintang Xinfu Chain Pharmacy Co., Ltd.

 1,776

 -

 $
 1,776

 $
 165,958

 Luquan
Shengcaofeng Biotechnology Co., Ltd. is an entity controlled by Mr. Huiliang Jiao, a Director of the Company.

 Sichuan Aixintang Xinfu Chain Pharmacy Co.,
Ltd. is an entity controlled by Quanzhong Lin,
CEO of the Company.

 Due
from related parties

 Due
from related parties consisted of the following as of the periods indicated:

 SCHEDULE OF RELATED PARTY TRANSACTIONS

 Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.

 $

 $
 9,708

 Chengdu Fuxiang Tang Pharmacy Co., Ltd.

 26,125

 Chengdu Zhiweibing Pharmacy Co., Ltd.

 1,738

 -

 Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd

 34,622

 Sichuan Aixin Investment Co. Ltd

 9,310

 Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.

 -

 12,502

 Total

 $
 12,400

 $
 83,102

 Due
from related parties

 $
 12,400

 $
 83,102

 Due to related parties

 Due
to related parties consisted of the following as of the periods indicated:

 Quanzhong Lin

 $
 1,051,429

 $
 140,644

 Yirong Shen

 87,325

 89,892

 Huiliang Jiao

 82,152

 -

 Tianfeng Li

 -

 Mianyang Aixin Cunshan Pharmacy Co. Ltd

 -

 Chengdu Aixin International travel service Co, Ltd

 5,087

 6,346

 Total

 $
 1,226,885

 $
 236,882

 Due to related parties

 $
 1,226,885

 $
 236,882

 The
amounts of due from related parties and due to related parties described above were for working capital purposes, payable on demand,
and bear no interest. All the related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major
shareholder of Aixin Life). Yirong Shen was a major shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase Agreement,
and she serves as the supervisor of Aixin Shangyan Hotel. Mr. Huiliang Jiao is the Director of the Company. Tianfeng Li is the CFO of
Aixin Life.

 Office
leases

 In
May 2014, the Company entered a lease with its major shareholder for an office. The lease term was for three years expiring in May 2017
with an option to renew. The monthly rent was RMB 5,000 ($ 704). The Company was required to prepay each year's annual rent at 15th
of May of each year. The Company renewed the lease until May 28, 2028 with monthly rent of RMB 5,000 ($ 704), payable quarterly. The future
annual minimum lease payments at December 31, 2023 are $ 8,450, $ 8,450, $ 8,450, $ 8,450, and $ 3,521 for each of the years ended December
31, 2024, 2025, 2026, 2027, and 2028, respectively.

 F- 21

 Runcangsheng
has an office lease with Xiaoyan Zhou, wife of Huiliang Jiao, the Company's Director, from March 2020 to February 2023 with a monthly
rent of RMB 3,000 ($ 414). Runcangsheng renewed the lease until February 28, 2026 with monthly rent of RMB 5,000 ($ 690). In July 2023,
Xiaoyan Zhou entered into an agreement with Runcangsheng to increase the monthly rent for 2022 by RMB 2,000 and to change the lease expiration
date to December 31, 2023. The lease will be converted to an annual contract starting from January 1, 2024.

 14.
 INCOME TAXES

 The
Company was incorporated in the United States of America ("USA") and has operations in one tax jurisdiction, i.e. the PRC.
The Company generated substantially all of its sales from its operations in the PRC for the years ended December 31, 2023 and 2022, and
recorded income tax provision for the periods.

 China
has a tax rate of 25 % for all enterprises (including foreign-invested enterprises).

 The
components of the provision for income taxes for the years ended December 31, 2023 and 2022 consisted of the following:

 SCHEDULE OF COMPONENTS OF THE PROVISION FOR INCOME TAXES

 2023

 2022

 For the Year Ended December 31,

 2023

 2022

 Current:

 China

 $
 4,367

 $
 ( 761
)

 Total current

 4,367

 ( 761
)

 Deferred:

 China

 15,152

 1,858

 Total deferred

 15,152

 1,858

 Total income tax expense

 $
 19,519

 $
 1,097

 Deferred
tax assets as of December 31, 2022 and 2021 consisted of the following:

 SCHEDULE OF DEFERRED TAX ASSETS

 Deferred tax assets:

 Accumulated amortization

 $
 13,204

 $
 15,556

 Less: valuation allowance

 ( 13,204
)

 -

 Deferred tax assets, net

 $
 -

 $
 15,556

 The
following table reconciles the statutory rates to the Company's effective tax rate for years ended December 31, 2023 and 2022:

 SCHEDULE OF EFFECTIVE INCOME TAX RATE

 2023

 2022

 Statutory U.S. federal income tax rate

 ( 21.0
)%

 ( 21.0
)%

 Foreign tax rate differential

 ( 3.3
)%

 ( 3.8
)%

 Change in valuation allowances

 25.2
 %

 25.0
 %

 Other

 -
 %

 ( 0.2
)%

 Effective combined tax rate

 0.9
 %

 0.0
 %

 As
of December 31, 2023, the Company had approximately $ 5,371,806 net operating loss carry-forwards available to offset future taxable income
in China primarily from Aixin Shangyan Hotel and Aixintang Pharmacies. The Company's net operating loss carry-forwards begins to
expire in 2024. After consideration of all information available, management believes that uncertainty exists with respect to future
realization of its deferred tax assets resulted from net operating loss carry-forwards due to the Company's net loss, and established
a full valuation allowance of deferred tax assets resulted from net operating loss carry-forwards.

 F- 22

 Uncertain
Tax Positions

 Interest
associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative
expenses in the statements of operations. For the years ended December 31, 2023 and 2022, the Company had no unrecognized tax benefits
and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

 15.
 STOCKHOLDERS' EQUITY

 On
August 17, 2020, by unanimous written consent in lieu of a meeting, the Board adopted resolutions authorizing a one (1)-for-four (4)
reverse stock. The reverse stock split became effective on October 27, 2020. According to the Articles of Amendment, the Company is authorized
to issue 20,000,000 shares of blank check preferred stock at $ 0.001 par value and 500,000,000 shares of common stock at $.00001 par value
per share.

 Pursuant
to resolutions adopted by the Board of Directors and the holders of a majority of the outstanding shares of common stock of AiXin Life
International, Inc. on January 6, 2023, the Company filed an amendment to its Articles of Incorporation with respect to a proposed 1
for 2 "reverse" split of its common stock (the "Amendment"). Completion of the proposed reverse stock split was
to be effected on a date determined by the Board of Directors only upon receipt of notice from the Financial Industry Regulatory Authority
("FINRA") that it would process the proposed reverse stock split. The Company received notice from FINRA and its common stock
began trading on a post-split basis on February 17, 2023.

 As
a result of the reverse split, every two shares of the Company's issued and outstanding common stock were automatically combined
and converted into one issued and outstanding share of common stock. The Company has approximately 24,999,834 shares of outstanding common
stock after giving effect to the reverse stock split and the elimination of fractional shares.

 All
share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

 As
of December 31, 2023, and 2022, the Company had 24,999,834 common shares issued and outstanding, after reverse stock split adjustment.

 Stock
Awards Issued for Services

 On
October 22, 2019, the Company granted and issued 18,750 shares to its employees and contractors under its 2019 Equity Incentive Plan.
The stock awards were valued at $ 337,500 based on the post-split closing price of $ 18 on the grant date.

 On
October 24, 2019, the Company granted and issued 275,000 shares to its employees and contractors under its 2019 Equity Incentive Plan.
The stock awards were valued at $ 1,520,200 based on the post-split closing price of $ 5.528 on the grant date.

 The
stock awards will vest over five ( 5)
years from the grant date, and the grantee will forfeit a portion of the shares granted ("Shares Granted") if the grantee
is no longer employed by or contracted with the Company. Specifically, the
grantee will forfeit 80% of Shares Granted if no longer employed by or contracted with the Company on the date that is one year from
the grant date, forfeit 60% of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from
the grant date, forfeit 40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years
from the grant date, and forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four
years from the grant date. Effective on the 5 th year from the grant date, none of the shares will be subject to forfeiture.

 For
the years ended December 31, 2023 and 2022, stock-based compensation expenses were $ 371,540 and $ 371,540, respectively. As of December
31, 2023, unrecognized compensation expenses related to these stock awards are $ 301,127. These expenses are expected to be recognized
over 0.81 years.

 F- 23

 Capital
Contribution

the year ended December 31, 2023, the Company received capital contributions in the aggregate amount of $ 145,300 from Yunnan Shengshengyuan
and Yun Chen, the former shareholders of Runcangsheng (see Note 1), who remained as related parties of the Company after the completion
of acquisition of Runcangsheng.

 16.
 OTHER INCOME

the year ended December 31, 2023, the Company had $ 369,857
 other income, mainly consisted of local
government grant for supporting Runcangsheng to become leading enterprise for plant, producing and marketing Chinese herbal medicine
by utilizing local and natural resource of Chinese herb, building a primary processing plant with an annual processing capacity of 1,500
tons of Chinese medicinal materials, as well as supporting Runcangsheng on integrated innovation and application of deep processing technology
for health products.

 17.
 STATUTORY RESERVES

 Pursuant
to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit
before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 Surplus
reserve fund

 The
Company is required to transfer 10 % of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus
reserve fund until such reserve balance reaches 50 % of the Company's registered capital. During the years ended December 31, 2023
and 2022, the Company made $ 0 and $ 0 contribution to statutory reserve fund.

 The
surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years' losses, if any,
and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion
to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance
after such issue is not less than 25 % of the registered capital.

 Common
welfare fund

 Common
welfare fund is a voluntary fund to which the Company can elect to transfer 5 % to 10 % of its net income, as determined under PRC accounting
rules and regulations. The Company did not make any contribution to this fund during the years ended December 31, 2023 and 2022.

 This
fund can only be utilized on capital items for the collective benefit of the Company's employees, such as construction of dormitories,
cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 18.
 OPERATING CONTINGENCIES

 The
Company's operations in the PRC are subject to specific considerations and significant risks not typically associated with companies
in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments
and foreign currency exchange. The Company's results may be adversely affected by changes in governmental policies with respect
to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among
other things.

 The
Company's sales, purchases and expenses are denominated in RMB and all of the Company's assets and liabilities are also denominated
in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are
required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain
supporting documentation to affect the remittance.

 F- 24

 Litigation

 The
Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment
matters, and litigation regarding intellectual property rights.

 In
October 2020, Jian Yiao (the "Plaintiff") filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. ("Aixintang
Pharmacy", or the "Defendant") in Zhangjiagang People's Court in Jiangsu Province. The complaint alleges that
Jian Yiao is entitled to $ 392,305 (RMB 2,500,000) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase
agreement entered in March 2020 (the "Purchase Agreement"). Aixintang Pharmacy claimed that the Purchase Agreement was falsely
entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined
that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay
$ 392,305 (RMB 2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion of appeal in the Jiangsu Suzhou Intermediate
People's Court against the determination reached from the first trial.

 In
February 2021, the judge in the Jiangsu Suzhou Intermediate People's Court denied the Defendant's motion and upheld the
judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion of re-trial to the Jiangsu High People's
Court on the basis that the Purchase Agreement was forged, the motion was accepted by Jiangsu High People's Court in July
2021. Due to the impact of COVID-19 pandemic, Aixintang Pharmacy was unable to provide any new evidence to the Jiangsu High
People's Court. Consequently, in September 2022, the Court rejected the Defendant's motion and upheld the judgment
rendered in the second trial.

 In
April 2021, Jian Yiao applied for the first execution of the judgement; a total of $ 97,748
(RMB 694,000)
was executed. On June 13, 2023, Jian Yiao applied for the restoration of execution. The total amount executed this time was $ 110,818
(RMB 786,800),
and the remaining amount including overdue interest of $ 139,692
(RMB 991,800)
was not executed. As of March 27, 2024, the amount that was frozen from this case was $ 35,672
(RMB 253,266),
the total amount executed was $ 212,412
(RMB 1.51
million), and the bank accounts of Chengdu Aixin Tang Haichuan Pharmacy Co., Ltd and its three branches were still frozen as of this
report date.

 In
November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding. As such,
the Company did not accrue contingent losses from this legal proceeding as of December 31, 2023.

 The
Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results
of operations or cash flows.

 19.
 ACQUISITION OF SUBSIDIARY

 Runcangsheng

 On
July 19, 2022, the Company entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd ("Shengshengyuan")
and Yun Chen (collectively "the Sellers"), who own 95 % and 5 % equity interest of Yunnan Runcangsheng Technology Co., Ltd
("Runcangsheng"), respectively.

 Under
the terms of the Transfer Agreement, the Company purchased all of the outstanding equity interest of Yunnan Runcangsheng for an aggregate
purchase price of RMB 31,557,820, or $ 4,418,095, adjusted by $ 116,802, the amount equal to the initial net worth estimate minus the audited
net worth of Runcangsheng as of December 31, 2021.

 In
addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from
Runcangsheng. The acquisition was completed on September 30, 2022.

 F- 25

 The
following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition. Goodwill as a result
of the acquisition of Runcangsheng is calculated as follows:

 SCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED AND LIABILITIES ASSUMED

 Total purchase considerations

 $
 4,301,293

 Estimated fair value of assets acquired:

 Cash

 $
 446,381

 Accounts receivable

 144,813

 Accounts receivable-related party

 133,011

 Advance to suppliers

 3,455

 Other receivables and prepaid expense

 127,909

 Inventory

 469,594

 Property and equipment

 1,677,272

 Intangible assets

 1,406

 Operating lease right-of-use assets

 1,990

 Total assets acquired

 3,005,831

 Estimated fair value of liabilities assumed:

 ( 89,801
)

 Accounts payable-related party

 ( 160,911
)

 Advance from customers

 ( 4,790
)

 Government grant

 ( 921,473
)

 Taxes payable

 ( 21,156
)

 Operating lease liability

 ( 15,182
)

 Accrued liabilities and other payables

 ( 1,314,995
)

 Total liabilities assumed

 ( 2,528,308
)

 Total net assets acquired

 477,523

 Goodwill as a result of the acquisition

 $
 3,823,770

the year ended December 31, 2022, the Company recorded a goodwill impairment equal to the goodwill resulting from the acquisition of
Runcangsheng.

 The
following condensed unaudited pro forma consolidated results of operations for the Company, Runcangsheng, Aixin Shangyan Hotel and Aixintang
Pharmacies for the year ended December 31, 2022 present the results of operations of the Company, Runcangsheng, Aixin Shangyan Hotel,
and Aixintang Pharmacies as if the acquisition of Runcangsheng occurred on January 1, 2022, respectively.

 The
pro forma results are not necessarily indicative of the actual results that would have occurred had the acquisition been completed as
of the beginning of the periods presented, nor are they necessarily indicative of future consolidated results.

 SCHEDULE OF BUSINESS ACQUISITION PRO FORMA

 For the
 Year Ended

 $
 3,168,061

 5,605,508

 ( 2,437,447
)

 Other income

 34,839

 Income tax expense

 1,097

 $
 ( 2,403,705
)

 20.
 SUBSEQUENT EVENT

 The
Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through
the date the financial statements were issued and determined the Company has the following material subsequent event, on February 29, 2024, Aixin Shangyan Hotel moved to a new address for a total lease period of 121.5 months. During
the initial five-year period, the total annual lease payments amounted to $ 169,016 per year (equivalent to RMB 1.2 million). Subsequently,
for the remaining duration of the lease, there will be a yearly increase of 5 % in the lease payments.

 F- 26